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EDITORIAL
PROGRESS

IN CARDIOVASCULAR
MEDICINE
By Dan Hackam, BSc., Editor-in-Chief

e pi te recent declines in mortality, the toll of
cardiova cular disea e (CVD) in pre ent ociety is
till taggering. CVD accounted for 38% of all
death in Canada in 1994, more than any other cau e of
death, including cancer (28%). Twenty-three thou and
individuals die each year as a result of a myocardial
infarction. Cardiovascular disea e cost the Cana dian
economy approximately 19 billion every year in medical
ervice , hospitalization expen e , lo s of income and lo s
of productivity. With the increa e in the proportion of the
population that is elderly, the total burden of CVD is
expected to rise, at least for the next 15 year .1
The term "cardiovascular di ea e" is a broad one and
refers to many different entities, depending on the
speciali t you peak to, the organ sy tern affected, the age
of the patient, whether the di ea e wa acquired or
congenital, and o forth. To many, CVD refer to
atherosclerosis, which is a spectrum encompa sing
ischemic heart di ea e (angina, myocardial infarction,
ischemic cardiomyopathy, udden cardiac death),
cerebrovascular di ea e (stroke, transient cerebral
i chemia, va cular dementia), peripheral va cular di ea e,
and arterial aneury mal di ea e. Mo t, but not all, article
in this issue of the journal deal with athero dero i .
Medical cience has made va t trides in the past halfcentury toward understanding the underlying
mechani ms of cardiova cular di ease and innovating new
treatment . Epidemiologi ts, including tho e invol ed in
the cia ic Framingham study, have given us an
appreciation of the inherent risk factors that contribute to
CVD: moking, hypertension, hyperlipidemia, diabetes
mellitu , and age. With the exception of age, the e ri k
factor are largely modifiable: it i likely that public health
efforts, focu ing on improvement in diet and exercise, are
re pon ible for the dramatic declines in CVD incidence
and mortality een in the pa t everaJ decade .
In term of the secondary prevention of va cular
disea e (that is, the prevention of event occuring in
patient with pre-existing disea e), clinical inve tigator
have hown us that a multitude of effective
pharmacological therapeutics are available, and thi has
led to much excitement in recent year . Example include
beta-blocker and ace inhibitor for the prevention of
death in heart failure patients, tatins for the prevention of
heart attack and troke , warfarin for the prevention of
troke in atrial fibrillation, ju t to name a few.
Unfortunately, this body of evidence i va tly
underutilized in much of clinical practice in orth
America: for instance, one recent tudy howed that only
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27% of hypertensive patients are adequately treated. Here
too, then, there is room for improvement.
Diagno is and therapy of acute cardiovascular event
( troke, myocardial infarction, unstable angina) have also
made great leap in the modern era, giving further
credence to the u e of the term "progress" in the title of
this editorial. The u e of radionuclide imaging tudie a
well as more accurate cardiac enzyme have
revolutionized the detection of coronary artery di ea e
and myocardial infarction, re pectively. Thrombolytic
agents, such as recombinant tis ue-type pla minogen
activator and treptokina e, have roughly halved the
mortality of heart attack patients presenting to hospital.
And more revolutionary treatment are on the way:
neuroprotective agents for acute troke, angiogene i
promoter in coronary artery disease, as well as a
multitude of other experimental approaches to the
problem of myocardial revasculariza tion, technique
which may one day replace coronary artery bypas
grafting and angiopla ty.
The epidemic of cardiova cular disease in the western
world i a real one, with staggering economic and human
consequences. One can only hope that scientific advance
in the coming century, in combination wi th better
implementation of measures devi ed in the pa t century,
will u her in the beginning of the end of this modem-day
courge.
REFER£ CES

1. lAboratory Centre for Disease Control, 1996.
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EDITORS: NAJI TOUMA AND HELEN L EWANDOWSKI

AN INTERVIEW WITH
DR. DOUGLAS BOYD
By Naji Touma and Helen Lewandowski

of We tern Ontario and director of the Minimally Inva ive
Cardiac Surgery Program at LHSC-UC.
Do you consider yourself a researcher or a clinical
surgeon?
Honestly, I really don't think of myself as a re earcher
per e. I am are earcher but a clinical re earcher. My be t
work i really done in the operating room. My kill and
experti e are in urgery and urgical techniques. Some of
the e technique have to be innovated and in order for
that to happen, work has to be done in the lab; but the lab
work alway involve practical model uch a tudie on
~al . I gue s I am a re earcher but most of my work is
clinical. In fact, ince I have been here, I would spend four
days in the operating room and one day on re earch.
~tely, with _
this new technology, it is more like two days
m the operating room and three days in the lab.

r. Dougla Boyd is a cardiac urgeon at the London
Health Science Centre- University Campus
(LHSC-UC) who ha a pecial intere t in roboticsa i ted urgery. On September 24 1999, Dr. Boyd and hi
team performed the fir t ucce ful clo ed-che t, robotic
a i ted beating heart ingle bypa on John Penner, 60, of
Seaforth. Thi new procedure could revolutionize the
world ?f cardiac urgery and i propelling London'
reputation as a world class facility for cardiac re earch and
innovation.
Boyd re~eived hi MD and cardiac surgery
trauung at the Uruver ity of Ottawa and the Ottawa Heart
In titute, respectively. His primary po t-cardiac training
wa in_~~art tran plant urgery and the development of
the artlfioal heart. He_wa later attracted to London by it
world cia reputation as a transplant centre . He is
currently a i tant profe or of urgery at the Univer ity

D
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Could you discuss the technology behind the robotics
assisted heart bypass that you recently performed at
LHSC-UC?
. w_e have been concentrating our efforts in minimally
mva 1ve urgery lately on beating heart techniques. We
know that the mailer the incision is, the more difficult it is
to maneuver conventional endo copic instruments to be
able to do the job. B fore we knew we were going to be
a~le to use a robot, I went to the lab and u ed about fifty
ptg heart in a training model in order to learn the
dexter~ty . r~quired to perform coronary bypass with very
mall rna 10n . We learned very quickly that there are a
number of problems that have to be overcome before that
job can be done. One problem i visualization. The two
dime~sional c~era available at the time did not give us
the kmd of visual dexterity required. That is when we
tarted experimenting with three dimensional
vi ualization sy terns. Three dimensional cameras gave us
a better perception of depth and improved the vi ual
dexterity. Another problem wa tabilization. To operate
on the beating heart, one ha to be able to locally tabilize
the area so that ana tomosi
could be performed
afterwa rd . Yet another problem wa in trumentation.
Conventional endo copic in truments did not allow
sufficient degrees of freedom to operate freely wi thin
mall ~ci ions a in the open heart ituation. For example,
th~ ability to _move one's hands left and right and look at
thing fre~Iy_ 1~ reduced greatly. One i also limited by the
angle of mc1 ton and the di tance from the heart to the
~h~ ~ wal_
I. We found that the operation through small
mci JOn IS doable but not practical. For example, to do
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one single graft, it took u 90 minutes while in the open
heart situation, it took us only 10-12 minute . In addition
to the time, the accuracy left something to be desired in
that we were not able to obtain the same kind of quality
grafts as in the open heart procedure. So there were a
number of factors that made us realize it is not qui te so
easy to perform heart surgeries through small incisions.
All of a sudden, this new robotic technology comes
along that would allow the surgeon the arne dexterity
enjoyed outside the chest with absolute preci ion .
Movements of the surgeon outside are digiti z d by
computer control and translated to a robotic manipulator
attached through pin sized holes within the chest wall.
The surgeon sits down in front of a control console and
manipulates surgical instruments by looking at a
magnified TV screen. This view comes from a little 3D
camera that is attached to a robotic arm that is in turn
hooked up to a computer controller and a head et. The
robot supporting the camera is activated by a
sophisticated voice activation software that only
recognizes the surgeon's voice. The robot only responds to
the commands of the surgeon and allows for different
camera movements. Hence, the visualization inside the
chest is controlled by voice command . The surgeon is
sitting at the console, holding instruments very similar to
the ones used in open heart surgery. The movemen ts of
these instruments are digitized by computer control and
transmitted to the instruments inserted within the chest. A
surgeon could scale very gross movements on the console
to very fine movements in the chest. For example a 6 em
movement outside can be translated to a 6mm movement
inside. A surgeon could also move his / her hand from a
certain position to a more comfortable position by
stepping off a clutch. The computer control also has builtin filters so that very fine tremors are screened out.
Another feature is the ability to scale a 180° rot a tion
outside to a 360° rotation inside. Hence, the robot has the
effect of increasing a surgeon's dexterity. This is a very
interactive system or a robot in the loop that enhances the
urgeon's skills but doe not take over the operation.
Could y ou discuss the benefits of minimally invasive
surgery as opposed to open heart surgery?
There are two factors that make a heart u r gery
invasive and in turn force patients to stay an average of
one week in the hospital after the operation. The first is the
incision which is large enough to strip the breast bone and
necessitate time for healing. The second is the use of the
heart-lung machine. When one takes a patient's blood
supply, reroute it into the heart-lung machine (which
takes over the functions of both the heart and the lung)
and recirculates his blood volume about 20,000 to 30,000
times in this artificial surface, something has got to
happen. You never get something for nothing. Thing that
happen, and they have been very well documented years
ago, include: a total body inflammatory response: blood
coagulation due to exposure to an artificial surfac . The
incidence of strokes after heart surgery incre ases
dramatically with age. Our studies have shown that this is
largely due to the use of the heart-lung machine;
manipulating the blood vessels or having to insert tubes
into the aorta. Any manipulation of the aorta ca uses
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microemboli that could go to the brain. Microemboli from
the pump itself could also go to the brain. Dr. Merken, a
professor of anesthesiology, has demonstrated that the use
of the heart-lung machine causes a 20-30% increa e in
neuro-cognitive dysfunction. That being said, there is
merit in avoiding the heart-lung machine and invasive
surgery.
In minimally invasive surgery, we have not only
avoided the use of the heart-lung machine, we have also
done small incisions so we don ' t need to spread an
incision about eight inche as in open heart surgery. In
fact, one small working port of 2-3 em long is enough to
get the heart stabilized. This enable us to not break any
bone and have only a small amount of tissue trauma and
ultimately make the surgery a lot more comfortable. This
is likely to reduce the need for transfusions and the overall
morbidity and complication of the surgery.
When do you think this new technology will move from
the exp erimental o r r esearch s ta ge to become m o re
routine surgery?
In my own practice now, it is almost routine because I
am doing a robotic surgery every week. However, before
it is widely adopted, I think it is very important that this
new procedure undergoe rigorou scientific evaluation
and we have to be very careful before we proceed any
further. For example, we do not yet know if these devices
are safe. We have been using simple robotics for years and
have had no complications associated with the robot
whatsoever. We anticipate that this will be the same but
until we have an appropriate number of cases, we can't
cientifically say it is safe. Once safety is shown, we will be
able to demonstrate very clearly the benefits of this
technology. After that, we will adopt the robot in routine
urgery. I believe that within the next two years, the u e of
robotics will become mainstream.
What d o you think the limitations of this technology
are?
I think cost is a major i ue. This is a very expensive
technology. Although, ultimately I believe this technology
will pay for it elf. We compared low risk patients who
underwent robotic beating heart urgery and conventional
surgery. Of tho e 30 patients we looked at, we saved
$45,000 by adopting the robotics technology. At this rate,
we fore ee that our robot will pay for itself within one
year. We anticipate that if we can get 24-48 hour stays and
patients up and out of the hospital and back to work
quickly, this technology will pay for itself; but right now,
the cost is the greatest limiting factor. This technology is in
a rapid state of evolution. I don' t think the unit we have
now will be the same unit used two years from now. We
currently have contracts with a pri ate company that we
will be involved in helping them develop th eir
instruments. In return, we will get upgrades in the
equipment in order to stay up to date.
Other than th e b y pa ss, do y ou fo r e s ee u s ing th is
technology for other types of surgery?
Absolutely, there is no question about that. I believe
very strongly that in the next two years, we will be doing
beating heart robotic valve replacements, robotic
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arrhythmia operations and even pediatric surgery.
Could you discuss the genesis of this technology and
how it developed?
Robotic research really started in the early 90's. There
were two major groups in California working on it
independently. One was the S military with the Stanford
Re earch Institute and the other was ASA and the Jet
Propul ion Lab . The e two groups had different
objectives.
The goal of the military group that contracted out to
the Stanford Research Group was to have a robotic
manipulator on a bunker like tractor trailer. The idea was
to have the ability to move wounded oldiers quickly into
this portable hospital with robot and have surgeons on
their command console performing urgery from mile
away. With the advent of fiber optics technology, data
transmi sion could be done almo t at the speed of light.
The objective of the group at the Jet Propulsion Lab of
ASA was to have a robot on a mission to Mars where
astronauts could go for two years without a hospital. The
idea was to have a technician deploying the robot on
board of the spacecraft and have a surgeon on earth
perform any potential surgeries. This idea is not o far
fetched and there is no question in my mind that this will
be something available within seven years.
Could you talk about how important private funding
such as the Ivey Foundation gift is for maintaining and
developing this research technology?
Right now, I think we have established our elve as a
major robotic surgery centre in the world. One of the
obligations we have is to further robotic surgery and if we
are going to do that in a scientific way, we have to have
the foundations. The additional money from Ivey will not
only support our research effort but also our clinical
efforts. Just having a robot will not make us a world class
facility; we need research, teaching and clinical
applications. This generous Ivey gift will help in laying
down the e foundations. It will not only fund the robotic
program but also the imagery program. It will enhance
our ability to link robotic urgery and interventional
cardiology. This will make London a leader in the world
in this minimally invasive approach to heart disease.
Could you discuss other important current issues in
cardiology and cardiac surgery?
There is no question that angiogene is and the whole
i ue of genetic research plays an important role. Also,
stem transfer technology or the ability to transfer heart
muscle cells into dead areas and regrowing it. Other
important research areas include : myocardial
revascularization, cardio-la er reva cularization in
a ociation with genetic manipulation, robotics, catheterba ed interventions, and endocardioly or ethocardioly.
What would you tell medical students who may be
interested in pursuing cardiac surgery as a career?
Cardiac surgery is an extremely demanding but al o
an extremely rewarding career. This is really an exciting
time to be a cardiac surgeon. Heart surgery has been
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practiced the same way for almost 30 years. In the last few
years, even while I was undergoing my cardiac surgery
training, it is being completely changed . Right now, we
are about to redefine the way cardiac surgery is practiced
and that is really incredible. The advent of things like
computers, genetics and robotics have greatly impacted on
cardiac surgery and that i very exciting.
Q
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AN UNUSUAL CASE OF CHEST PAIN
By Dan Hackam, BSc., Editor-in-Chief
45-year old gentleman (A.B.) pre ent to hi family
phy ician with a 24-hour hi tory of evere chest
pain. The pain is localized to his left anterior che t,
i harp and tabbing in quality, and wa fairly sudden in
on et and has not remitted ince yesterday. The pain i
worse with recumbency, cough, and deep inspiration, and
better with itting up and taking hallow breath . A.B.
took a pirin with only moderate relief.

A

CBC reveals a left- hift with mild leukocytosi (WBC
11.3) and a neutrophilic predominance. Cardiac enzyme
(myoglobin, troponin-1, CK-MB) and ESR are mildly
elevated. A re ting electrocardiogram (ECG) reveals the
following: normal sinus rhythm, rate 98, ST elevation in
multiple contiguous leads. Che t X-ray reveal a normal
heart ize with no evidence of pleural effusion or
pulmonary infiltrate .

PLEASE STOP A 0 A SWER THE FOLLOW! G
QUESTIO S:

PLEASE STOP A 0 A SWER THE FOLLOW! G
QUESTIO S:

1) What is your differential diagno i for che t pain
in thi gentleman?

8) Given the abnormality on ECG, what diagno i
mo t likely?

2) What other que tions on hi tory would clarify the
differential diagnosis?

The patient i referred to a cardiologi t for further
a e ment. Echocardiography (ECHO) reveals evidence
of a mild pericardia! effu ion, with no evidence of
pericardia! thickening, valvular abnormality, or dyskinetic
myocardial segment . Ejection fraction is 55%.

3) Given the mo t likely diagnosi , what particular
finding on phy ical examination would you be
diligent to eek out?
Examination of the head and neck, abdominal,
re piratory and mu culo keletal sy tern i unremarkable.
Turning your attention to the cardiova cular ystem, you
obtain the following parameter : HR 100 and regular, BP
140 /70, JVP 3 em above the ternal angle. Carotid are
bri k bilaterally with no evidence of bruit. On insp cting
the precordium, you note no abnormal lift , heave , or
pul ations. On palpation, there i no parasternal lift and
the apex beat i located in the fifth inter pace,
midclavicular line (i t is normal in timing, duration and
intensity). On au cultation, you note normal h art ounds,
a Grade IT / VI y tolic ejection murmur at the base with no
radiation to the carotid , no extra heart ounds, and no
rub.
PLEASE STOP A 0 A SWER THE FOLLOW! G
QUESTIO S:
4) If a carotid bruit were pre ent, what would thi
indica te, and what clinical entity on the
differential diagnosi would thi make more
likely?
5) What is the significance of a para ternallift? What
would a di placed apex beat tell you?
6) What is the ignificance (if any) of the murmur?
7) What initial investigations would you order?
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PLEASE STOP A 0 A SWER THE FOLLOW! G
QUESTIO S:
9) What are the etiologie of thi condition?
10) What i the progno i of thi condition?
11) Outline, in general and p cific term , the
management of thi condition?
ANSWERS:

1) One can never be faulted for placing at the top of
the differential tho e entitie that might endanger
the life of the patient, and therefore mu t be ruled
out. Given the udden on et of evere che t pain,
myocardial infarction or i chemia, aortic
di ection, or pulmonary embolus are all po ible.
However, pericarditis is more likely, given that
the pain of acute pericarditi i often pleuritic,
relieved by sitting up and aggravated by
recumbency and deep breathing.
2) The four cardinal cardiac ymptom are: che t
pain, dy pnea, palpitations and y ncop e. In
addition to the e, one would a k about symptom
of heart failure: orthopnea, paroxy mal nocturnal
dy pnea, and ankle welling. Che t pain related to
exertion, emotion, cold weather or meal , or in the
pre ence of diaphore is, nau ea, or vomiting, or
against a background of coronary risk factors
( making, hyperten ion, diabetes, family hi tory,
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and h yperlipidemia) m ake infarction / ischemia
more likely. One would al o a k about habits such
a tobacco and ethanol con umption, as well as
medications, and other medical conditions (for
in tance, lupus [SLE] and other connective tissue
disorder are associated with pericarditis).
3) The sine qua non findin g of pericarditis is the
pericardia! friction rub. It may have up to three
components per cardiac cycle and i high-pitched,
scratching, and grating; it can ometime be
elicited only when firm pre ure with the
diaphragm of the tetho cope is applied to the
che t wall at the left lower ternal border. It is
heard mo t frequently during e piration with the
patient in the sitting po ition. The rub i often
incon tant and the loud to-and-fro leathery ound
may disappear within a few hours, possibly to
reappear the following day.

o n
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11) The treatment of pericarditi is virtually always
ymptomatic and directed toward optimizing the
comfort of the patient . Bed res t and antiinflammatory treatment with a pirin, if nece ary
up to 900 mg qid, ma y be given . If thi s i
ineffecti v e, one of the nonsteroidal anti inflammatory agents, such as indomethacin (25 to
75 mg qid) or a glucocorticoid (e.g., predni one, 20
to 80 mg daily ) u ually suppresses the clinical
manifestation of the acute illness and may be
u eful in p a tient in whom the purulent and
tuberculou form of pericarditi have been
excluded. Anticoagulant hould be avoided. After
the patient ha been a ymptomatic and afebrile for
about a week, the do e of the anti-inflammatory
agent is gradually tapered. When recurrences are
multiple, frequent, disabling, and continue beyond
2 year , pericardiectomy ma y be effective in
terminating the illness.
Q

4) A carotid bruit indica te turbulent flow in the
carotid artery and i diagnostic of cerebral
v a cular disease. Becau e athero clerosi is a
generalized disease, the finding of a carotid bruit
would make coronary i chemia or infarction
omewhat more likely.
5) A para temal lift is palpated in right ventricular
hypertrophy. A di placed apex can be found in left
ventricular dilatation.
6) The murmur de cribed has all the characteristics
of a benign ("functional") flow murmur, which i
often een in healthy, young adult and in highflow sta tes uch pregnancy, exerd e, and anemia.
The e characteri tic are : mid y tolic timing,
Grade II or le , non-radiating, be t heard in the
pulmonic area, non-mu ical in character.
7) The following investi gation are appropriate :
complete blood count (CBC), erythroc y te
edimentation rate (ESR; a non- pedfic marker of
inflammation), cardiac en z ymes, electrocardiogram, and che t x-ray.
8) Pericarditis.
(viral, bacterial,
9) Differential : infectiou
tuberculous, fungal, protozoal), a ociated with
m yocardial infarction (actuely, or days to weeks
later; the latter is known a Ore ler's syndrome),
collagen vasc u lar di ea e (SLE, periarteriti s
nodo a, rheumatoid arthriti ), uremia, neoplasm
(brea t, lung, renal, melanoma), infiltrative
di ea e, drug , trauma, radiation, and idiopathic.
10) The progno i i dependant on the underlying
etiology. Acute idiopathic (or viral) pericarditis i
u ually elf-limited and abate wi thin 1 month.
One or more episodes of recu rrent pericarditis
occur in up to one-fourth of patients. Constrictive
pericarditis is a rare complication.
U. W.O. Medical Journa l 70 (1}
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DEFECTIVE PACEMAKERS
LEGAL LIABILITY

AND

By Mahmoud Sharaf, MEDS 2002
ith the development of pacemakers and
implanted defibrillators, patients pron e to
cardiac arrhythmia by reason of ischemic di ease
or congenital abnormality have seen dra m atic
improvement in quality of life and life expectancy. The
pacemaker consists of an external unit, either single or
dual-chambered, with a lead embedded in the right
atrium, or two leads implanted in atrium and ventricle 1•
The pacemaker sets the heart rate and can a d just
d ynamically to suit systemic activity levels 1•
The combination of intense patient reliance on these
devices to sustain an active lifestyle and the inevitable
tendency of mechanical parts to malfunction can result in
cardiac events, and even death. The courts are a frequent
recourse for settlement of claims of manufacturer liability
for the complications of pacemaker malfunction. There are
several actual and potential claims that plaintiffs can use.
This paper will serve to discuss a few of them using
illustrative examples.
In the case of Tracy v. Telectronics Pacing Systems, Inc.,
Ronald Tracy of St. Clair County, Michigan brought forth a
lawsuit against the manufacturer after his pacemaker
failed, forcing him to replace it at the Cleveland Clinic at
substantial personal risk and expense •. The J-lead
pacemaker has a thin, flat intracardiac lead that is
abnormally prone to metal fatigue, thereby incapacitating
the pacemaker. The proceedings in the U.S. District Court
indicated the manufacturer was aware of the fault as early
as 1992, but did not recall the unit until1994, a year before
this trial 1• The court decided in favour of the plaintiffl.
The Food and Drug Administration ascertained from
Telectronics, Inc. that 22 000 persons have received the Jlead model which the company estimates has a 17%
failure rate 1• It is estimated that 2 individuals have died as
a result of this malfunction•. There are currently 60
pending cases against Telectronics Pacing Systems, Inc. in
U.S. courts 1.
In Ontario there are 2 cases pending ag a inst
Medtronics, Inc.'s Canadian subsidiary, out of
Mississauga 1. In 1998, Sudbury residents brought a class
action s uit against the company because of fa ulty
polyurethane insulation on the leads. Any of the thou and
Ontarians having received the 4004 model (between 19891995) is eligible to participate in the suit 1•
Susan and Jeff Blanchard of London, Ontario brought
forth a suit in ovember, 1998 in the Ontario Court of
Justice against the same manufacturer of the 4004 model
alleging negligence in the design, development, testing,
manufacture, licensing and distribution of their product.
They seek $275 000 in assorted damages•.

W
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The risk of serious atrial thrombus formation pursuant
to pacemaker lead implantation is rare (only about 2%t
However, the possibility of claims being drafted based on
thrombogenic lead configuration can not be discounted.
Another interesting potential cause for future claims is
the proposed link between cellular phone use and
interference in pacemaker signaling. The ew England
Journal of Medicine study (May 29, 1997) indicated that if
cellular phones were operated directl y over the
precordium, interference could be noted in 20 % of
individuals. Serious interference wa noted in one third of
this twenty percent. Normal operation of cellular phones
at ear level had no role in producing interference•. There
have been no cases to date brought to general attention
that have been argued along these lines, but this may not
dissuade enterprising lawyers from trying.
The last, and perhaps most interesting, potential cause
of lawsuits in the future is the Y2K non-compliance issue.
This cause celebre of Ann Couffou, Managing Director of
the Giga Year 2000 Relevance Service, was serious enough
to warrant her testimony before the House Subcommittee
on Science and Technology in 1997 1•
The Veterans Adminis tration as ked 5 pacemaker
companies about Y2K readiness. One company refused
outright to cooperate while the other four indicated
readiness would be achieved before the end of 1999 1•
In actuality, most pacemakers (including those made
by Medtronic, Inc. and PaceArt, Inc.) have no datecomputi ng chips, and are thus Y2K-proofl . Some
pacemakers contain chips that serve to record cardiac
traces for physicians to study. These date-computing chips
would cease to record information on New Year's Day,
and thus will sacrifice the close monitoring required in
some patients•. Implanted defibrillators, which assess
arrhythmia and rectify it, do use date-computing chips. If
these monitors have recorded no event in 6 months time,
then the defibrillators will not subsequently function,
assuming the long inactivity means that the device should
be replaced because it may be defective. If no event has
been recorded since 1900 (which is the case on 01.01.2000),
then th e defibrillators will s top, not in line with
replacement schedules•.
Some manufacturers of date-computing chips ha ve
switched to an 8-digit date format to avoid Y2K problems,
like the British manufacturer of CriSPR. Others are still
considering the problem 1•
In conclusion, the grounds for successful liability suits
for pacemaker malfunction will primarily rest on
demonstration of mechanical defect present at production
or abnormal tendency to wear out. It is important to show
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multiple cases of malfunction for the model in question.
The technology of pacemakers ha greatly improved over
the decades and lawsuits, despite their un savoury
conno tations, ha v e pla ye d an integr al part in th e
con tinuous dri v e toward s product quality and
standardization.
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A BRIEF REVIEW OF TRUNCUS ARTERIOSUS
By John D. Stein and Jason A shley

INTRO DUCTIO N
Truncu Arteriosu , fir t de cribed in detail in 179 , i
a congenital defect of the great ve el invol v ing
incomplete eparation of the pulmonary artery and the
aorta during embryogene is. The condition affect 1 in
12,500 births 1 and patient pre ent with cyan i ,
tachypnea (very rapid ventilation), murmur , swea tinp
during feeding, a failure to thrive and hepatomegaly .
Other anomalie a ociated with TA include ventri cular
eptal defect , truncal valve regurgitation and incr a ed
pulmonary va cular re i tance 1• Untreated, thi condition
has a 65% mortality rate in the fir t 6 months of life
increasing to 75 % within the fir t year 1• Cau e of
mortality include excessive pulmonary blood flow,
conge tive heart failure and progre ive cyanosis due to
accelerated pulmonary va cular ob tructi e di a e .
Palliative urgical intervention performed before the e
conditions appear ha lowered the two-year mortality to
approximately 20%.1
Embryology and Etiology
In the normal development of the great ve e ls,
truncal ridge form in the truncus during the fifth and
ixth week of embryogenesis. The left anterior ridge
meet and fuse with the right po terior ridge (Fig. 1)
during the eventh week of ge tation thu forming two
lumen which give rise to the aorta and pulmonary artery.
The fusion of the truncal ridges al o occur in the fetal
heart contributing to ventricular eptum formation . The
failure of the e ridge to fu e ha been u ed to explain
Truncu Arteria u , and by exten ion, the ob rve d
ventricular eptum defect . 1 Thi model of development
ha been accu ed of being an oversimplification and not

A

B

fully accounting for the po ibility of Truncus Arteria u
without a ventricular eptaJ defect. 1 Admittedly however,
thi occurrence i exceeding ly rare wit h only 2
documented case .
Truncu Arteria u i frequent ly as ociated with
DiGeorge' Syndrome, a condition where the thymus and
parathyroid gland fail to develop from the neural ere t.
Ablation of the cardiac neural cr t in chick embryo has
b en hown to re ult in per i tent Truncu Arteria u . A
theory that the etio lo gy of Truncu Arteria u s ma y
involve orne genetic defect or teratogenic insult affecting
the neural ere t may explain the frequent a ociation of
the e two congenital malformation .1 This i an attractive
idea ince any damage to the neural ere t that would
comprorni e truncal ridge fu ion could have the potential
of al o interfering with the normal development of the
thymu and parathyroid glands.
Anatomical Classification of Truncus Arteriosus
At pre ent there are two main y tern for cla sifying
Truncu Arteria u . The first, introduced in a classic
report by Collett and Edward in 1949 4 wa widely
adopted. In general the defect wa cla ified according to
th e arre t in development which corre pond to the
po ition of pulmonary branching from the truncu . (Fig. 2)
Type I. Type I involve a h ort pulmonary trunk
which further divide into a left and right pulmon ary
artery. Thi type i further subdivided into 7 categories
(Table 1).
Type II. In Type II Truncu Arteria u the right and
left pulmonary arterie ha ve separa te but do e origins
from th dor al wall of the Truncu Arteria u . This type
is further subdivided into 4 categorie (Table 2).

c

D

Figure 1. Embryogenesis of the Aorta and Pulmonary A rteries ari ing fro m the Tru ncus Arteriosus at the 5th (A ), 6th (B), 7th (C), and 8th (D)
week of gestation.
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Figure 2. A comparison of the Collett & Edwards and Van Praagh & Van Praagh Clas ifications ofTnmcus Arteriosus.

Type ill. In type ill Truncus Arteria us the right and
left pulmonary arterie have eparate origins from the
right and left lateral walls of the truncu . This type is
further subdivided into 4 categorie (Table 3).
Type IV. Type IV Truncu Arteria us is characterized
b an ab ence of pulmonary arterie a well as a lack of
any 6th aortic arch derivatives. Perfu ion of the lungs
occurs by way of the bronchial arteries. Type IV i further
ubdivided into 4 categories (Table 4).

Table 3

Table 1

Type I
Subtype 1
Subtype 2
Subtype 3
Subtype 4
Subtype 5
Subtype 6
Subtype 7

Single pulmonary trunk arising from the Truncus Arteriosus
(from the left side unless otherwise noted)
Pulmonary trunk from left side.
Pulmonary trunk from right side.
Patent ductus arteriosus.
Patent ductus arteriosus and coarctation of the aortic arch.
Complete atresia of part of the aortic arch.
Right aortic arch.
Double aortic arch.

Subtype 1
Subtype 2
Subtype 3
Subtype 4

Type Ill
Subtype 1
Subtype 2

Subtype 3
Subtype 4

Separate origins of the right and left pulmonary arteries from
the right and left lateral wall of the truncus.
Ductus arteriosus is absent and both 6th aortic arches present.
Patent ductus arteriosus with only one 6th aortic arch present
and supplying one lung. The other lung perfused by the
ductus arteriosus or bronchial arteries.
Right aortic arch and both 6th aortic arches present.
Right aortic arch with only one 6th aortic arch present and
supplying one lung. The other lung perfused by the ductus
arteriosus or bronchial arteries.

Table 4

Table 2

Type II

An alternative cia ification sy tern was offered by
Van Praagh and Van Praagh 7 to include in tance of
Truncus Arteria us w ithout ventricular eptal defects
(VSD) and further, to exclude Collett and Edward' Type
IV category . It wa argued that Type IV hould be
con idered a ca e of failed pulmonary artery formation
rather than a failure of the aorta and pulmonary artery to
eparate.

Separate but close origins of the right and left
pulmonary arteries
Ductus arteriosus is absent.
Patent ductus arteriosus.
Patent ductus arteriosus with coarctation and atresia of
the aortic arch.
Right aortic arch

Type IV
Subtype 1
Subtype 2
Subtype 3
Subtype 4

Pulmonary arteries are absent
Bronchial supply to lungs via descending aorta.
Bronchial supply to lungs via descending aorta and aortic arch.
Bronchial supply to lungs via aortic arch.
Right aortic arch and bronchial supply to the lungs via
descending aorta.
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Table 5

Type A
Subtype 1
Subtype 2
Subtype 3
Subtype 4

Table 6

Truncus Arteriosus with VSD
Partial separation of a main pulmonary artery from the truncus.
No main pulmonary artery, right and left branch off from
the truncus separately.
Absence of single pulmonary artery (left or right).
Ipsilateral lung receives collateral perfusion.
Atretic or absent aortic arch with large patent ductus arteriosus.
A main pulmonary artery arises from the ascending aorta.

Type B
Subtype 1
Subtype 2
Subtype 3
Subtype 4

Truncus Arteriosus without VSD
Partial separation of a main pulmonary artery from the truncus.
No main pulmonary artery, right and left branch off from
the truncus separately.
Absence of single pulmonary artery (left or right).
Ipsilateral lung receives collateral perfusion.
Atretic or absent aortic arch with large patent ductus arteriosus.

c

Figure 3. A. Truncus Arteriosus with aortic cross-clamping, pulmonary artery constriction, and aorto-bicaval bypass in place. B. Transventricular
closure of the ventricular-septal defect using a Dacron Patch has been performed. The pulmonary trunk has been excised from the truncus. The
resulting neoaortal defect is closed with a homograft patch. The pulmonary trunk is sutured to a homograft conduit which is in turn sutured to the
rim of the ventricular defect. C. In cases where the pulmonary artery graft cannot envelop the entire ventricular defect, an homograft hoot may be
implemented. 3f4 of the hood circumference is sutured around the remaining rim of the ven tricular defect. The pulmonary artery is su tured to the
remaining 1f4 of the hood's circumference to complete the continuation between the pulmonary artery and the right ven tricle. 2

In their scheme, Van Praagh and Van Praagh cla sify
Truncus Arteriosus with ventricular septal defect as Type
A. (Fig. 2) The exceedingly rare occurrence of Tuncus
Arteriosus without ventricular septal defect occurs w hen
the pulmonary infundibulum develops normally as do
separate pulmonary and aortic valves. Within the trunk
however, there is a defect in the septum which would
normally separate the aorta and main pulmonary artery
such that there is direct communication between th two
and mixing of oxygenated and deoxygenated blood. Van
Praagh and Van Praagh classify this type of Trun cus
Arterios u s as Type B. These two broad categorie are
further ubdivided as outlined in tables 5, 6.
Given the variable morphology of this condition, a
review of each procedure devised for each s ubtype is
beyond the scope of this review. Instead, a de cription of
the latest procedure for addressing the mo t common
form of Truncus Arteriosus will be undertaken.
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Repair of Truncus Arteriosus Type 1-1 I Al
The g o a l o f the procedure to repair Truncu s
Arterios u s Ty pe 1-1 I A l is to restore, as nearl y as
possible, the regular course of blood flow from the heart to
the lung and systemic circulation. To begin, the patient is
put on pediatric cardiopulmonary bypass ( Fig 3-A) w hich
may also include deep hypothermic circulatory arrest to
extend the time the patient can be su tained on bypass. 1·2.3·4
The pu lmon a r y trunk is d ivi de d fr o m th e Truncu s
Arteriosus and the resulting defect, in w hat i now the
neoaorta, is closed.
To co rrect any regurgitative flo w diagnosed preoperatively, repair of the truncal valve would be indicated
prior to closure of the neoaorta. This involves removing
the smalle t valve lea£let (u ually one of four) and do ing
th e inc i ion to br ing se p a r a te d le a fl e ts into clo e
a ppro ximation . 1 The ve ntricul a r s eptal d e fec t is
approached through a right ventriculotomy, and do ed
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with an albuminized Dacron or Gortex patch (Fig 3-B).5
The exci ed pulmonary artery is fashioned into a tube
with the aid of an allograft patch if nece ary (Fig 3-B).
The pulmonary trunk is then sutured to the right ventricle
at the site of the ventriculotomy (Fig 3-B). This final
communication may implement a non-valved Dacron
conduit 1 or a valved homograft. If the graft is unable to
completely surround the ventricular defect a homograftpericardia! hood may be implemented to channel blood
flow from the ventricle and into the pulmonary artery (Fig
3-C).

Post-Operative Mortality
The morbidity associated with the repair of Truncus
A rteriosus has certainly been reduced with recent
technological innovations that improve the surgeon's
ability to maintain an infant on cardiopulmonary bypass.
However, one of the most significant factor contributing
to a reduction in mortality for repair of this condition is
the indication that such repair be performed before the
patient reaches ix months o f age. 5• 11 • 1 In this way, a
s ignificant contributor to earl y death , pulmonar y
morbidity due to protracted pulmonary hypertension, can
be preempted with early repair of the defect.
While a patient age of le s than six months of age is
de irable for reducing mortality, more stringent
requirements may be necessary for minimizing morbidity.
Hanley et al. reported that morbidity, a indicated b y
pulmonary hypertension, was increased by postponing
surgery beyond 1 month of age. 11 While not an immediate
contributor to death, Hanley et al. sugge t that " ... an
inten ive care unit team with less experience managing
pulmonary va cular problems could theoreticallY. increa e
the significance of this factor as a ri k for death." 1
The age of the patient ha s been demon trated to
greatl y improve intermediate urvival. For repairs
performed on infants less than 30 days old, survival at 1
month ha been reported at 87% and 81% at 3 months and
beyond5 . Hanley et al. reported 83% of patients urviving
to 4 months post-operativel y and a many as 76 %
urviving to a late as 22 months po t-operatively.
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Conclusion
Truncus Arteriosus is a rare cardiac congenital defect.
While the mortality rate of the condition is very high in
the untreated infant there are procedures to repair ve sel
architecture which have promi ing rate of succe . The
opportunity for a favourable outcome is maximized with
earl y intervention as the equelae of pulmonary
hypertension and the associated pulmonary morbidity can
be mitigated or eliminated.
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TAOISM AND THE ADVENT OF
ANCIENT CHINESE MEDICINE
ByVadimShennan
retro pective view of civilization has shown that
cientific advancement of a ociety can only take
place if the social infra tructure allows fo r it.
Ancient China was no exception in that the tructure of
ociety and the conditions of the time were uch a to
allow for advancement in medicine. More specifically,
ancient Chine e society fostered the Taoist reli gion,
thereby allowing Taoist follower to pur ue their ultimate
goal of immortality, thus indirectly advancing medical
knowledge, mainly in the field of pharmaceutic .
Society wa capable of fo tering the ideas of Taoism
ince the underlying belief that Chinese so ciety
pre cribed to paralleled the paradigms of Taoism. The e
beliefs were centred around the doctrine of Yin and Yang,
in which ature was a ingle, unified y tern with polar
and complementary aspect . When they are in balance, life
i harmonious. However, when the delicate balance i
up et, di a ter looms 1• The fir t follower of Tsou Yen'
philo ophy merged with the Taoi ts, who then adopted
T ou Yen' ideas. Furthermore, the a pect of Taoism that
dealt with the earch for immortality had originated from
folk medicine3 . Thus, since the Taoi t religion conformed
to prevailing ideas held in the culture, uch as that of Yin
and Yang, and was born of the magico-religiou part of
ociety, Taoi m wa able to progre within the ociety
generally unabated.
Another parallel between social attitudes and Taoi m
that allowed it to flourish wa that both were cone rned
with the idea of prevention. In ancient times, China w a a
bureaucratic feudalism where great importance wa
attached to the prevention of trouble both in politics and
in p r onal health3 . As the term bur aucracy irnplie , th re
would be little imagination on the part of government
emplo ee to olve problems ince they would all be dealt
with in a preordained mechani tic fashion . This then
nece itated a need to prevent potential problems from
ever ari ing. Prominent member of ociety, uch a
Emp ror H ia Tzu-Liang, e tabli hed the first permanent
ho pital in 491AD. Before uch time, ho pices had been
formed only in time of locu t plague, evere drought or
other type of epidemic 3 . Thi action, on the part of the
Emp ror was most probably due to the prevailing attitude
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of prevention pre ent in ancient China. Taoism mirrored
thi ba ic principle in their philo ophies of immortality 4•
By earching for immortality, the Taoi ts were concerned
with keeping the health of the individual so as to prevent
the occurrence of any di ease which could potentially lead
to death.
By being devout Taoist , many monks were able to
advance their social standing by ri ing to positions in the
Emperor' s court. Since their philo ophie were favored by
the ruling class, the religion wa free to develop. Their
e calation through the ocial hierarchy was facilitated by
the de ire of Emporer to drink the formula of life. To
fulfill this desire, the y enli ted the knowledge and
cientific kills of the Taoi t , and with it came the open
upport of the religion. The fa cination Emperor had with
Taoi t beliefs of immortality i reflected in a preface to one
recipe for the elixir. It de cribe the Yellow Emporer'
journey to the Taoist Chung Huang-chih to tell him that he
i giving up his place on the throne to pursue Tao (the
order of things) . The Taoi t philosophy was a trong
current under a great number of rulers, especially from
the Fir t Emperor onward through the Han dynasty. The
Taoi t were favored by ruler to the point that their
religion wa actively furthered .
One uch ruler, Thopa Kuei, instituted a profe or hip
of Taoi m and alchem with facilities for the tudy and
preparation of elixir . The Mongol , like Thopa Kuei,
were al o very receptive to various Taoist practice 6 • For
instance, in 1276, Khubilai i ued an edict in which he
ummoned the head of the South Taoi t clergy to Shang-tu
from whence they had a formal pokesman in the capital.
From this point on and until the end of Mongol rule,
Taoism held a major po ition in the religious Jive of the
ruler and the Taoist influence wa there in the court and
government. The influence Taoi m exerted upon the court
was evidenced strongly between the years 1307 and 1322,
when on many occa ion there were edict i ued that
demanded the protection of the Taoist religion 6 . The
Taoist were very capable of attaining influence in the
ruling ection of society and with thi influence the Taoi t
philo ophy was further fo tered .
With this fo tering by th court and their political
influence a een in Mongol time , it is obviou that the
religion was anything but per ecuted. A long a the
religion i not per ecuted by the ruler, it is allowed to
flouri h and thereby attempt to achieve its goals. Alchemy
was the main occupation of the Taoi ts and it flouri hed
during the Mongol rule6 • It was through these alchemical
practices that the pharmaceutical knowledge of ancient
China developed.
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A con equence of the Taoi t earch for immortality
w a that many recipe for the elixir of life were created,
w hich amounted to a wealth of knowledge about "lifeprolonging drug ". Although many of the e elixir proved
to be impotent, thi doe not detract from the fact that due
to Taoist work in alchemy, the amount of experimentation
increa ed, leading to the increa ed knowledge of drug in
general. One of the thing that Taoists living in olitude
occ upied them elve with wa the writing of
compendium of pharmaceutics. Thee b came known a
the Pen-t ' ao 7 . The de criptions of elixir were followed
with Taoi t monk ' to in ight and experience on how to
achieve long life without aging . The Taoi t Ma Chih
compiled a collection of drug by adding another 133
ty pe to the repertory of the Pen-t ' ao, which were u ed
then and now a ucce ful pre cription 7 . In another of
the Pen t ' ao , one of the many recip for immortality
include ulfur, which found u later in civilization a an
antidote to ar enic poi oning7 .
The u e of ulfur wa one of many ucce sful drug
a nd recipe
that came into u e through the
e perimentation of Taoi t alchemist . There were many
more, one of which wa ammonium chloride. Medically, it
w a u ed to timulate exp ctoration. It wa introduced by
Arab , who had picked it up from their Chine e
alchemical colleague . Moreo ver, T'ao Hung-ching,
another Taoi t alchemi t, wa quick to ob erve through hi
alchemical experiment that mercury wa able to change
gold and ilver into a pa te. It turned out that he had
di covered the principle of amalgam and this wa to
have an effect on health care ince the e amalgam were
then u ed for filling teeth 7.
Taoists also dabbled in iatro-chemi try, leading to
further advancement in m dicine. By preparing mixtures
of androgens and e trogen in a relatively purified form,
they were able to treat many hypo-gonadic condition .
Thi advent of medicine had come about ince exual
endocrinology and pecial e ual practice had always
b en one Taoi t method of attaining immortality 3 .
Ev identl y , Taoi m ha made a distinctive mark on
medicine through con tant experimentation and
development of new therapie .
Mo t of Taoist ucce in medicine wa een in
pharmacopoeias, where the Taoi t philo ophy led to more
w ork and expan ion of work on drug literature. One
author of the pharmaceutical , Tang Shen-wei, combined
the Chia-yu pu-chu Shen-mung pen-t ' ao and the T' uching pen-t 'ao into a ingle work that wa more practical
for the practitioner. He al o in erted an additional 662
treati e of drugs and e panded the complete work by
approximately 29,000 instructions for drug application .
He did not write into the books any of hi own view , but
in tead quoted from other author and referenced other
material. ine of tho e reference pertained to other Pent 'ao , 9 were from other medical literature, one from a
Buddhi t work, and 35 were from Taoi t work 7•
The way in which the ancient Chine e ociety can be
viewed then, i a a cyclical arrangement. One can tart by
aying that Taoi t experiment in alchemy led to advances
in drug knowledge and other general field of medicine.
However, thi would not have been pos ible, were it not
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for the fact that ociety, on all levels, fostered the
development of Taoism, thu allowing it to p ur ue its
goal with the utmo t freedom. With this freedom, then,
the Taoists were able to influence odety into ub cribing
to their philo ophie , in piring them to make medical
advancement with Taoi tic tendencie in mind .
Therefore, just as the Taoi t believed that everything was
circular and interconnected in their odety, o they proved
it with their progre in medicine.
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PSYCHOSOCIAL RECUPERATION
FOLLOWING CARDIAC SURGERY
By Dan Mendonca
ardiac surgery and angioplasty have advanced to
the point where fatality rates for these procedures,
performed electively in patients under 70 years of
age, are less than 2% in many medical centers 1 •
Unfortunately, there are patients who do not benefit to the
extent that would be expected from successful surgery.
For these patients, a poor social outcome is associated
with lingering somatic complaints and a lack of
confidence concerning physical exertion. These patients do
not engage in activities of the type that their improved
cardiac tatus might allow. Poor psychosocial adaptation
is also linked with social isolation and low compliance
with medical and exercise regimens 2 •
It is well known that psychological distress figures
prominently in a patient's rehabilitation following surgery
for cardiac disease. Timberlake et al (1997) provide the
following benchmarks regarding the pattern of depre sian
after such surgeri: Eight days following surgery, SO % are
depressed due to discomfort, pain, and estrangement from
the home setting. At eight weeks, 24 % and at tw elve
months, 22% are still depressed. Given, for example, that
most coronary bypass patients at London Health Sciences
Centre (LHSC) will be discharged post-operatively after
five days or less, this means that many will have to cope
with depressive symptoms at home . Depre sive
symptoms increase the probability of visits to the
emergency department and frantic calls to h e alth
professionals on account of a cognitive state of
helplessness and other symptoms involved in depre sian.
Similarly, a sub-clinical level of pessimism involving
negative self-perception has been found to be associated
with a reluctance to return to work and a reduction in
leisure activities4 •
Using a prospective sample of patients admitted for
coronary angioplasty and coronary artery bypass, Levine
et al (1996) found that both psychological depression and
disease severity predicted the number of days of rehospitalization when patients were followed fo r six
months after discharge 5 . Statistical analysis revealed the
independent contribution of psychosocial variables (in
particular, in predicting frequency of patient symptoms)
after indicators of left ventricular function (e.g. angina,
dyspnea and fatigue) had been controlled fo~. With this in
mind, it should be possible to improve our abili ty to
predict which patients will recover well and which will
recover incompletely after heart surgery.
A recent study has found that patients with less severe
disease pre-operatively may be more prone to depre sion
following surgerr. It is possible that those patients who
were most incapacitated prior to surgery received the
greatest relief from their operation. Alternatively, patients
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who were under the impression that their disease severity
was not very serious may have been ill-prepared for the
subsequent incapacitation. Langosch et al (1992) reported
that patients who perceived their operation as a purely
technical event (avoiding emotional involvement) were
more depressed post-operatively 6 . It is important,
therefore, to take into account patients' expectations and
their understanding of the extent of their disease.
During the early phase of recovery, there is heightened
somatic concern and anxiety. Anxiety, in this case, results
in activation of the sympathetic nervous system, a key
modulator of cardiovascular function. Strategies aimed at
inducing a relaxation response might be useful during this
initial phase . Unfortunately, a h igh level of anxiety
provides the motivation for relatively swift learning of
maladaptive conduct. A perceived reduction in fear
reinforce negative behaviours such as phobic responses,
superstitious acts, and avoidance behaviour 7•
With reference to social disability, it has been found
that 50 % of marriages may deteriorate after a myocardial
infarction . This might be due, in part, to changes in role
imposed during the recovery process which often affect
self-esteem. Patients and family could benefit from the
opportunity to interact with well-adjusted former patients
to develop positive expectations regarding the future.
Patients report experiencing pecific problems of
emotional adjustment following cardiac surgery. In a
study involving focus groups of former patients, Border et
al (1985) report the following 9 : i) going through a
"downer" (e.g. crying for no reason, memory problems,
crying because one cannot return home), ii) feeling fearful
on leaving the security of the hospital, iii) fearing they will
appear less attractive to their partners on account of their
scar. Patients may go through different phases in terms of
accepting emotional support. Some patients may prefer to
"crawl into a hole" and wait while they either "die or get
better" . Others opt to have family milling about them,
talking and doing all kinds of things.
Chest pain is perhaps the major symptom that
concerns patients, spouses, and personnel. Patients should
be encouraged to mentally review the experience of chest
pain and its implications 6 • Medical staff can clarify
misconceptions and provide new information to aid
patients in appraising their physical condition. Patients
can be taught to notice whether they change their rate of
breathing, tense up specific muscles, change their posture,
or focus on specific thoughts during the experience of
chest pain. Techniques which can be used to counteract
the anxiety associated with chest pain include breathing
exercises, deep muscle relaxation techniques, imagery,
and diversion (e.g. focusing on the idea that the pain will

- - - - - - - - - - - - - - - - - - - - - - - - - U. W.O. Medical Journal 70 (1) 2000

Promotion

t

quickly pass
One of the key ingredient of depre ion following
urgery is " learned helplessne s"-ie, a belief that the
patient cannot meaningfully alter their own recovery.
With respect to counteracting this effect, two major foci
have been identified: sy mptom reporting and activity
progression 6 • Both strategies are directed at helping
patients regain a sense of personal control. In the fir t case,
patients can be taught specific vocabulary which allows
them to accurately describe bothersome symptoms (eg,
chest pain). Positive reinforcement is given to patients
w hen de criptors give clear information about the pain
experience. Pain in the chest wall, for instance, can be
readily differentiated from anginal pain. In the second
instance, patients can be taught to assess the body's
respon e to exercise and thu participate in planning
activity progression. This might involve taking the pulse
before and after specific activitie . In this context, fatigue,
shortness of breath and chest pain might be viewed as
indicators of the body' s slowly improving response to
exercise (rather than imminent threats) . The patient
experiences a sense of control in helping to determine
when their heart can successfully manage a particular load.
In addition to monitoring physical symptom and
activity progression, patients can be taught ways to better
manage recurring worries regarding their future . These
thoughts lead to changes in mood which can impact on a
patient's ability to improve. The cognitive technique of
" thought stoppinf is one which can be used to arrest
such ruminations 0 . Patients may also be disturbed by
fluctuations in affect which are commonly experienced
following heart attack. Counselor might be used to help
patients articulate their troubling feelings and place them
into perspective.
Interventions designed to promote patients'
perception of control are one approach to improving
psycho ocial recovery following a cardiac event. Patients'
perception of control (relating specifically to their cardiac
disease) appears to be adaptable (amenable to change)
and, indeed, predictive of later psychosocial recovery. In
studies where patients were involved in planning a pects
of their own rehabilitation programme, psychological
distre s was found to decrease a perceived control among
patients increased 2•
Artinian et al (1995) sought to determine whether
phy icaJ, psychological or social recovery differ for men
and women during the first six weeks following coronary
artery b y pass 11 . Women in the study reported a
significantly higher number of physical symptoms. This
wa especially true for activities involving ambulation.
Women al o had more ymptom of depre sion than men.
(It is worth noting that female patients were more likely to
be without a spou e.) Importantly, female patients
experienced lengthier recoverie and were less likely to
have adequate spou al support (e.g . with home
management activitie ).
In recent year , controversy has ari en over the i sue
of long-term psychological maladjustment in patients
following open-heart surgery. While Timberlake et al
(1997) confirm an increase in the prevalence of depre ion
following surgery, they report an eventual decrease in
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prevalence to a level below that een prior to surgery 3.
Perha ps patients' improved cardiovascular function
following surgery can account for the long-term decline in
depressive symptoms.
Beck et al (1995) report that the crucial component of
depression may be the cognitive dimension 1 · Further
investigation is needed to elucidate the course of
depression and artXiety, particularly the cognitive core,
following cardiac surgery. (The cognitive core refers to
perceptions of diminished self-worth, helplessness and
pe sirnism regarding the future). Providing interventional
therapy for all patients receiving open-heart surgery would
be both expensive and time-consuming. It may be possible,
however, to identify those patients who may be at risk of
showing poor postoperative psychological adjustment.
SUMMARY
Although most patients experience a successful
psychosocial recovery following cardiac surgery, a
significant proportion experience persistent distress which
impacts negativel y on physical well-being and
reintegration into ordinary work, leisure, and domestic
activities. The potential economic benefit of assisting the
psychosocial recuperation of such patients is substantial.
Fundamental information regarding the mechanisms of
emotional maladjustment could prove indispensable to
the cardiac care team. This should continue to be an area
of focus for cardiac rehabilitation re earch.
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INTRODUCTIO
n the emergency room etting, early diagno i i
important in the initial treatment and management of
patient presenting with acute on et of che t pain .
Early monitoring in the coronary care unit and the u e of
thrombolytic therapy greatly decrea e morbidity and
mortality 1 • Diagno i ha traditionally been ba ed on
clinical
history,
physical examination, and
electrocardiographic (ECG) findings. When World H alth
Organization (WHO) criteria (pre entation of che t pain
over 20 minute , evolutionary chan§e on the ECG, and
abnormal level of cardiac enzyme ) are used to da ify
patients with uspected myocardial infarction, only 50% of
all che t pain ufferer admitted to the CCU are confirmed
a having thi condition. Although the ECG can be
performed ea ily and rapidly, pecific change ma y be
ab ent or inconclusive in the early hour in about half of
the patient arriving at ho pita] with acute myocardial
infarction (AMI) 3 . Furthermore, approximately 2% of
patient with AMI are inadvertently ent home4 • It i for
this rea on that mea urement of biochemical marker of
myocardial mu de cell damage play an important role in
the diagno i of AMI.
In the pa t, te t for lactate dehydrogena e, aspartate
transaminase, and creatine kina e were developed and
widely u ed . The e te ts were later replaced by newer
technology uch a minicolumn and electrophoretic
eparation methods for mea uring the erum CK-MB
i oenzyme, a more cardiac- pecific marker5 . But the e
traditional cardiac marker (total CK and CK-MB activity)
do not aid in the early diagno i of AMI becau e they peak
too late and are not pecific for cardiac injury. In r cent
years, the earch for more en itive and pecific marker
of myocardial infarction ha brought about a new
generation of biochemical cardiac markers such a the
rna concentration assay of CK-MB, CK i oforms of the
i oenzyme CK-MB (MB2 / MB1 ratio), myoglobin, and
troponin I and T. In the following review article, the e
new biochemical markers will be examined.

I

MYO GLOBI
Myoglobin, an oxygen-binding cyto olic protein of
low molecular weight, is normally found in cardiac and
keletal mu de. When necro i of the e mu des occur ,
myoglobin is relea ed into the erum and can be detected
by radioimmunoa ay as early as 1-4 h after cell death
with a peak between 4-12 hour and a return to norma11824 h later6•7 • Woo concl uded that becau e myoglobin i an
early and en itive marker of necro is, it i valuabl for
early detection and exclusion of AMr. However, becau e
myoglobin i al o found in keletal mu cle, it ha poor
22
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pecificity, and can lead to many fal positive in patients
pre enting with keletal mu de trauma. Some re earcher
have sugge ted simultaneous mea urement of a keletal
mu de pecific marker, carbonic anhydra e Ill to re olve
thi limitation 10 .
Myoglobin ha been compared with CK-MB (activity
and rna ) in a number of tudies with inconsistent
finding . One tudy howed that the te t for CK-MB mass
was superior to that of myoglobin ''. However, Brogan
reported that myoglobin wa a more ensitive marker of
myocardial necro i than CK-MB (mass) during the first
3h of pre entation in the emergency department 12 • Thi
wa upported by Tucker, who howed that the en itivity
within 4 h of the on et of ymptoms was 78% for
myoglobin ver us 63% for CK-MB mass 13 • Finally, another
study howed no significant difference in the performance
of myoglobin compared to CK-MB rna 15 • Bakker
concluded that the be t predictor of AMI within 4 h after
on et of che t pain u ing WHO criteria were the
combination of ECG and myoglobin 14 •
Although myoglobin lacks p cificity, it early relea e
sugg~ t that it may
co~e an ~portant dia~o tic tool
for triage of che t pam patients m the future 11 • 3• 16 • This is
support d by the fact that orne ho pita! emergency
department have already in tituted the rou tine u e
myoglobin to aid in triaging patients presen ting wi th chest
pain (Ed. Note - LHSC-UC routinely measures myoglobin in

?

the emergency department).

CREATINE KINASE
Creatine kina e i a cardiac enzyme that is relea ed
into the blood when myocardial necro i occur . It con i ts
of three i oenzyme - CK-MM, CK-MB, and CK-BB, but it
i the CK-MB i oenzyme which i most widely u ed a a
biochemical marker for the diagno i of AMI 16• 17 •
Specifically, erial mea urement of CK and CK-MB are
u ed to diagnose myocardial cell damage and its
characteri tic ri e and fail in serial measurement i nearly
pathognomic for AMI. The a ay of CK-MB i oenzyme
and the calculation of it percentage relative to total CK i
the tandard of reference for the diagno i of AMI 1 •
Although the en itivity of CK-MB activity for AMI
diagnosis is very high, cardiac pecificity is comprorni ed
in patient with keletal mu cle tra um a, myocarditis,
chronic renal failure, cardiac urgery, a well a rare
ectopic production in patient with tumor 19 •
Thi problem ha led to effort to find more specific
marker for AMI. In earlier studie , electrophoretic or
chromatographic procedure were u ed to mea ure levels
of CK-MB. Thi led the way for the production of CK-MB
monoclonal antibodie , which were e sential in the
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development of rapid and co t-effective a ay procedure
u sing fully automated analyzer 5 . The development of
automated rna
a ay for CK-MB also led to
improvement in clinical en itivity and specificity and
turnaround time when com~ared to catalytical
determinations done in the pa t 11 • 7 • However, CK-MB i
not a perfect biochemical marker becau e -12 h may be
required after the on t of ymptoms for the test to be
elevated above normal and yield a high en itivity and
s pecificity 19 (although CK-MB has been noted to rise
earlier in orne patient with large infarcts). Another major
drawback is that CK-MB mas concentration ha been
hown to increase in the first 48-72 h with a return to
normal within 72 h after the on et of chest pain in patient
with known AMI. This leaves a relatively short diagnostic
window of only 2-3 day 22. 23 .
CK ISOFORMS OR SUBFORM
In addition to the three i oenzymes of CK, both CKMM and CK-MB can be metabolized by enzymatic
cleavage of the terminal ly ine amino acid from the "M"
ubunit. High-voltage electrophoresis technique can be
u ed to eparate and measure CK-MB and it two i oforms
- CK-MB 2 and CK-MB 1 in an attempt to improve CK-MB
ensitivity in the early tages of AMI. Bhayana found that
time to po itivity of both the rna s monoclonal a ay of
CK-MB and the i oform as ay were comparable, but noted
greater difficulty in performing and interpreting the
i oform assaf~. Hetland and Dickstein reported that the
i oform ratio was the mo t en itive test in the early 0-3 h
after the onset of chest pain and at adrnis ion to ho pital 15 •
In the following 3-5 h, no ignificant difference among the
ensitivitie of myoglobin, CK-MB i oform ratio and CKMB mass concentration wa found 15 • Puleo performed a
tudy comparing CK-MB activity with CK-MB i oform in
diagno ing AMI and ha recommended widespread CKMB i oform testing after finding reliable detection of AMI
within the first 6 hour after the onset of symptoms 25 .
However, no study comparing CK-MB rna with CK-MB
i oform has been done at the pre ent time.
There are some disadvantages to u ing CK-MB
i oform te ting. The time to perform isoform quantitation,
difficulty of the procedure, lack of a practical 24-hour tat
a ay, difficulty in interpretation, a well a high co t will
restrict the wide- pread implementation of this te t until
further development are made.
TROPONIN
The troponin complex play an important regulatory
role in the contraction of triated muscle. Thi complex
con i t of three protein ubunit -troponin C, which
bind to calcium and regulate contraction, troponin I,
which inhibits actomyo in A TPa e, and troponin T, which
bind the troponin complex to the tropomyo in strand 22 •
Troponin T and troponin I have amino acid sequences
that differ in skeletal and cardiac muscle at various
location 22 • Antibodie have been developed which
recognize the e cardiac- pecific equence , and it i the e
antibodies which form the ba i for cardiac troponin T
(cTnT) and cardiac troponin I (cTnl) immunoa ays 22 •
Troponin C cannot be utilized a a cardiac-specific marker
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b e cau e it amino acid es uence i identical in both
keletal and cardiac mu cle . CTnT differ from cTnl in
that the former i found in great amounts in the cyto olic
pool and has a longer life pan in the bloodstream. Cardiac
troponin T al o ha a lower ab olute cardiac pecificity
than cardiac troponin I 19 •
Quantitative as ay for both cTnT and cTni te t have
been hown to be more en itive and pecific than CK-MB
for the diagno i of AMI 19 • The enhanced pecificity allow
fo r more accurate diagno i of cardiac injury, especially
when keletal mu cle trauma is pre ent. As well, troponin
level remain elevated up to 7-14 days after an AMI 1 •
Thu , troponins can be mea ured long after myoglobin
and CK-MB have returned to normal levels. This broader
diagno tic window i advantageous in the minority of
p a tient who delay eeking medical care becau e of
equivocal ymptoms or other rea ons. However, the fact
that troponin can detect cardiac damage days after
infarction limit it ability to detect reinfarction.
A recent pro pecti ve tudy examined the use of a
rapid, qualitative troponin T and troponin I te t in patients
arriving to the emergency department with acute che t
pain . The result indicated that no patient was
inappropriately di charged when the troponin T bed ide
te twas routinely u ed 3 . Furthermore, when patient were
te ted 6 h after the on et of pain, 94% of patient with MI
and without ST-segment elevation had a po itive troponin
T te t, and 100% had a po itive troponin I te . Although
the diagno tic pecificity of the e tests were omewhat
low, the e figures are nonetheless significant.
Cardiac troponin T has been recognized as a highly
en itive and pecific a ay for AMI in a number of
tudie 23.26. Wu demonstrated in their tudy that cTnT wa
a ensitive marker of myocardial damage during the fir t 6
h, and wa comparable with the "gold standard" CK-MB
mas a ay. After thi time, the clinical sensitivity of cTnT
urpa ed that of CK-MB because of the prolonged relea e
of cTnT into the blood 23 . The same study, however
reported a diagno tic pecificity for cTnT of only 46%, a
lower pecificity than in earlier papers. Another tudy
found that cTnT to be more efficient than CK-MB in
determining and excluding AMI 17• Bakker found that the
diagno tic ensitivity of troponin T wa much better than
that of myoglobin, CK, and CK-MB activity 14 .
Cardiac troponin I, unlike CK-MB, is highly specific
for myocardial ti ue, and i not found in the blood of
healthy individuals 19• Troponin I ha been shown to have
great progno tic value. Antman examined the prognostic
value of cardiac troponin I in patients with either unstable
angina or non-Q-wave myocardial infarction. He found
that cTni i an independent ri k factor identifying patients
with un table angina or non-Q wave MI who are at
increa ed ri k of death 27 • The progno tic value of cTni wa
found to be greater in tho patients presenting more than
6 h after the onset of che t pain 27 . Antman a! o reported
that there wa a direct relationship between the amount of
cTni and mortality. That i , the hi:9her the level of cTni,
the greater the ri k of mortality-. The e findings are
ignificant in that cTni allow for the early identification of
patient at increa ed risk of death.
A di advantage for troponin use is that the assay for
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troponin requires a dedicated instrument that i not
widely available, as well as 90 minute for completion.
Furthermore, the cost of the reagents is much higher than
tho e for CK-MB. A relatively new rapid troponin test
a ay, which allows the determination of troponin levels
in whole blood at the patient's bedside shows some
promise. It can be performed con v eniently in the
emergency room or in laboratories, and can potentially be
used to aid in the triage of chest pain patients.
CONCLUSIO NS
Early diagnosis of myocardial infarction is of great
importance in decreasing morbidity and mortality,
especially with recent advances in thrombolytic therapy.
Although the ECG remains the standard test for
diagnosing AMI and initiating thrombolytic therapy, often
it is unable to guide the clinician to definitive
management. Therefore, alternative diagnostic methods
must be used, especially in those patients without ECG
changes or with unstable angina 3 . ew biochemical
markers have been shown to facilitate successful
intervention by identifying individuals at risk of sud den
death from an ischemic cardiac event. These markers are
not only useful in aiding in the diagnosis of AMI, but they
ma y also have valuable prognostic utility as w ell.
Specifically, cardiac troponin I is an important prognostic
marker of acute coronary syndromes or unstable angina.
This allows some patients to be discharged home rather
than being admitted to hospital resulting in enormous
savings to the health care system.
Myoglobin, CK-MB, and troponin have all been
shown to be valuable diagnostic tools for reliable and
rapid detection of patients with AMI Early recognition of
m yocardial cell death will allow appropriate triage of
patients with chest pain and the selection of therapeutic
strategie .
ACKNOWLED GMENTS
The author would like to thank Dr. Karl D. Theakston,
MD, for his input in preparing this paper. Dr. Theakston is
an emergency physician and Chair of the Qu a lity
Improvement Committee at the London Health Sciences
Centre, University Campus.
REFERE CES
1. GUSTO Angiographic lnve tigator . The effects of tissue plasminogen
activator, streptokinase, or botlr on coronary artery patency, ventricular
function , and survival after acute myocardial infarction . New England
jounral of Medicine, 1993;329:1615-1622.
2. Report of the joint International Society and Federation of Cardiology/World
Health Organization Task Force and Standardization of Clinical
omenclah~re.
omenclature and criteria for diagnosi of ischemic heart
disease. Circulation 1979; 59:607-8.
3. Gibler WB, Young GP, Hedges JR, et a/. Acute myocardial illfarction in
chest pain patients witlr non-diagnostic ECGs: serial CK-MB sampling in
the emergency department. Annals of Emergency Medicine, 1992;21:504-12.
4. McCarthy BD, Beshansky JR, D'Agostino RB, Selker HP. Missed diagnoses
of acute myocardial infarction in the emergency department: results from a
multicenter study. Annals of Emergency Medicine, 1993;22:579-82.
5. Mercer, DW. Role of cardiac markers in evaluation of u peeled myocardial
infarction. Postgraduate Medicine, 1997;102(5);113-7.
6. Cairns ]A, Missirlis E, Walker WHC. Usefulness of serial determinations of
myoglobin and creatine kinase in serum compared for assessment of acute
myocardial infarction. Clinical Oremistry, 1983;29(3):469-472.

24

7. Bhayana V, Co/10e S, Pellar TG, Jablon ky G, Henderson AR, Combination
(multiple) testing for myocardial infarction using myoglobin, creatine
kinase-2 (mass), and troponin T. Clinical Biochemistry, 1994;27(5):395-406.
8. Gibler WB, Runyon ]P, Levy RC, et a/. A rapid diagnostic and treatment
center for patients with drest pain in the emergency department . Annals of
Emergency Medicine, 1995;25:1-8.
9. Woo ], Lacbawan FL, Sunheimer R et a/. Is myoglobin useful in the
diagnosis of acute myocardial infarction in the emergency department
etti1rg? American journal of Clinical Pathology, 1995;103(6): 725-9.
10. Vuori ], Rasi S, Taka/a T, Vaananen K. D ual-label time resolved
fluroimmunoossay for simultaneou detection of myoglobin and carbonic
anhydrase 111 in serum. Clinical Clremistry 1991;37:2087-2092.
11 . Mair ], Artner-Dworzak E, Diensti A , et a/. Early detection of acute
myocardial infarction by measurement of rna s concentration of creatinekinase-MB. American journal of Cardiology, 1991;68:1545-50.
12. Brogan GX, Friedman S, McCuskey C, et a/. Evaluation of a new rapid
quantitative immunoassay for serum myoglobin versus CK-MB for ruling
out acute myocardial infarction in the emergency department . Annals of
Emergency Medicine, 1994;24:665-71.
13. Tucker ]F, Collins RA, Anderson A], et a/. Value of serial myoglobin levels
in the early diagnosis of patients admitted for acute myocardial infarction.
Annals of Emergency Medicine, 1994;24(4):704-708.
14. Bakker A], Koelemay M]W, Gorgels JPMC, eta/. Troponin T and myoglobin
at admission: value of early diagnosis of acute myocardial infarction .
European Heart Journal, 1994;15:45-53.
15. Hetland 0, Dickstein K. Cardiac markers in the early hours of acute
myocardial infarction: clinical perfomrance of creatine kinase, creatine kinase
MB isoenzyme (activity and moss concentration), creatine kinase MM and
MB subform ratios, myoglobin and cardiac troponin T. Scand J Clin Lab
Invest, 1996;56:701-13.
16. Adams JE Ul, Schedrtman KB, Landt Y, Ladenson JH, Jaffe AS. Comparable
detection of acute myocardial infarction by creatine kinase MB isoenzyme
and cardiac troponin I. Clinical Chemistry, 1994;40(7):1291-1295.
17. Apple FS. Acute myocardial infarction and coronary reperfusion : serum
cardiac markers for the 1990s. American Journal of Clinical Pathology,
1992;97:217-26.
18. Wu AHB, Gomet TG, Bretaudiere JP, Panfili PR. Comparison of enzyme
immunoassay and immru10inhibition for creati11e kinase MB in diagnosis of
acute myocardial infarction. Clinical Chemistry, 1985;31 :470-74.
19. Chan KM, Ladenson ]H, Pierce GF, Jaffe AS. Increased creatine kinase in tire
absence of acute myocardial infarction. Clinical Chemistry, 1986;32:204451 .
20. Adams JE, Bodo GS, Davilla-Roman VG et a/. Cardiac troponin 1: a marker
witlr lrigh specificity for cardiac injury. CirClllation, 1993;88:101-106.
21 . Alonsozana GL, Christenson RH. The case for cardiac troponin T: marker for
effective risk stratification of patients with acute cardiac ischemia. Clinical
Chemistry, 1996;42(5):803-808.
22. Mair J, Artner-Dworzak E, Leclrleitner P, et a/ . Cardiac troponin T in
diagnosis of awte myocardial infarction . Clinical Chemistry ,
1991;37(6):845-852.
23. Wu AHB, Valdes R, Apple FS, et a/. Cardiac troponin T immunoas say for
diagnosis of acute myocardial infarction . Clinical Chemis try,
1994;40(6):900-7.
24. Blrayana V, Cohoe S, Leung FY, Jablonsky G, Henderson AR Diagnostic
evaluation of creatine kinase-2 ma s and creatine kinase-3 and -2 isoform
ratios in early diagnosi of acute myocardial infarction. Clinical Chemistry,
1993;39:488-495.
25. Puleo PR, Meyer D, Wathen C, et a/. Use of rapid assay of subforms of
creatine kinase MB to diagnose or rule out acute myocardial infarction . ew
England Journal of Medicine, 1994;331:561-566.
26. Kallrs HA, Sclreffold T, Noe A , et a/. Diagnostic efficiency of troponin T
measurements in acute myocardial infarction. Circulation, 1991;83(3):11079.
27. Antman EM, Tanasijevic Mj, Tlrompson B, eta/. Cardiac-specific troponin I
levels to predict tire risk of mortality in patients witlr acute coronary

syndrome. New England journal of Medicine, 1996;335(18):1342-1349.

Q

- - - - - - - - - - - - - - - - - - - - - - - - U. W.O. Medical Journal 70 (1) 2000

Featur e

A rti c les

HYPERTENSION IN PREGNANCY:
AN UNUSUAL ETIOLOGYA CASE REPORT
By Andrea Lausman

H

ypertension pre enting in, or being aggravated by
pregnancy i a common occurrence. It is e timated
that 6-10% of nulliparous women 1 will have a
pregnancy complicated by hyperten ion. If a woman
develop hypertension during her pregnancy, most
clinicians initially a ume the diagno i of preclampsia or
pregnancy induced hypertension . It is important to
remember, however, that occasionally, the etiology of a
condition characteri tic or pecific to pregnancy may be
the re ult of some other pathology. A ca e is presented
below in which the etiology of hypertension occurring in
pregnancy was an aldo terone- ecreting adrenal adenoma.
Primary hyperaldosteronism is a rare, but welldocumented disea e occurring during pregnancy. There
have been less than twenty ca e reported, the majority of
which were due to an adrenal adenoma. Since surgery is
the treatment of choice for active adrenal tumour , it i
important to document the presence of a neopla m o that
it can be treated appropriately.

CASE REPORT
A 33 year old nulliparou woman pre ented to the
emergency department at 17+4 weeks gestation
complaining of acute onset of proximal leg weakness. This
came on quite uddenly after a three week hi tory of
migraine headache , vomiting, and migratory myalgias
involving her lower limb bilaterally including her right
hip, calf, left foot and calf. Significant past medical history
includes a two year hi tory of hyperten ion and
headache , for which she wa taking atenolol.
On phy ical examination, abnormal finding included
a blood pressure of 190 / 110, decreased power in the hip
flexor and dor iflexor at the ankles bilaterally, and
pitting edema bilaterally to the knees. The only abnormal
laboratory value wa a erum potas ium of 1.8 mmol / L
(ref. 3.3 -3.5 mmol / L}, and U wave present on the ECG.
There wa no proteinuria.
At this point, a tentative diagnosis of
h y peraldosteronism was made, and the patient was
admitted to ho pital. Her pota sium level was tabilized
using pota ium boluses and supplements. Inve tigations
in hospital included a renal ultrasound and serum
aldo terone level . o adrenal masse were een, but the
aldo terone level was found to be elevated at 2041pmol / L.
The blood pres ure was stabilized using atenolol, and the
patient was placed on potassium supplements.
At 29 week ge tation the patient had an abdominal
MR1 which demonstrated a 2.5 em adenoma on the left
ide. This confirmed the diagno is of an adrenal tumour; it
was concluded that the tumour was most likely secreting
aldo terone.
As she continued with her prenatal care, her blood

pre ure was found to be high, but stable at 170/100. Her
urine was normal until 33+{; weeks ge tation when she had
1+ protein on the urine dip tick. A 24 hour urine collection
for protein wa done, and wa found to be within the
normal range at 400mg / day. Subsequent urine dips were
normal, until her antenatal vi it at 36+5 weeks, when he
again had 1+ protein in her urine. Her blood pre sure was
becoming more volatile at this time as well. Since the
patient was non-compliant and refu ed admi sion to
ho pital for fetal-maternal monitoring, she was induced at
37 weeks gestation. She had a normal labour and vaginal
delivery which produced a healthy infant.
She has been sub equently referred to a surgeon for
the removal of her tumour.
DISCUSSION
Primary hyperaldosteronism, due mo t commonly to
adrenal adenoma or bilateral adrenal hyperplasia, is the
cau e for approximately 1-2% of hypertension found in
non-pregnant adult 2• It i more common in women (2:1},
and usually occurs between the age of 30 and 50 years.
However, there are les than twenty case report of
aldo terone ecreting adrenal adenoma presenting
during pregnancy.
The mo t common pre entation, in pregnancy as well
a non-pregnancy is ymptoms of fatigue, muscle
weakness, nocturia, lassitude and headaches. Blood
pressure i mildly to severely elevated. In pregnancy,
however, a complicating factor may be uperimpo ed
preclamp ia; it may present quite a challenge to
appropriately interpret all of the clinical findings.
The laboratory value which are abnormal include a
low erum pota ium, high serum aldo terone, low erum
renin, and often a metabolic alkalosis . A definitive
diagnosis can be made using CT scanning or MRI. Since
CT scanning during pregnancy is not desirable, and MR1
is an imaging modality which is becoming more
acce ible, these tumour may be identified using MRI. A
renal ultra ound i often the first radiologic procedure
done; however, as this ca e demonstrated, renal / adrenal
ultrasound may not be helpful in making the diagnosi .
In a non-pregnant adult, the treatment of an
aldo terone secreting adenoma is surgical re ection3 .
However, medical treatment, in the form of
pironolactone, an aldosterone antagonist, can be used to
stabilize blood pressure and treat hypokalemia 4 • Other
anti-hypertensives, such a calcium channel blockers and
ACE inhibitors have been tried with some success5•
Problems specific to the pregnant state ari e in the
treatment of hyperaldosteronism during pregnancy.
Spironolactone i known to have antiandrogenic effects in
humans; as well it can cause feminization of male rat
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fetu e when adrnini tered to pregnant rats, it i therefore
not recommended for u e during pregnancy 6 . Si nce
urgery i the definitive treatment, it i po ible that if the
di ea e wa medically unmanageable, using antih y perten ive and pota ium upplement , then
adrenalectom could be performed during pregnancf.
In conclu ion, hyperten ion during pregnancy i not
an uncommon clinical finding . Although the va t majority
of hypertensive, pregnant women will be diagno ed w ith
preclamp ia, it i important to remind one elf that the
differential diagno i of hyperten ion in pregnan y i
quite diver e, and the ca e that one i dealing with may
have a more unu ual etiology that expected.
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FACTOR V LEIDEN MUTATION AND
VENOUS THROMBOEMBOLISM
By Chantal Vaidyanath, BSc.

enou thrombo i i a multicau a] di ea e in which
genetic and acquired ri k factor interact in an
individual to determine whether or not a
thrombotic event will occur at a pecific point in time. 1
Recently, the Heart and E trogen Replacement Study
(HERS), the fir t major placebo-controlled clinical trial of
hormone replacement therapy (HRT) in the econdary
prevention of coronary heart di ea wa published. Over
an average of 4.1 years of follow-up, HRT failed to reduce
the overall rate of coronary heart di ea e event , but
increa ed thromboembolic events (a econdary outcome
mea ure) by 2. 9 time .2 In the pa t five year , advance in
the genetic of thrombo i have re ulted in the elucidation
of novel coagulation abnormalitie that predi po e to
venou thrombosi . In particular, a defect in the
hemo tatic pathway, called activated protein C (APC)
re i tance, and it underlying mutation, factor V Leiden,
were found to be common in the population (3 % to

V

7% ) . 3. 1 0. 1 ~ . 15, 1 6

They are a ociated with ubstantially higher ri k of
venou thromboemboli m among patient with a coexi tent predi po ition for thrombo i , uch a advanced
age, u e of oral contraceptive , hyperhomocy teinemia,
and deficiencie of protein C and protein S.3 To date, the
thromboembolic ri k in po tmenopausal women with the
factor V Leiden mutation ha not been tudied. The intent
of thi review is to e tabli h a rationale for research into
the po ible a ociation of venou thromboemboli m in
po tmenopau al e trogen u r and the APC re i tance
phenotype, or the factor V Leiden mutation.
Risk Factors for Venous Thrombosis
Ri k factor for venou thrombo i are different from
those for arterial thrombosi , and are cla ified into
genetic and acquired ri k factor . Many acquired ri k
factors for venous thrombosi have been identified, uch
a pregnancy, the puerperium, immobilization, urgery,
trauma, lupu anticoagulant, malignant di ea e, and
female hormone .1 For example, oral contraceptive u e i
a ociated with a four-fold ri k for venou thrombo i
above ba eline.6 The ri k of venou thromboemboli m
with hormone replacement therapy are also welle tabli hed. Prior to the HERS trial, re earcher in Britain
and in the United State found relative ri k estimate for
venou thromboemboli m in current u er of hormone
replacement therap y of 3.5 and 3.6, re pectively,
compared with non-u er or pa t-u ers.~.s
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The genetic ri k factor for venous thrombo is include
di order of the clotting y tern, uch a protein C and
protein S deficiencies, antithrombin III deficiency,
prothrombin 20210A, hyperhomocysteinemia and
re i tance to activated protein C. 1 Re i tance to APC wa
fir t de cribed in 1993 by Dahlback et al, and it ha been
ub equently hown that in the majority of ca e , it i
caused b what is now known a the factor V Leiden
mutation.
Activated Protein C Resistance and the Factor V Leiden
Mutation
In the protein C / protein S pathway of coagulation
inhibition, protein C i activa ted (ie becomes an active
protea e) when it bind to thrombomodulin, an
endothelial membrane protein .9 On a pho pholipid
urface, activated protein C, in the pre ence it cofactor,
protein S, and calcium ion , inhibits coagulation by
proteolytic cleavage of activated factor V and VIII, thu
mainly acting on the feed-back activation of the intrin ic
pathway of coagulation. 10·11 (Fig. I). The factor V Leiden
mutation involve a single adenine-for-guanine point
mutation in the gene encoding for coagulation factor V
which lead to the replacement of arginine by glutamine at
po ition 506. This po ition i one of the three cleavage ite
on factor V for APC, and thu the mutation cau e the
activated form of factor V (Va) to be degraded at a slower
rate than normal factor Va. 3 Thi results in the APC
re i tance phenotype, which cau e increa ed thrombin
forma tion and a lifelong hypercoagulable tate. 12 The
factor V Leiden mutation is inherited in an auto omal
dominant fa hion. 10 In 1997, the pre ence of a factor V
genetic component other than factor, the HR2 haplotype,
was de cribed in patient who did not have the VRSOOQ
mutation . This genetic component, i also able to
contribute to the APC re i tance phenotype in patient
with venous thromboemboli m. 13 The original factor VR506Q
mutation will be the focu of thi review, however,
becau e it has been tudied exten ively, and henceforth,
u e of the term " factor V Leiden mutation" will refer to
the VRSOOQ mutation.
Unlike other inherited defect of hemo tasis, such as
protein C and S deficiencie , and antithrombin III
deficiency, factor V Leiden mutation is common. The
carrier frequency of factor V Leiden mutation in healthy
control populations ranges from 3% to 7% in Europe and
the United States and may be as high a 15% in orne
elected group . 1 0 · 1 ~· 1 5 · 16 It is mo t prevalent in white
per ons (5.27%) and i notably uncommon in Asian and
African populations, a fact that may explain the decrea ed
ri k for venou thromboembolism in these groups. 17·1
Fact or V Leiden Mutation and Risk of Venous
Thromboembolism
In referral populations of patient with venou
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Figure I. The mechanism of action of the antithrombin III
and protein C natural anticoagulant pathways. The "a"
beside the roman numeral of a coagulation factor indicates
activation, and "i " indicates degradation, or inactivation.
PL = phospholipid.28
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thromboemboli m, factor V Leiden mutation is the mo t
common identifiable risk factor, with a prevalence of 11%
to 37%. 10•14•19.20.2 1 Heterozygous carrier of factor V Lei den
have a even-fold increa ed relative risk for venous
thromboembolism versu non-carriers. Homozygous
individuals have an alarming 80-fold increased relative
risk of thrombo is. Still, mo t homozygou patient do not
develop thrombosis until adulthood and may remain
symptom-free until old age.21 Thi is likely becau e venous
thrombo i a result of the interaction between concomitant
risk factors in a given individual. ' Homozygous
individuals al o experience their thrombo i at a much
younger age than heterozygous individuals (31 v . 44
year ) and non-carriers (46 year ).
lntere tingly, studies have found that the majority of
patient with venous thromboembolism who were
identified as homozygous for the factor V Leiden mutation
were women, and it was felt that these patients had
become ymptomatic due to their u e of oral
contraceptive .2 1.22 An earlier population-based ca econtrol tudy had in fact shown that women who carried
the factor V Leiden mutation and who used oral
contraceptive had a more than 30-fold increase risk of
thrombo is compared to women who did not hav either
ri k factor. 6 Clinical studies al o indicate that factor V
Leiden mutation is associated with increased risk for
venous thrombosis during pregnancy.23.24.25 Thus, there i
ample evidence of an interaction between genetic and
acquired risk factors for venous thrombosis, where in
combination they can produce an effect that exceeds the
sum of their separate effects.
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Future Directions
This year, the fir t report of an acquired activated
protein C resistance ~ the ~o ~enopaus_al period, wa
publi hed by MarcucCI et al. 1 Thi APC resistance wa not
a ociated with the factor V Leiden mutation, but with
high pia rna levels of factor VIII, which the author
propo e would require more APC for a comparable
anticoagulant effect. The author admit, however, that the
factor V genetic component marked by the HR2 haplotype
may be responsible . everthele s, thi finding in
postmenopausal women rai es the question of risk of
venou thromboembolism in users of hormone
replacement therapy who have APC resi tance or who are
carriers of either factor V genetic mutation. Given that the
ri k of venous thrombosis increa e with age, 26 and that
HRT in it elf increases thromboembolic risks, it i po ible
that po tmenopau al women with the factor V Leiden
mutation who are taking hormone replacement therapy
could be at a very high risk for venous thromboembolism.
The e are question which need to be addressed if
phy icians are to be informed abo ut the risks of
pre cribing hormone replacement therapy. At a simpler
level,even the effect of menopause on the incidence of
venous thrombosis is yet to be determined.
The study of APC resistance could become relevant in
explaining the increa ed ri k for venous thrombosi
associated with postmenopausal estrogens. Should we
screen for the presence of APC resistance in women
reque ting HRT? This que tion has been debated in the
literature concerning oral contraceptive use. Let us
consider the example of creening for factor V Leiden in
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women requesting oral contraception, assuming that all
fatal thromboembolic event are attributable to the factor
V Leiden mutation. Vandenbroucke et al estimated that
almo t half a million women would require screening to
identify the 20, 000 to 25,000 women who carry the
mutation and would be denied oral contraception, in
order to avoid one death per year. 27 The costs of such a
program would be formidable.
For now, physicians must be aware that a careful
empha is on thromboembolic events in both the per onal
and family histories of patient can often identify those
who might need to avoid oral contraception and hormone
replacement therapy, or who hould be anticoagulated if
they choose such treatments. But perhaps in patients
identified as being high risk, it is justified to investigate
the coagulation statu . Thi would identify patients for
w hom hormone replacement therapy need not be
withheld, and would differentiate them from patients who
hould only take hormone replacement therapy if they
take concomitant anticoagulant therapy. Thus screening
for APC re istance, particularly in high risk populations,
should be considered.
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HEART DISEASE IN WOMEN:
RESOLVING MISCONCEPTIONS
By Matthew A. Crystal

n the past decade there has been a strong drive to
discover the sex differences regarding heart disea e. 1
Many misconceptions have been corrected in the
literature; however, men, women and their physicians
alike are still not keeping abreast of new discoveries. From
a physician' s standpoint, educating one' s patients can be
one of the most effective means of preventive medicine.
Unfortunately, misconceptions still prevail, allowing
symptom recognition and lifestyle changes to become less
effective as time passe .
What are these misconceptions and what are the fa cts?
Heart di ease is now the number one killer of both men
and women in the United States and Canada. 1•2.3 It had
been believed for a long time that heart disea e only
affects older women who are post-menopau al. While it is
true that the effects of e trogen have a cardia-protective
function, this only delays the on et of di ea e. Studies
have shown that a woman's first pre entation to the health
care sy tern is between three and ten years later than men
on average, but the outcome for women are wor e after
having a myocardial infarction.4 The e patterns reinforce
the notion that women should be better educated about
their risks of heart disease.
Life tyle improvements and risk factor modifications
have been implemented aggressively with men, in order
to reduce their prevalence of heart di ea e. This same
aggressive preventive medicine should be used in
affecting the outcomes that women face . Although 41% of
all deaths in women are related to heart di ease, women
continue to believe that their major health ri k is breast
cancer. In the 1990 Ontario Health Survey, 81% of women
stated their most serious health concern to be br a t
cancer,5 when in reality the number of women who die
from heart disea e each year is almost a great as the
number of deaths in women from all cancer combined. 2
These misconceptions not only give women fa ! e
impressions about their general health, but their abili to
modify their risk factors is severely hindered a well .
As a member of the health care system, the phy ician's
role is to diagnose, treat and educate patients. Education is
an incredibly important factor in successfully
implementing preventive medicine protocols. When
people are empowered with knowledge they are more
likely to respond to ri k factor modification . Wher do
mo t women receive pertinent health information? Their
physicians. Herein lies another problem. A 1997 study in
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the Journal of Women's Health report that 59% of the
subjects who responded believed that their primary care
phy ician had inadequately coun eled them about heart
di ease. Ma ny women also felt that they were never
properly assessed for heart di ease risk factor .2
The e bia es have been propagated, hi torically, by
the exclusion and under-representation of women in
cardiova cular clinical trials. 6 As national regulations have
changed in the pa t decade, study populations ha ve
become more repre entative of the pa tient population
that are een each day. The e change have led to many
large scale re earch projects that will report their finding
on women's health in the early part of the 21st century.7
The goal of such projects is to correctly asse s the health
ri ks of women, while correctly documenting the sign
and ymptom with which they will pre ent.
What is known already? Gender difference have been
de cribed in clinical presentation and in ri k factor
profile . For example, re earch has shown that women
uffer from heart di ea e, with an average age of onset ten
years greater than that of men. Women are more likely,
however, to face a worse prognosi after a myocardial
infarction than men, and their prognosi following
urgical therapy for coronary artery di ease i al o wor e
than that for men. In terms of clinical pre entation, che t
pain in women is not as specific an indicator for heart
di ea e a is the ca e with men. This does not allow one to
di rni the po sibility of heart di ease. On the contrary, a
very careful history hould be elicited to ensure that the
number one killer of women i not overlooked, especially
becau e 50% of women with heart di ea e first pre ent
with angina.
Men and women do share a lot of symptoms and risk
factors, but in different ways and wi th a different
emphasi . Smoking i a strong predictor of heart disease in
both men and women, to the point that women who
moke lo e their protective e trogen advantage and are
ju t as likely to develop heart di ea e men of the same
age.1 Diabete is a prominent ri k factor for men and ha
been hown to be more o in women. In term of
cholesterol status, hypertriglyceridemia and low level of
HDL are more predictive than total chole terol status and
elevated LDL level ; the oppo ite i true for men. Another
modifiable risk factor which has been ignored to a large
extent in women i edentary lifestyle. Men tend to lead
more active lives than women, with an a tounding 83% of
women in a elf-reporting database being rated a
inactive. The e difference do exi t, but many of th e
strategie for modifying ri k are not different.
Re earch protocols have come a long way in the Ia t
ten yea r to actively report on women's health issue .
With re pect to heart di ea e, women have been shown to
have similar risk to men that sho uld not only be
recognized, but monitored and treated with pecial
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empha is on the gender differences that do exist. Women
have different needs than men, but the important thing to
remember is that every patient who visits a doctor has
their own pecial story, needs and risk factors. The most
important tool that we have still remains a good, detailed
hi tory. ever underestimate its usefulness.
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GLYCOPROTEIN lib/lila RECEPTOR
ANTAGONISTS: NOVEL ANTIPLATELET
AGENTS IN CARDIOVASCULAR
MEDICINE
By Tisha Joy, Meds 2001

oronary artery disease (CAD) is one of the leading
causes of death in developed countries . The
atherosclerotic plaques in CAD consist of two main
components: a fibrous cap and a lipid core. Disruption of
the fibrous cap leads to exposure of the underl y ing
components such as lipid, foam cells, and tissue fa ctor,
resulting in platelet aggregation and ultimately, thrombus
formation . This process of atherosclerotic plaque
disruption leading to platelet aggregation and formation
of associated thrombus defines the acute coronary
syndrome (ACS), a continuum of clinical manifestations
ranging from unstable angina to non Q-wave myocardial
infarction or Q-wave myocardial infarction.1 Platelets are,
thus, key players in the triggering of the a cute
manifestations of CAD.
Antiplatelet therapy, such as aspirin, has beco me
mainstay in both the primary and secondary prevention of
cardiovascular events. However, aspirin is a relati vely
weak antiplatelet agent since it is only able to prevent
thromboxane A2-dependent platelet aggregation without
an y inhibition of thromboxane A2-independent
aggregation. Circulating mediators for thromboxane A2independent platelet aggregation include adenos ine
diphosphate (ADP), thrombin, serotonin, and shear rate.2
In fact, more than a hundred different mechanism can
result in platelet activation. Yet, regardless of the pathway
chosen, all mechanisms lead eventually to a final common
pathwa y involving the platelet surface gl y copro tein
llb l illa receptor.
The glycoprotein llb I ma receptor, a member of the
integrin family, is the most abundant receptor on the
platelet surface. For platelet aggregation to occur, a
conform a tiona! change in the glycoprotein lib /I lia
receptor from the inactive to the active state must occur
before the receptor will bind to its primary liga nd,
fibrinogen . Fibrinogen causes platelet crosslink ing
necessary for aggregation by simultaneously binding to
the glycoprotein lib I lila receptors of two adja cent
platelets.3 Thus, since glycoprotein lib I Ilia receptors
comprise the final common pathway leading to platelet
aggregation, blocking these receptors via antagonists
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would be an effective means of pre venting platelet
aggregat ion, thrombus formation, and ultimatel y,
cardiovascular ischemic events.
Abciximab is one such glycoprotein llb I ma receptor
antagonist that is currently being investigated for clinical
use. It is a chimeric monoclonal an tibody Fab fragment
(c7E3) tha t binds w ith high avidity to the glycoprotein
lib /lila r eceptor as well as to th e " v$3 vi tronectin
receptor, which is invol v ed in smooth muscle cell
migration and proliferation.4 The fir t large-scale double
blind randomized control trial to investigate the potential
benefits of using abciximab to prevent cardiovascular
events was EPIC (Evaluation of 7E3 for the Prevention of
Ischemic Complications). This trial involved 2099 patients
undergoing high-risk atheroplasty or atherectomy. All
patients received a pirin as well as heparin. The patients
were then randoml y assigned to one of three treatment
arms: 1). abciximab bolu s + abciximab infusion; 2).
abciximab bolus + placebo infusion; or 3). placebo bolus +
placebo infusion. The treatment arm of abciximab bolus +
abcixim a b infusion demonstrated a significant 35%
reduction in the composite primary end point of death,
nonfatal myocardial infarction, refractory ischemia, or
urgent revascularization within 30 days, when compared
to the placebo group. Only a 10% reduction was noted in
the abciximab bolus group compar d to placebo. There
was, however, a two-fold increase in the risk of bleeding
complications and need for transfusions in the abciximab
bolus + abciximab infusion group compared to control.
Yet, the reduction in ischemic ev ents noted in th e
abciximab bolus + abciximab infu ion treatment arm
persisted at both 6 months and 3 years followup.s-7
The EPILOG (Evaluation in PTCA to Improve LongTerm Outcome with Abciximab Glycoprotein lib I Ilia
Blockage) trial was conducted next to determine whether
low-risk patients could also benefit from abciximab. The
trial wa prematurely terminated ince the abcixim ab
treatment group had a 57% reduction in the composite 30
day endpoint of death, myocardial infarction, or urgent
revascularization as compared to control (standard
heparin therapy). Interestingly, unlike the EPIC trial, there
was no increased risk of bleeding in the abciximab
treatment group . It was determined that the high e r
bleeding rate in the EPIC trial were due to the use of hi gh
do e adjuvant heparin therapy. Thus, the EPILOG tri al
demon trated two critical points : 1). The benefits o f
reductions in ischemic complication from abci xima b
treatment could be extended to low-risk patients; and 2).
The risk of bleeding complications could be decreased by
using only low do es of adjuvant heparin therapy.
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The ability of platelet glycoprotein Ilb I rna receptor
antagonists to not only prevent progre sion to myocardial
infarction in patients with unstable angina but al o avoid
myocardial infarction at the time of coronary intervention
wa fir t demonstrated in the CAPTURE (Chimeric 7E3
Antiplatelet Therapy in Unstable Angina Refractory to
Standard Therapy) trial. Patient were randomly assigned
to receive either abcixirnab or placebo infu ion prior to
angioplasty and continuing until 1 hour after the
procedure. The trial was terminated prematurely ince
there wa not only a 29% decrease in the compo ite 30 day
e ndpoint of death, m y ocardial infarction, or
reva cularization but al o a ubstantial 71% reduction in
th e progression to myocardial infarction prior to
percutaneous transluminal coronary angioplasty (PTCA).
The re ult of this trial, thu , showed that abiciximab
could a! o provide benefit for patients with unstable
angina not undergoing angioplasty.9
Ba ed on the results of the above trial , it eem s
rea onable to con ider the po ible application of
abciximab to the management of acute myocardial
infarction. Animal studie have demonstrated increa ed
thrombol y tic activity a well a prevention of earl y
reocclusion after reperfu ion with the admini tration of
glycoprotein Ilb / illa receptor antagoni ts.10•11 Pilot studie
w ith humans have indeed reported improved patency
rate of infarct-related artery v ia increa ed peed of
reperfusion, although only a small number of patients
were involved.12 Based on the e encouraging re ult , the
potential for using glycoprotein lib I Ilia receptor
antagoni t in the management of acute myocardial
infarction does certainly exist.
Abciximab i just one o f the many glycoprotein
Ilb I Ilia receptor antagonists being currently studied. The
y nthetic agents under inve tigation include lamifiban,
e ptifibatide (Integrilin), and tirofiban which, unlike
abciximab, are all specific for the glycoprotein Ilb / llla
r e ceptor alone . All four agent can onl y be u ed
parenterall y.~ Oral glycoprotein lib/lila receptor
antagoni t al o exi t, including ibrafiban, xemilofiban,
and lefradafiban. Trial with oral agents are currently
underwa y to determine efficacy and afety . Thu far,
tudie have reported consistent blockade of receptors
ranging from 50- 0% depending on the agent. However,
the e studies have noted an increa e in mucocutaneous
bleeding with the oral agent _1 3- ts Yet, the importance of
the oral agent lies in their potential use in both acute
ituations a well as in econdary prevention. Table 1 lists
orne of the po sible indications for the oral glycoprotein
Ilb I Ilia receptor antagonists.
Since the glycoprotein lib / Ilia receptor antagoni t act
a t the final common pathwa y required for platelet
aggregation, the e antagoni t offer everal important
advantages: 1) their effect on platelet aggregation will be
considerably more potent than any of the other available
antiplatelet agent ; 2) their efficacy can not be bypassed by
redundant pathways of platelet activation; and 3) the
on et of action of parenteral agent is nearl y
in tantaneous . 16 These advantages together with the
clinical trials supporting the u e of glycoprotein Ilb / illa
receptor antagonist to reduce i chemic complications
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Table 1 Potential Indications of Oral Inhibitors of Platelet
GPIIb/llla Membrane Receptor
Acute Indications
Percutaneous coronary interventions
Acute coronary syndromes
Unstable angina
Non Q-wave Ml
Ml with ST elevation
Secondary Prevention
Percutaneous coronary interventions
Acute coronary syndromes
Stroke
Prevention of acute events in patients with stable disease
Primary prevention in high-risk individuals
Control of atherothrombosis and progression of coronary
artery disease

explain the huge intere t currently in these antagonists as
a novel means for combatting the acute manifestations of
cardiova cular di ease, and in particular, as a possible
addition to the current therapy for the acute coronary
yndromes, including Q-wave myocardial infarction, non
Q-w ave myocardial infarction, and unstable angina.
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THE RATIONALE AND EVIDENCE
FOR THE USE OF BETA BLOCKERS
IN THE MANAGEMENT OF CHRONIC
HEART FAILURE
By Munir Boodhwani
Introduction
eart Failure i a major cau e of morbidity and
mortality in orth America. The incidence of heart
failure in the general population varies from 1 to 5
per 1000 per annum and can be as high as 40 per IOOO per
annum for people over the age of 75 year . The prevalence
ranges from 3 to 20 per 1000 for the general population
and can be a high a 130 p r 1000 in people over the age
of 65 year . 1 De pite the heavy burden of di ease, there i
no univer ally agreed upon definition of heart failure. The
diagno i is made clinically and therefore, there i no one
' gold standard' te t to confirm the diagno i .1 The primary
igns and symptom include hortne
of breath,
orthopnea, paroxy mal nocturnal dy pnea, fatigue ,
peripheral edema and elevated jugular venous pressure.
Thi article will briefly discus the medical management of
chronic heart failure focu ing on the role of beta blocker .

H

Medical Management of CHF
The medical management of chronic heart failure
(CHF) i a complex undertaking and typically involves the
use of multiple da e of drugs. The goals of treatment are
to reduce symptoms, decrea e the number of recurrent
ho pitalizations, and to improve urvival. 2
Diuretic are often the firs t line treatment for acute
exacerbations of heart failure . They work by reducing
excessive salt and water ret ntion and therefore, decreas
the preload which, in turn, re ults in a decrease in
ymptom from pulmonary and ystemic conge tion.
Although the impact of long-term diuretic u e on urvival
is difficult to evaluate, their ability to reduce symptom
ha made them one of the mainstays of heart failure
2
!re~t~ent. Angioten in Converting Enzyme (ACE)
inhibttor have made a igrlificant impact on heart failure
treatment and numerous Randomized Controlled Trial
(RCTs) have been conducted to evaluate their impact on
urvival. It ha been found that ACE inhibitor reduce
mortality by about 23% when compared to placebo. This
effect was hown to be con i tent aero all ew York
Heart A ociation (NYHA) cla e and all ACE inhibitor .4
Digoxin, a cardiac glyco ide which is commonl y
pre cribed in heart failure, has been shown to have no
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impact on mortality but doe decrease the risk of
hospitalization by approximately 30%.5 Additional drugs
u ed to treat heart failure include organic nitrates, calcium
channel blocker (e.g. Amlodipine), antiarrhythmics (e.g.
Amiodarone), Angiotensin II receptor blockers (e .g.
Lo artan), Spironolactone a well as Beta Blockers which
will be di cus ed below.
Rationale for Beta Blocker Use
The sympathetic nervou system has long been known
to play a sigrlificant role in the pathophy iology of heart
failure. When ventricular dy function lead to a decrea e
in cardiac output, there is a baroreceptor-mediated
increa e in sympathetic tone, which has several
con equence . ln the short term, it results in increa ed
m y ocardial contractility, tachycardia, arterial
va ocon triction with a con equent increa e in afterload,
and venoconstriction with a consequent increase in
preload. Long-term activation of these compensatory
mechanisms re ult in remodeling and hypertrophy of the
myocardium and al o leads to myocyte toxicity, apopto is,
and altered gene expression? orepinephrirle is known to
be directly toxic to myocardial cell , an effect mediated
through calcium overload and induction of apoptosis.6
Since the failing heart is dependent on this constant
y mpathetic drive, beta blockade wa thought to be
contraindicated in patients with heart failure. 6•7 However,
if beta blockers can be tolerated in the hort-term, then
they have been shown to have beneficial effects on
ventricular function likely due to reduced myocardial
toxicity. An up-regulation of P-receptor expre sion, which
occur in response to treatment with a beta blocker, is al o
as ociated with improved ventricular function?
Important Properties of Beta Blockers
Beta Blocker have certain important characteri tics
w hich can affect their efficacy and u efulness. They are
briefly described below:

•

Cardio selec tive v s. nonselec tive-PI receptors are
responsible for mo t of the cardiac effects of beta
blocker wherea P2 receptor are prevalent in
pulmonary ti sue. Therefore, cardioselectivity of beta
blockers is imply a mea ure of the ability of the drug
to more potently antagonize the PI receptor as
opposed to the P2 receptor. This is al o thought to be
the reason why cardioselective beta blockers are better
tolerated in a thmatic patients . Bucindolol,
propranolol, and carvedilol are examples of
nonselective beta blockers whereas bi oprolol and
metoprolol are example of cardioselective ones.
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Lipophilicity vs. hydrophilicity-The lipophilicity o f a
beta blocker allows it to penetrate the central nervous
system and therefore, potentially alter the vagal tone
which is already altered in heart failure.
In ve r e Agonism-Thi is a property by which an
antagonist may inactivate an unoccupied active state
receptor. An agent with a high degree of inv rse
agonism may have a greater degree of negative
inotropic and chronotropic effect.
!SA /Partial Agon ism-A beta blocker with this
property partially timulates the receptor while
blocking the effects of the ympathetic nervous sy tern
on the receptor.
Ancillary properties-Carvedilol has a very prominent
non-hemodynamic property i.e. antioxidant eff cts
which may play a role in heart failure possibly by
reducing apoptosi in myocardial tissue.9

Evidence for Beta Blocker Use
Although numerous RCTs have been conducted on
heart failure patients to evaluate the effects of beta
blockers on hemodynamic , exercise, and quality of life,
relatively few RCTs have measured the impact of beta
blockers on morbidity and mortality. The re ults of three
of the major trials, which involved a large number of
patients and used mortality as their primary endpoint, are
discu sed below.
In May 1996, The U.S. Carvedilol Heart Failure Study
Group published the results of a trial that involved 1094
patients and compared the effects of Carvedilol to plac bo.
This trial was discontinued early due to the obvio us
survival benefit in the Carvedilol group. The conclusions
were that the relative ri k reduction (RRR) in mortality
due to Carvedilol was 65% and there was also a relative
risk reduction of ho pitalization due to cardiovascular
cause of 27%. 10
The Cardiac Insufficiency Bi oprolol Study II (CIBIS11), published in January 1999, studied the effec t of
bisoprolol (a cardioselective beta blocker) on patient wi th
YHA cla s ill or class IV heart failure. This trial was also
stopped early and demonstrated a reduction in risk of
mortality of 32% as well as a significant decrease in the
number of sudden deaths (RRR- 44%) in patient on
bisoprolol vs. placebo. Although, the effect wa consi tent
across both NYHA classes, the greatest effect was een in
patients with NYHA class ill heart failure at ba eline.11
The third major trial i the most recent and w as
published in June 1999. Metoprolol CR / XL Randomized
Intervention Trial in Congestive Heart Failure (MERITHF) tudied 3991 patients with NYHA class II - IV heart
failure and was also stopped early due to a 34% reduction
in all-cause mortality. It also demonstrated a significant
decrease in su dden deaths (RRR- 41%) as well as deaths
from worsening heart failure (RRR - 49%), which w as
consistent across all NYHA classes.12
In addition, a meta-analysis of double-blinded,
placebo-controlled, randomized trials pu blished in May
1998 combined the results of 18 trials with a total of 3023
patients . The authors concluded that beta-blocka de
increased ejection fraction by an average of 29% a nd
reduced the risk of all-cause mortality by 32%. Another

36

important finding w a that there was no difference in
mortali ty risk reduction between cardioselective and
nonselective agent .13
Some Considerations
It i important to note a few characteristics pertaining
to the above trials, which help determine the criteria for
beta blocker use.
•

•
•

•

In all three major trials above, beta blocker we re
added to standard optimal therapy, which included
ACE inhibitor and diuretics. 1 0- 1 ~ In the Carvedilol
trial, the patients were also on digoxin. 10
All p atients included in these trials were stable in
terms of heart failure symptoms, regardless of the
NYHA class that they belonged to.10- 12
The mean age of the patients included in these trials
was between 58 and 63 w ith very few patients over
the age of 75 years. 1a- 12 A significant portion of patients
in the general population presenting with symptoms
of heart failure are over the age of 75 years.
Since ventricular fibrillation has been documented a
the m ajor cause of sudden d e ath in heart failure
patient , the ignificant decrease in sudden death in
th e beta-blocker group u ?zges ts a po s ibl e
antiarrhythmic effect of the drug.

Conclusion
Beta blocker ha ve been known for many year to
have beneficial effects in patients with coronary artery
di sea e . Their role in the treatment of heart failure,
however, has been unclear and they have traditiona lly
been av o ided for fear of exacerba tion of the di sea e
process. Recent s tudies have clearly demons trated a
survival benefit of long-term beta blocker u e in addition
to treatm nt with ACE inhibitors and diuretics in patient
with table symptoms of congestive heart failure . Thus,
beta blockers should be given to all patients with mild to
moderate heart fa ilure in the absence of a n y
contraindications ( evere asthma, etc). The role of beta
blockers in treating YHA class IV i till unclear, and
caution should be exercised when treating elderly patient
(age > 75) due to lack of clear evidence. Ongoing trials ar e
currently underway to determine the effects in these high
risk group a well a in patients with asymptomatic left
ventricular d ysfunction.
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PULSUS ALTERNANS: MECHANISM
AND CLINICAL SIGNIFICANCE
By Peter Kim

Definition and History
ut us alternan (mechanical alternans) i the
phenomenon of alternating trong and weak beat in
the pre ence of regular interval . It i not
ynonymou with electrical alternans which indicate a
beat to b at alternation in one or more component of the
electrocardiogram. Pul us alternan wa fir t described
under e perimental condition in a frog' heart over a
century ago by Ga kell. 1 The clinical de cription of pul u
alteman by Traube was made even earlier in 1872. Since
then, alternan ha been tudied both in human and
experim ntal animals and there ha been continuou
debate about its underl ying mechani m and clinical
igni£icance.

P

Proposed Mechanisms
The cia ic debate about the m ec hanism which
precipitate put u s alternan i taged between the
hemodynamic argument and the contractility argument.
The former employ the concept of alternating ventricular
filling and the latter, an intrin ic defect in the myocardium
a a po ible factor contributing to the alternating b at .
Recently, a cellular mechani m hypothe i ha emerged.
The Hemodynamic Argument

Thi argument i ba ed on the Frank-Starling
mechani m that involve the alternation of ventricular
filling (preload). 3 A ventricular premature contraction
(VPC) i one of the event that ha been ob erved to r ult
in pul u altemans. It has been propo ed that although the
VPC would have a relatively low ventricular filling, the
beat following it would have an enhanc d troke volume
and it y tole would la t longer. On the next beat, the
dia tole would be horter and a a con equence, the
re ulting lower ventricular end dia tolic volume would
re ult in lower troke volume and aortic pre ure. This
equence wo uld continue, manife ting a alternating
trong and weak pul e . Thi h y pothe is wa fi r t
ugge ted by Wenckebach~ in 1902. Although there have
been orne tudie in animals and humans that support
thi hypothe i , 5 recent studie again t the h ypothe i
have ugge ted that the hemodynamic abnormality i not
the primary mechani m underlying pul u altemans. 6
The Contractility Argument

Thi argument is based on the h y pothesis of an
intrin ic myocardial defect that inevitably re ult in an
aberrant contractility of the heart. Although it is till not
clear what the ba ic mechani m of the contra ctile
disturbance due to the myocardial defect is, a few studie
on pre ure-volume relationship in an intact h ea rt
demon trated alternation of contractility a the primary
mechani m underlying alternans. 7 In a tudy on i olated
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canine heart preparation , the lope of the end- ystolic
pre ure-volume relation hip wa ignificantly greater
than tho e of weak beat , ugge ting that alternating
contractile tate i the ource of alternans. 9 Alternation of
ventricular filling was ob erved in the e studies, but it wa
econdary to the changes in contractility.
The Cellular Argument

Alternation of the action potential duration and
alternation in intracellular Ca 2+ cycling to and from the
sarcoplasmic reticulum have been the ba i of thi
argument. It was been uggested that alternation of action
potential duration would re ult in mechanical alternans by
altering sa rcopla mic reticular Ca 2+ release. There are
everal line of evidence against this theory 10 and
mechanical alternan ha been a sociated with both
prolonged and hortened action potentials. 5 Although
action potential duration doe not eem to play a major
role in mechanical alternans, there i mounting evidence
for the role of calcium in alteman . Recent studie have
shown the phenomenon of " calcium alternan s"
~alternating large and mall calcium currents in regular
mterval ) a odated with mechanical alternan in i olated
animal ventricular mu cle. 10• 11 Thi ob ervation upport
the role of Ca 2 + as the principal factor in mechanical
alternan , and the favored view at present is that
mechanical alternan repre ent a Ca 2 + cycling
phenomenon involving the arcopla mic reticulum.
Clinical Relevance of Pulsus Altemans
Phy ica/ Examination

Puls us alternan i more readily recognized b y
phygmomanometry than by palpa tio n . As the blood
pre sure cuff i lowly deflated, only alternate bea ts are
heard for a number of millimetr of mercury below the
sy tolic level and then all beat are heard. When the
y tolic pre ure alternate by more than 20 mm Hg, it can
b detected by palpation of peripheral pulse (e pedally
the femoral) rather than the central pulse. 12 To avoid the
uperimpo ition of re piratory variation of the pul e,
palpation hould be carried out while the patient hold
hi / her breath in mid-expiration. Total alternan occurs
when the left ventricular ystolic pre sure is less than the
aortic pressure o that the aortic v alve fai ls to open,
re ulting in apparent halving of the pul e rate. Decrea e in
venous return by maneuvers uch as tilting the patient in
upright position and nitroglycerin administration may
e aggerate pulsu altemans and a i tin it detection.12
In the cour e of it detection, pulsus altemans should
be differentiated from conditions with similar examination
characteri tics. Pulsu bigeminu occurs when the cardiac
rhythm i bigeminal with the premature beats decrea ing
stroke volume and sy tolic peak pre sure. Put u
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paradoxu i a decrease in pulse amplitude of greater than
10 mm Hg during in piration and i cia ically een in
pericardia! tamponade, po ibly in con tricti ve
pericarditis (although le s commonly), and in obstructive
airway di ea e 13•15 • In this condition, when the patient has
a rapid re piratory rate which i equal to the heart rate,
the phy ical findings may re emble pulsu alteman .13•14
Clinical Significance of Pulsus Altemans
Pul u alternan occurs mo t commonly in heart
failure and implies left ventricular systolic dysfunction. It
is also found in patient with evere myocardial di ea e
due to aortic steno i , sy tem ic arterial hyperten ion,
coronary athero clero i , and dilated cardiomyopathy. 12
Thi i mo t likel y due to the contribution of these
conditions to ventricular d y function. Pul u alteman i
often a ociated with the third heart ound (53) and
disappears with treatment of heart failure . 12 It ha s
however, been de cribed in patient with normal hearts
for brief periods during or after an epi ode of
upraventricular tachycardi a . Therefo re, it should be
emphasized that the ab ence of pulsus alternans doe not
excl ude left ventricular sy s tolic d y function 3 and
conver ely, its pre ence is not nece sarily indicative of
di ea e. 12 everthele , pul u alternan i a helpful
finding in diagno ing and confirming the left ventricular
ys tolic dy function. Presence of pul s us alternans
indicate a poor progno is.13

Conclusion
The mechanism underlying the pul u alternans i yet
to be elucidated. However, it i generally accepted that
pul u alternans reflects event occurring at the cellular
level rather than the hemodynamic . The favored view at
pre ent is that pulsus alternan is associated with Ca 2+
cycli ng phenomenon invol v ing the arcoplasmic
reticulum. It i po sible that the initiation of the alternans
is at the cellular level, but it i further augmented and
perpetuated by al teration in the hemodynamic . In the
clinical etting, pulsus altemans i as ociated with heart
failure and severe myocardial di ea e. It may be helpful in
diagnosis of left ventricular dy function.
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HORMONE REPLACEMENT THERAPY
FOR CORONARY ARTERY DISEASE
IN THE DOMAIN OF EVIDENCE
BASED MEDICINE
By Mandy Schwartz and Natalie Gomperts

INTRODUCTION
he field of medicine is evolving such that clinical
practice is being guided by the findings of Evidence
Based Medicine. This allows physicians to provide
the best po sible treatment for their patients based on
vali d outcomes . The use of Hormone Replacement
Therap y (HRT) for the reduction of coronary artery
di ea e (CAD) in postmenopausal women is no exception.
With the abundant literature on the benefits of HRT, it is
s urprising to note the low rate of use of HRT in
po tmenopausal women who are at high risk for CAD or
have existing disea e. This article postulates reasons for
current prescribing practices and patient compliance
regarding HRT by examining the current information
available to patients and their doctors.

T

CORONARY ARTERY DISEASE IN WOMEN
In Canada, coronary artery disease (CAD) is cited as
being the leading cause of mortality. In women, deaths
due to coronary artery disea e outweigh the number of
deaths due to cancer and is econd only to bone and joint
disea e in limiting daily activities and decreasing the
autonomy of affected women.1 Overall CAD incidence is
higher in men than in pre-menopausal women. However,
after the menopause, the incidence in women increases to
rate equivalent to men, sugge ting the protective role of
e trogen in women. A SO year old woman has a 46%
lifetime probability of developing CAD and a 31% chance
of dying from heart disease.2
THE BENE FI T S O F HOR M O NE REP LA CEM ENT
THERAPY
Over the past 20 year more than 30 epidemiological
tudie on hormone supplement and CAD have been
carried out. The e studie provide evidence of the lower
morbidity and mortality from coronary artery d i ea e
amo ng u ers of HRT than among non-users. 3
Observational studies comprise the majority of this
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literature. These studies demonstrate the risk of coronary
artery disease in HRT u ers as being 30-50% that of nonusers.4 The relative risk among users compared with nonu ers of HRT is 0.55-0.65 from meta-analyses.4 In terms of
secondary prevention of CAD, HRT users have been
shown to have had 84% fewer cardiac events than nonusers of HRT.4 Mechanisms of action proposed by these
studies include the improvement of endothelial function,
alteration of lipid profiles with a reduction in LDL
cholesterol and increase in HDL cholesterol, and reduced
insulin resistance . 1•5 Guidelines referring to the
cardioprotective effects of HRT have been published by
the American College of Physicians and the Society of
Obstetricians and Gynaecologists of Canada . These
guidelines recommend that "women who have coronary
artery disease or who are at risk of coronary artery disease
are likely to benefit from hormone therapy" .1• 2
USE OF H ORMONE REPLACEMENT THERAPY
Regardless of the biological and epidemiological
evidence, as well as published guidelines supporting the
benefits of prescribing HRT to those at risk for or who
already have CAD, HRT use remains low. 4 An American
longitudinal study of 2,500 women, showed that the
overall rate of use was only 12.3%.6 Further, a recent study
by Wise et al proposed that HRT u e would be higher in a
population of postmenopausal women who presented
wi th CAD to an academic cardiology clinic in Toronto
between January 1996 and August 1997. These authors
based their hypothesis on the current guidelines and
literature that supported HRT use for CAD. It was further
thought that women at higher risk for CAD would be
more likely to use HRT if informed about its potential
benefits.6 The results of thi tudy revealed that only 13%
of women who had CAD were currently using HRT, while
only 22% of those at high ri k for CAD were current
users. 6
REAS O N S FOR LO W R ATE OF HORMO E
REPLACEMENT THERAPY USE
In light of the evident cardioprotective benefit of
HRT, why does use remain low? Firstly, the perceived
threat of brea t cancer pla ys a significant role in
determining whether a woman feels confident about
star ting therap y, regardle s of literature finding .2
Secondly, women may al o worry about the side effects of
HRT such as irregular bleeding, weight gain and
symptoms of premenstrual syndrome? These factor not
only deter the start of HRT but may also contribute to
early ce ation of therapy.
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Thirdly, due to the nature of CAD and its modifiable
ri k factor , phy icians may not con ider the role of HRT
in patient management. The main mechani m of HRT a a
cardioprotective agent i it effect on erum lipid level .
Phy ician may bias their treatment of abnormal lipid
level towards the u e of lipid lowering af ents, proven
effective by randomized control trials . A well the
recommended guidelines are unclear as to do ing
regimen , pretreatment inve tigations, follow up and
duration of therapy. Thi may lead to phy ician confu ion
regarding when to pre cribe, how long to pre cribe for,
and whom to pre cribe HRT therapy to. La tly, in thi era
of evidence based medicine, the greate t po ible reason
for low pre cribing practice of HRT i that the evidence
upporting the use of therapy i not robust. 9 Tho e tudies
advocating a reduction in mortality and morbidity of CAD
in u er are ba ed on ob ervational data with inherent
methodological flaws .9
LIM ITATIO NS O F OBSERVATIONAL STUD IES
With the limitations of ob ervational tudies, the
cardioprotective finding of HRT may be mi lead ing.
Many participants taking part in the e tudie initiated
hormone therapy to reduce menopausal ymptoms, and
prevent o teoporotic fracture , rather than to reduce their
ri k of CAD.7 The e participant tended to be leaner, more
health conscious and from higher socio-economic
backgrounds than non u er of HRT, thus indicating a
election bia in these tudie .7 Due to the e factors,
occurrence of CAD would be le s likely within the tudied
population. 10 As such, the healthy u er effect may have
bia ed the re ults in favour of a cardioprotective effect of
HRT? Furthermore, women who were prone to adver e
outcome , uch as a cardiac event de pite u e of HRT,
were more likely to have di continued therapy. This could
lead to an increa ed prevalence of urvivors participating
in the ob ervational tudie 10 • Due to the controver ial
nature of the protective finding of HRT, and in the r aim
of evidence-ba ed medicine, mo t phy ician may only
feel confident in prescribing therapy in light of the
outcome of Randomized Control Trials (RCT).
HRT AND RANDOMIZED CO NTROL TRIALS
Currently, two orth American randomized trial are
available for consideration. It is hoped that these
e perimental tudie will help to re olve quest ions
regarding the effect of HRT on cardiova cular ri k. The
fir t, the Heart and Estrogen I Proge tin Replacement
Study (HERS) examined econdary prevention of heart
di ea e in postmenopau al women. 10 The HERS t rial
randomized 2,763 po tmenopausal women with exi ting
heart di ease to either an e trogen and proge tin
intervention or to a placebo group. The e women were
followed for an average of 4.1 year with main outcome
mea ure including the occurrence of non-fatal MI or
CHD death . Secondary outcome of un table angina,
coronary revascularization, conge tive heart failure,
re u citated cardiac arre t, troke or tran ient i che mic
attack and peripheral arterial di ea e were a! o included.
Re ult of the tudy were worrisome in that they howed
no overall significant difference between the treatment
and placebo groups for primar y or econdary
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cardio a cular outcome . 1 Further, the trial found a
pattern of early increase in the risk of CAD event,
although a slight improvement wa noted at the four year
follow-up . 10 This improvement uggests that follow-up
over a longer period of time might reveal a more
ignificant outcome. 10 Unfortunately the trial did not
extend it follow-up period o evidence of this effect i not
available. Based on the e finding , the trial doe not
recommend HRT for the econdary prevention of CAD,
although, it recommend that women already receiving
treatment should continue on HRT, due to the potentially
favorable long term effect . 1° Finally, the trial did not
evaluate the effects of unoppo ed estrogen therapy for
women having undergone hy terectomies, nor did HERS
evaluat the cardioprotective b nefit of hormone therapy
for women at high ri k for CA D . 10 Thus, the
recommendations made by HERS cannot be extrapolated
to the cohorts and should be u ed with caution . The
econd tudy, the Women ' Health Initiative (WHI)
enrolled 27,500 women in March of 1993 and will not be
completed until 2005.'-7 The tudy will evaluate the effect
of HRT on women without exi ting CAD. The trial will
include both women who have undergone a hysterectomy
and are receiving unoppo ed estr ogen therapy and
women with an intact uteru receiving combined estrogen
and proge tin therapy. 10 Re ult of this study will
hopefully re olve some of the i ues rai ed by the HERS
trial.
CONCLUSIONS
With the advent of evidence-based medicine,
phy icians must wade through conflicting da ta regarding
the prevention of CAD when considering prescribing
hormone therapy for their patient . Alth ough the gold
tandard i the Randomized Control Trial, HERS remain
elu ive in providing coherent prescribing practice for
women at high ri k of CAD. Due to the limitation of
HERS, publication of comprehen ive guideline will have
to wait for the new millennium, when results of further
RCTs are available.
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HEART

DISEASE

AND

GENETICS
By Cecilia Kerner

Introduction
eart disease is the most common cause of mortality
and morbidity in orth America. Due to the large
numbers of people affected, there ha v e b een
substantial resources directed in finding the causes and
possible cures for various heart conditions. Through out
this research, many risk factors such as h y pertension,
smoking, obesity and diabetes have been elucida ted .
Family history of cardiac disease is also a very important
factor used to identify patients who may be at r isk .
However, until molecular techniques became available,
the genetics of how heart disease is passed down within
families has been poorly understood. Current technology
has now allowed for a search of common varia n ces
(polymorphisms) and mutations of genes related to heart
disease. So far, several mutations of candidate genes for
different cardiac problems have been identified within
certain families. More research is still needed to determine
how these mutations may cause disease and how to
determine the prognosis of severity for a specific
mutation. Heart disease is a complex illness and it must be
understood that there will never be one responsible gene.
The purpose then is to have a bank of responsible genes
that can be used to screen individuals early in life in order
to implement good lifestyle habits and to monitor those
with the genes carefully . The discovery of these genes
along with the identification of other risk factors will help
in gauging an individual's risk and play an important role
in preventive medicine.

H

Familial Hypertrophic Cardiomyopathy (FHC)
FHC is an autosomal dominant disease that affects
two out of one thousand individuals 1• It causes an increase
in myocardial mass and myofibrillar disarray resulting in
fibrosis , abnormally small coronary vessels and
arrhythrnias 1 • Those who suffer are at a higher risk for
sudden and premature cardiac death . There have been
several mutations found in contractile proteins, a
tropomyosin, troponin T and cardiac myosin binding
protein C within families who have FHC 1 • Over fifty
mutations have already been identified most of which
exhibited a defect in their organization within cells 1• An
example would be a mutation found in a tropomyosin,
which is a component of muscle thin filaments an d is
encoded on chromosome 15 . The mutation involves a
substitution of a negatively charged glutamic acid by a
neutral glycine near the calcium binding domain 2 • The
resulting protein is believed to disrupt assembly and
function of the sarcomere structure2 . Heterozygotes of

ABOUT THE AUTHOR
Cecilia Kerner is a second-year medical student at the
University of Western who previously completed a BSc.
Honours in Biology/Biotechnology at the University of
Ottawa.
44

m y osin mutations are not protected because when
mixtures of normal and mutant myosins were created an
overall decrease in motility and activity occurred 1• It is
believed that the severity of FHC among families depends
on the type of mutation. Mutations that alter the amino
acid and occur at actin-myosin junctions or at the essential
light chain binding domain have a poorer prognosis 1 •
Those with mutations where the charge of the amino acid
remains the same have been shown to have a higher life
expectan~. In studies of large unrelated families sharing
the same mutation an association between a specific
genotype and survival rate have been shown3 . However,
there is still a range on severity observed within related
individuals which confirms that this disease has other
factors involved.
Coronary Heart Disease (CHD )
Coronary heart disease is usually due to
athero s clerosis in the ep icardial coronary arteries
occluding the arterial lumen and limiting blood flow
feeding the heart. When the supply of oxygen cannot meet
the myocardial demand due to stenosis, ischemia occurs
leading to angina pectoris or myocardial infarction.
Family history is a serious risk factor for CHD and many
genes are believed to be involved. Since CHD can be
combated with drugs or lifestyle changes, screening may
become important in both prevention and treatment. It is
believed that the genotype may influence CHD risk by
interacting with other risk factors such as cholesterol
levels and blood pressure 4 • There are several candidate
genes that encode proteins related to known risk factors;
not all of these genes are mutations but instead are a
common variant of a gene. Apolipoprotein E for example
has three common polymorphisms, E2, E3 and E4, which
influence plasma lipid concentrations4 • It is a structural
component of circulating chylomicrons, VLDL and HDL
and affects the fasting plasma lipid levels5• E4 produces
cholesterol levels higher than average while E2 produced
lower levels and may in fact protect individuals from
coronary heart disease.
Angiotensin converting enzyme (ACE) converts
angiotensin I into the angiotensin IT, a vasoconstrictor that
may promote vascular smooth muscle growth. It also
degrade s bradykinin, a vasodilator and inducer of
endothelial factors 5 . This implies that concentration itself
may contribute to vascular tone, which is critical for
healthy coronary arteries. ACE concentrations are stable
within an individual and appears to be unaffected by
environmental factors suggesting that it must be
genetically determined 6 • There are two known alleles:
ACE I (insertion) and ACED (deletion). As Table 1 shows
ACED has the highest ACE concentration; its frequen~ is
found to be higher for patients with angina and MI . A
meta-analysis of fifteen studies has also correlated ACED
with an increased risk of MI4 •
Gene products involved in endothelial functions such
as fibrinogen, coagulation factors and PAl Bl have been
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Table 1: ACE genotype versus ACE serum levels
Genotype

ACE serum levels

Homozygous ACE Ill

299 +1- 49Jlg/L

Heterozygous ACE VD

393 +1- 67Jlg/L

Homozygous ACE DID

494 +1- 88 Jlg/L

implicated in CHD. They have been studied becau ether
are all involved in plaque formation and plaque rupture .
Candidate gene include tho e that determine adhe ion of
monocytes, expression of va oactive peptide and
va cular proliferation. However, few mutations have been
found which cau e abnormal protein tructure and it i
now believed that it i a mutation in the regulatory
regions of the genes which i re ponsible. Such a case has
been found in equence of the promoter of PAI-l that
cau e an alteration in transcrirtion cau ing an increa e in
athero clero i and thrombo is 7 .
Homocysteine levels are al o involved in endothelial
dy function by inducing cytotoxic peroxide formation and
inhibiting the va odilator nitric oxide ( 0), which can
lead to CHD. A commonly found C to T substitution in
MTHFR, an enzyme that convert homocysteine to
methionine, has a reduced activity and is more un table
than the wild-type protein .
Gen e-Gene Interactions
It is well known that activity for one gene i not
isolated but is influenced b y other genes and their
products. Since CHD is a very complicated di ea e it i
likely that there are many gene interactions contributing to
the di ea e . An example wa found in a well known
study, ECTM (Etude ca -temoin de l' infactus du mycarde),
which involved the ACE gene and the angiotensin II type
1 receptor 9 • An A to C ub titution in thi receptor i
as ociated with high blood pre ure and tho e who have
both this mutation along with the ACE D allele are at an
even higher risk for heart di ea e 9 •
Genetics and Environment
Heart di ea e has both a genetic and environmental
component. Both of these factor do not work alone but
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influence one another in determining an individual'
predispo ition for the illne s. It has been di covered that
equence within promoter region of genes that help
determine chole terol levels ( uch a LPL, apo A-1 and
apo C-ill) bind to fatty acids 7. This might imply that diet
not only acts in a d irect manner toward influencing
cholesterol level but also indirectly by affecting the
expre sion of involved protein . Screening for the e
particular sequences ma y help to encourage diet
modifications.
Genetics and D rug Therapy
Individuals re pond differently to drugs. Some people
have more positive re ults than other even if they are
imilar in age, gender and body ize. Again, genetic
variation may be the cau e for these differences. Such an
example exi t with polymorphi ms in the apo E gene and
the respon e to anti -hyperlipidemic drug . It ha been
found that men with the apo E4 allele do not respond as
well to lovastatin, an inhibitor of HMG-CoA reductase,
than men with the E2 or E3 allele 2• Probucol, another
chole terol-altering drug, however eem to be much
more effective for E4 genotype 4 • The mechani m involved
in genetic-drug interaction is still unclear but the
implication for this knowledge are very useful. By
knowing which drug are mo t efficient for a genotype,
we will be able to de ign drug therapie for each
individual.
Conclusion
We are just beginning to find polymorphism and
mutations of gene associated with heart disea e and there
are probably many more to be discovered. As the Human
Genome Project i coming to an end, the earch for these
gene may become more successful. Even with the
knowledge of re pon ible genes, there are everal
considerations to be made. Heart di ea e is very complex
and finding ab olute markers is not probable. Interactions
between lifestyle and environment differ between
population, which means that a particular genotype will
not imply equal risk. We will al o have to take the
genotype of a per on into the context of other known risk
factors to determine both progno i and treatment .
Screening individuals at risk ha been expensive and has

Table 2: Summary of candidate genes linked to heart disease
Gene product

Mutation

Effect

Disease

AC~

ACED allele

Increase in ACE concentration
affecting blood pressure and
vascular homeostasis

CHD

Apo Es

E4 allele

Increase of total cholesterol

CHD

PAl-1 7

Mutation in promoter

Decrease in fibrolytic function

CHD

Cto T substitution at nucleotide 677

Hyperhomocystein-emia

CHD

MTHFFf
AGTFR1

9

A to Csubstitution

Hypertension

CHD

2

15 known missense mutations

Abnormal sarcomere

Cardiomyopathy

a and~ myosin heavy chain 11

Formation of a/~ hybrid
(duplication and recombination)

Unknown

Cardiomyopathy

~-myosin heavy chain 12

Substitution of arginine for glutamine

Increase in frequency of sudden death

Cardiomyopathy

a tropomyosin
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had limited accessibility but now automated assay kits
which can identify mutations have been created . They
have shown to be sensitive, specific, reproducible and fast
with only a few drops of blood or saliva needed 10. A the
expense drops, it will allow both the patient and doctor to
treat or change poor habits early in life to improve health
and to reduce illness. Aside from lifestyle and drug
treatments, gene therapy, which is only at an experimental
stage may turn into reality. For example, a transfer of
vascular endothelial growth factors to sites of aiterial
damage, is being delivered during angioplasty to
encourage collateral development 4 • Although w ide
screening raises both ethical and legal issues such as
insurance policies, the overall benefit of identifying p ople
at risk for diseases where treatments exist to prevent a
premature death is very significant.
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CORONARY ARTERY BYPASS
GRAFTING: THE BASICS
By Shafie Fazel
Introduction
oronary artery disea e (CAD) continue to be the
leading cau e of morbidity and mortality in the
western world. Every year, 1.5 million people suffer
a myocardial infarction in the United State . Over onethird of these patients will die . A the bab y- boom
generation ages, the prevalence, incidence, total mortality,
and economic co t of CAD will increa e ignificantly_l

C

Anatomy, physiology and pathophysiology
The right and left coronary arteries arise from the
inu e of va l alva in the ascending aorta. The right
coronary artery (RCA) pa e in the right atrioventricular
groove, gives ri e to several acute marginal (AM)
branches, and in 90% of patient , ends as the po terior
de cending artery (PDA) in the posterior interventricular
groove (right coronary dominance). Thu , the main upply
of the right ide of the heart, including the SA and the A V
nodes, and the posterior fa cicle of the left bundle branch,
i the RCA. The left main coronary artery gives rise to the
left anterior descending artery (LAD) and the left
circumflex artery. LAD and it diagonal branche upply
the anterior and apical aspect of the left ventricle. The
perforating branches supply the interventricular eptum
including the right bundle branch and the anterior fascicle
of the left bundle branch. The LAD is a crucial coronary
artery in that it supplies the major portion of the left
ventricle. The circumflex artery proceeds laterally and
po teriorly around the left atrioventricular groove, giving
ri e to everal obtu e marginal (OM) branche . It supplies
the po tero-lateral and po terior aspect of the left
ventricle. In 10% of people, the circumflex artery provides
the posterior de cending coronary arte:1 (left coronary
dominance) and thus the AV node a well.
Coronary blood flow normally approximates 1 mL per
gram of myocardium per minute and delivers 0.1 mL of
oxygen per gram per minute to the heart. The extraction of
oxygen in the average coronary bed is 75% and may
increase to 100% in periods of stress. Coronary flow occurs
primarily during dia tole, and i a function of the
difference between sy temic diastolic pressure (in the
proximal aorta) and left ventricular end diastolic pre ure.
Coronary arterie po es ignificant va odilatory reserve,
allowing a three to six-fold drop in the coronary artery
re istance in periods of need.3
Athero clerotic di ea e of the coronary arteries will
even tually lead to an imbalance of oxygen supply and
demand that prevents adequate perfusion of the
myocardial tissue. The re ulting i chemia may progre to
infarction of the cardiac muscle in the distribution of the
respective coronary artery. Chronic arterial insufficiency
re ults in progressive dilatation of the left ventricle
ub equent to accumulation of minor infarctions leading

to conge tive heart failure (CHF) econdary to y tolic
dy function . The equelae of acute myocardial infarction
fall into two categorie : i) CHF due to pump failure or a
mechanical complication, uch a ventricular epta1 defect,
mitral regurgitation due to papillary muscle dysfunction,
left ventricular rupture, and cardiac tamponade; and ii)
life-threatening ventricular dy rhythmias or heart-blocks .~
Management
The management of coronary artery di ease (CAD)
may be divided into three progressive stages: i) life-style
modifications, ii) medical management, and iii) invasive
management. Life- tyle modifications include exerci e,
diet, and environmental modifications. Medical
management of CAD includes anti-angina medications
uch a beta-blocker , calcium channel blockers, ACE
inhibitors, and anti-platelet agents particularly aspirin.
Risk factor management uch as blood pre sure control in
hyperten ive patient , cholesterol control in
hyperlipidemic patients, and gluco e control in diabetic
patients are an integral part of the medical therapy for
CAD patient . The inva ive management of CAD, in
patients refractory to medical management, includes two
different approaches : i) percutaneou transluminal
coronary angioplasty (PTCA) and I or stenting, and ii)
direct reva cularization of the coronary arteries using
veno us and arterial conduit : coronary artery bypass
grafting (CABG)Y
Patient for whom an invasive intervention is
indicated fall into three categories. Fir t category includes
patients in whom angina refractory to medical
management is pre ent. Second category includes patients
in whom the extent of CAD, the ventricular function, and
the degree of inducible ischemia on stress testing are such
that surgery ma y improve survival. In this category,
CABG is indicated for patients with left main stenosis
greater than 50 %, three vessel di ease with ejection
fraction of le than 50%, three ve el disea e with ejection
fraction greater than 50% and significant i chemia, and
one and two ve sel di ea e with extensive myocardial
involvement with le ions not amenable to PTCA. Third
category include patients in whom CAD is pre ent
concomitantly with other conditions for which open-heart
urgery i indicated, such as evere aortic stenosi . In
general, PTCA and I or stenting is re erved for patients
with imple ingle-vessel di ease, or uncomplicated
multives el di ea e, providing that the lesions are distinct,
and not diffuse. 5
Surgical technique of CABG
Conventional surgical revascularization of the heart
involves five step : i) median temotomy and appropriate
di section through pericardium, ii) administration of
heparin, e tablishment of cardiopulmonary bypass (CPB},
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and inducing cardioplegic arrest, iii) anastomosis of
aphenous vein grafts (SVG), left internal mammary
(LIMA), inferior epigastric, gastroepiploic, and/ or radial
artery graft , 6 iv ) termination of CPB, and v) wound
clos ure . Establishment of CPB involves right-s ided
cannulation through the right atrium, and left sided
cannulation through the proximal aorta. Thus, the venous
retun:'- to the right atrium is drained into the heart-lung
machine,_ and after membrane oxygenation, is pumped to
the proxrmal aorta, distal to ite of application of a cro s
clamp . High-potassium cardioplegic solution,
administered to achieve arrest of the heart, is infused
proximal to the cross damp, through a small cannula in
pa~ents no~ suffering from aortic regurgitation (AR). In
patients with AR, retrograde cardioplegic infusion is
establish~d ~hrough cannulation of the coronary sinus.
The temunation of CPB, after the proximal ana tomo is of
!he bypass grafts to the proximal aorta is comple ted,
mvo~ve~ removing the aortic cross clamp, and weaning
~e eJec~g hea:t from the CPB machine by decreasing the
nght atrial dramage to the heart-lung machine. Once the
heart is able to sustain adequate systemic pre sure and
cardi~c ~utput, the C~B machine is turned off, circulating
heparm IS reversed W1th protamine, and the cannulae are
removed.2
CABG: Outcome, morbidity and mortality
Coronary b y pass grafting has been how n to
significantly improve anginal symptoms in over 90% of
patients. Likewise the incidence of myocardial infarction is
redu~ed . Succe ful ~evascularization improves resting left
ventricular wall motion and enhances exerd e ventricular
performance. Most importantly, revascularization of the
heart is demonstrated to significantly improve survi al in
patients with CAD . The greatest benefit is e vident in
patients with severe, multivessel CAD?
Oper~tive mortality ha been steadil y d e crea ing.
Even dunng the 1990's operative mortality decrea e d
~arthe~ from 3.57% ~ 1990 to 2.76% in 1997. Advanced age
1s an mcremental nsk factor for hospital mortality after
CABG (Table 1). The mortality rate al o varies with the
pre-op status of the patient. Mortality for elective CABG
was 3.6%, whereas mortality for alvage CABG was 30. %.
(urgent CABG operative mortality i 5.2%, emergent
CABG operative mortality i 9.9%).
Table 1. Mortality rate by age group
Age group

Number of Pts

Operative mortality rate

20-50
51 -60
61-65
66-70
71-80
81-90
>90

18717
38923
25879
21269
51040
8872
106

1.24%
1.42%
2.12%
2.60%
4.07%
6.71%
11%

Table 1. As expected, older revascularization patients tend to have higher
operative mortality rate . This data is compiled from 1997 U.S. data
(N-170000) on the Society for Thoracic Surgeons' web site: www.sts.org
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Table 2: Common complications of coronary artery revascularization
Complication
Atrial fibrilation
Transient stroke
Deep mediastinitis
Permanent stroke
Ventilation > 24 hrs
Dialysis dependant Renal failure

Incidence

Relative risk ratio

19.32%
0.75%
0.63%
1.69%
5.87%
0.92%

1.45
1.46
3.58
10.84
12.66
18.57

Table 2. Post-operative morbidity associated with coronary artery
revascularization is listed in decreasing rate of incidence. The relative risk
ratios (RRR) indicate the higher likelihood of operative mortality. The RRR are
statistically significant (P<0.005). The data was compiled from 1997 U.S.
data (N-1 70000) as reported on Society of Thoracic Surgeons' web site:
www.sts.org.

T_h e inci~enc~ of orne of the important morbidi ty
a soaated W1th thi operation are ummarized in Table 2.
~espective operative mortality relative risk ratios are
hste~ ~s ~ell . A major contributor to post-operati ve
~orbidity 1s the need for CPB, which induces a systemic
inflammatory response, and can cau e neurop ychological
a~d mu lti-organ d ys function . The advanta g e a nd
disadvantages of the CPB machine are discussed below.
CPB machine wa developed in the 1950 , and was
design d to facilitate cardiac surgery. It's advantage are
~um~rou . The heart i arrested and deflated, the urgical
field 1 blood-less, and the surgeon i able to perform the
?peration efficie ntl y, a ccuratel y, and quickl y. 2 Mos t
rmportantly, the surgeon upports the patient' circulation
usmg the CPB machine while corrective surgery is being
performed.
Di advantage of CPB machine are three-fold . First,
priming of the bypas circuit result in hemodilution and
po t-operative water retention, both of which can increase
the pos t-operative length of tay. Second, circulation
thr?ugh incompletely bio-compa tible CPB cannulae,
tubmg, and membrane oxygenator, results in damage to
blood elements, a systemic inflammatory response (SIRS),
and a po t-operati v e h y pocoagulable state . Th ird,
manipulation ~fa di eased ascending aorta can generate a
shower of micro and macro-embol i that ma y cau se
cerebrova s cular
accidents
(CV A),
and I or
neurop ychological dy function.2
The occurrence of CV As in heart-s urgery p atients
remain a significant draw-back to this s ucce s ful
operation. To avert emboliz ation of athero clerotic
plaque , urgeons routinely examine the aorta carefully to
locate a healthy segment for cannulation.2 Even with this
p~ecaution~ the rate of a cerebral e ent i approximately
8 Yo for patients over the age of 70, and 16% for patients
over the age of 80.9' 10 Recently, aortic filters have been
manufa ~ tured to ca pture e mboli shed during th e
cannulation of the aorta. The efficacy of such filters is
curr~ntly under study. Beating-heart bypass operations, if
feas1ble, can reduce the risk of CV As by avoiding aortic
manipulation 11 (discus ed below).
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I~ ~he h~p~ of decreasing operative mortality and
morbidity, muumally-invasive techniques of CABG have
evol~ed during _the past three to four years. These
techniques have mvolved the use of a smaller incision,
and / or attempting to bypass ve sels without the support
of the CPB machine. To summarize, the following
p~otocols have been developed: i) OPCAB, ii) MIDCAB,
m) Port-access, iv) ministernotomy CAB, and most
recently v) closed-chest CAB via endo copic methods.
~he OPCAB operation 12 - 16 involves a full-length
med~an sternotomy, but the bypass is attempted on the
beating heart using stabilizing instruments. In thi s
procedure, the surgeon does not have full access to the
posterior aspect of the beating heart. As well,
n:ta~ipulations of the beating heart may result in
significant hemodynamic instability by interfering with
venous return to the heart. Early studies indicated that
OPCAB is as safe as conventional CABG in selected
patients. Reported OPCAB operative mortality ranges
from 1.0% to 2.5%. 12- 16 As a result, the number of OPCABs
done are dramaticallJ increasing.
The ~CAB 17- operation most commonly involves
the graftmg of LIMA to LAD through left anterior
thora~otomy, or RIMA to RCA or PDA through a right
antenor thoracotomy, on a beating heart. Other arterial
conduits, such as the inferior epigastric and the
gastroepiploic artery have also been used. Direct
anast~osis of ~e SVG and radial artery to the ascending
aorta IS not possible through a small thoracotomy incision.
If the use of such grafts is indicated, the SVG and radial
artery can be anastamosed to the LIMA, and then to a
coronaqr artery as a "T" graft . Recentl y a lateral
MIDCAB 24 approach has been attempted to bypass OM
branches of the circumflex artery. The SVG is proximally
anastomosed to the de cending aorta in this procedure.
The lateral MIDCAB operation does not allow the surgeon
to have ac~ess to the LAD and proximal RCA . Early
concerns eXIsted that anastomo is carried out on a beating
heart~ through. a limited-access incision, may not be
technically preCI e, and may have a high occlusion rate.
Several studies, however, have shown that graft patency
after revascularization using the LIMA to LAD
anastomosis is con;]'arable between conventional CABG2517
30 and MIDCAB •
(graft patency > 90%). Furthermore,
the risk of CV As has been shown to be decreased in
MIDCAB as compared to conventional CABG.ll Growth
in the number of MIDCAB procedures, however, ha been
relatively flat becau e MIDCAB is mainly re erved for the
surgical therapy of single ve el disea e. As s uch, it
compete more or les directly with PTCA.
Another approach, the Port-access approach 31 · 36
in~olve establi hment of CPB and arrest of the heart by
u mg the femoral ve sel for right and left sided
cann ulation . The heart is arre ted with a cold blood
cardioplegic solution delivered through the central lumen
of a ~alloon occlu ion catheter in the a cending aorta, and
cardiOp ulmonary b y pas s is maintained with
femorofemoral bypass. This is followed by a left anterior
thoracotomy to access the coronary arteries. With the heart
arrested, the minithoracotomy affords enough room for
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Table 3. Pre-operative and intra-operative factors with
significant contribution to post-operative mortality
Pre-op factors
Cardiogenic shock
Prior Ml < 6 hrs vs no Ml
Resuscitation
Renal failure requiring dialysis
Renal failure
Prior Ml in 6-24 hrs vs no Ml
PTCA to OR < 6 hrs
Pulmonary hypertension
CHF
Prior CAGB
Arrythmia
Peripheral vascular disease
Immunosuppressive therapy
Prior non-cardiac operation
lntra-op factors
lntra-op IABP
Cryoprecipitate transfusion
FFP transfusion
Platelet transfusion
RBC transfusion
lnotropes leaving OR
Anti-arrythmics leaving OR
Ventricular pacing

Relative risk ratio
7.89
6.12
5.13
3.47
3.45
3.45
3.32
2.92
2.87
2.66
2.3
2.22
2.13
2.03
9.57
5.19
4.48
4.11
3.7
2.88
2.87
2.32

Table 3. Pre-operative status and intra-operative factors have predictive value
in determining the risks of operative mortality. Only statistically significant
(P<O.OOS) relative risk ratios above 2.0 are compiled in this table. The data is
obtained from the 1997 U.S. data (N-170000) on the Society for Thoracic
Surgeons' web site: www.sts.org.

the surgeon to bypa s multiple vessels on a deflated
ea ily manipulated heart. Early studies indicate that
operative mortality and §,raft patency are comparable to
c~~v_entiona~ CABG .32 · 6 However, this approach is
cn~c~ed . for Its prolonged CPB times, and the small yet
definite nsk of retrograde aortic dissection, particularly if
the femoral or iliac arteries are diseased.
. T~e ministernotomy CAB 37 approach is essentially
I~entical to the conventional CABG procedure with the
difference that the entry wound is smaller. That is, with a
smal~er in~ision, the surgeon has access to all coronary
?rte~es with full CPB upport. The ternotomy is made
infenor to the attachment of the third rib to the sternum.
The rninisternotomy CAB is still in its infancy. Dr. Doty
and c~lleague ·37 in Salt Lake City have reported thi
operation on_77 patients so far, with an average of 4.1
gr~s- ~~ pati~nt (comparable to conventional CABG). In
theu uu~al senes, they reported an operative mortality of
2 . ~~ - It IS not clear whether post-operative pain after a
mm~sternotomy is significa ntly les than after a full
median ste~otomy . It remains to be seen if this procedure
develop Its own niche in patient with a particular
concern for co metics.
. The clo ed chest CAB involves in ertion of urgica1
UIStrument and a robot-controlled video camera through
small 5 to 10 rnm inci ions in the che t wall. Bypass may
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Plate 1. Invasive management of CAD.
The rate of PTCA and CABG over the last two decades.
PTCA vs CABG
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Plate 1. Whereas the number of surgical revascularization of the heart has
steadily doubled over each decade, the number of angioplastic procedures
has grown exponentially in the past 20 years . PTCA is becoming
progressively effective when combined with stent placement and anti-platelet
drug (Abciximab) therapy. For complex and diffuse coronary artery disease.
however, the invasive procedure of choice remains surgical bypass grafting.

be attempted either on an arrested heart, u ing the Portaccess approach, or on a beating heart. The Port-acce s,
do ed che t CAB operation ha been reported in France
and Germany in 4 case . ·39 In all four ca es, the postoperative cour e has been uncomplicated, and LIMA
graft have been patent. The beating heart, closed che t
CAB has been successfully performed on one patient o
far . Dr. Boyd at the University Campu of the London
Health Sciences Centre, performed the fir t roboti callyassi ted, do ed chest, beating heart CAB on Sept 24 of thi
y ear. The post-operative course for thi patient wa
uncomplicated, and a post-operative angiogram showed a
perfect LIMA to LAD graft.
Closing
As 21st century approache , the future of ca rdiac
surgery is clearly headed toward minimally inv a ive
procedures. Closed che t CABG is a newly developed
procedure, and its advantages and disadvantages need to
be elucidated in multi-centre studie . It, how e ver,
provide an exciting opportunity for the cardiac urgeon
to ignificantly reduce the morbidity a sociated with full
sternotomy, on-pump bypass surgery . Alth o ugh
rninimally-inva ive operations may be technically very
demanding, they provide the surgeon with the atisfaction
of having achieved the arne e xcellent outcome of
conventional CABG, with onl y lightl y more bodil y
invasion than a PTCA.
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,.,..., Efllcls

~Cak:unj

~. defral as lll.9:le ad1IY,l a lll.9:le weakness 11 ar,n:lir1 Wi1l1 i'aeases 11 aeatroe ~
P'IQ 'l3l1l!s ., IJ'SIIer lta1 "" trnes lhe l«B' liml r:l ramal stcU!II! oaiSidind 1'1 ~ palet Willl Qlfuse
myalgia, lll.9:le 1ll1derness a weakness. .roa mor1<ed elevalo1 r:l CPK. "-'1s stcU!II! atMsed '> iBPiJI

10 mg. 20 mg ;nj 40 mg raiEis

TlfiW'EU!JC ClASSf!CAlXlN: ~ Me1abollsm flegla1Dr
ACTIONS AJIO CUMCAI.. PHARMACOLOGY
LI'ITOR (abvasla1l1 cab.ml IS a S)fllheOc ~ agert. k IS a seleciM!, ~ rl1biJr r:l3-11y011cy-3~A~ raiJclase. ThiS enzyme cataiyles lhe CIJ1'o'ln01 r:l tt.1G-CM '> ·
wl1ch IS <11 arty ;nj rare-lmlrlg Slllp 11 lhe bos)1'llhesiS r:l d'deslerti
LI'ITOR bM!B J*l!rna- ;nj 1iJqmen lew!lsl]ll rllbll1g tt.1G-CM ra1Jclase ; n j - ~ 11
lhe Ml' arll Ill' lncreasl1g lhe ruroer r:l hepaiJc Low Density l..ipoJrolel1 Ul) ret11!*JS on lhe cei-Slllacelor
eria1ced ~ ;nj calabolism r:l Low Densl1y lWllll!f1 il.lll
l.FITCJIIBIU:es I.Jl_-Odeslircl fJl_.q ;nj lhe ruOOer fii.Jl_ ~ LI'ITOR also IBI1D!s Very Low Density
~ ('vtll.-Q. senrn ~ (T~ arll nlinnella1e Densly~ Jll, as wet as lle
ruroerr:l ~ Bla!Xl~ IXI'IIaiW1I ~ tu i'aeases 1111 0ens11y ~ fO--Q
EleYa!i!d senrn c:llJi!sla1j rue'> elevalllll..ll_.C IS a ll'QP nsk facU b-lhe ~ r:l ~ clsease.
EleYa!i!d J*1!rna TG IS also a nsk facU lor~ c1sease. pr11o..0ty Wrue'> ira8asal n. a asmaled wi1ll
decreased tO..C a iraaasafi.Jl_-c.
AIDMslallliS I3IJdY aDsorbed at1er aa1 aarnsta~m; maxrrun J*1!rna txn:e'1llmms oau Wllhll 1 '> 2 tn.rs.
AlllMistatl1 raiEis a-e 95" m99'11. boa'lailallle IXJT'!)al8d '> sciJIO'S.
Mean distrbJoon r:latavasta1111s ~ 381
Alorvaslalrlls 0!98'llo IJoonj '> pasma IJOII!I1S
AIDMslallliS e>aensM!Iy mecald2ed 1]11 C)1DCirune P-450 3A4 '> CJ1ho. arll ~ dellvalNes arll m
VlrlOUS bela~ IJlXi,icls.~ 70'!1. r:l crtUalr1g rtibllay acawy lor tMl Co-A ra1Jclase IS
alll'baed maaJYe metiiJalilss.
AloMslalrl arll liS metaboites a-e eirmaled 1]11 bky l!liCII!1ion.less lta1 ~ ct a lbse r:l II racxwered
in liTe ldlowr1g aal a:tMslralm Mean pasma e61wliiJOI1 tall
r:l 11 tunn Is _...:ely
14 tn.rs. but lhe talf-ife r:llrilbby aciM!y lor tt.1G-CM ra1Jclase Is 20 m30 hotJS rue mlhe CXll1ll'iltAia1 r:1

prtlll1llly ll1l!l;lanod lll.9:le pa11, 1lnlemess a weakness, pa1lCUar1y I acc:anpnld 1]11 malaise a few<. l.FITCJI
lherapy stcU!II! ilsaJntnJed I il1il1<edly eleYaled CPK 1ew!ls oau a ~ IS liaiJilSed a SlJSili!CII!d.
Tl'e nsk r:l ~ ;nj ~ cb'l1g treatmert Willl tMl-CoA ra1Jclase rtiiDs is i'creased Wilh
ararrert alirns1ralion ct t)dosiD'n lin: aod dirlllaiMls. ~ ilaCI1 roan:~. a2!lle rifln;jals a
i'll!falll1tn!. P& 1tJere IS oo l!lijliiBlCe '> dale Willllhe use r:l LI'ITOR gM!I1 arnmn1ly witlthese it1Jgs, witllle
l!lD!IliD1 r:l a~ Sl1ltf Wlf1 ~ lhe benefits arll ns1<s r:l SLd1 a:mnd lherapy stoJd Ill
ca-eiUiy oaiSideied (see Pl£tAIIOONS. Drug l11eraclmsl
~ has been repmj 11 Ylll'f r.re C2llS Wlf1 l.FITCJI (see PFECAUIUIS, Drug t1eraalrisl
~
llJ1III ctjsltn:lo1 searo.y 1D myoglobruia has also been iepa1ed wilh tt.1G-CM ra1Jclase
Wibilas.
l.FITCJI ~ stcUl be ~willtl*ltx 1isar1rued 11 ~ palet ...,.., ac3e semiS W'dlm ~ r:l
a iil)tllllhr a l'elflJ a nsk facU ~ 10 lle deYeqrner1 r:l renal laUe seardry 10 ~ ISt.d1 as
SMil! ac3e i'B:b1, ~ ll'QP sugery, l31l!'a SMil! i11lllald:, tnb:lre ;nj ~ lisonlers, ;nj

trCO"'Jaaed semresl
PRECAUTIONS

liloml
The e11ects ol ab-lliHncklced - - in lipapullin ...,lnc:lutlng recU:tion olla\lll
c:holeAerol on canliovllcular liiOitlicity or II'10fWiy or -ll'lOfWiy line not been Beb-e riSiiUJli1Q lherapy
l.FITCJI (abvasla1l1 cab.mj, .., atll!fTlll stcU!II! made '> W11IOI eleYaled senrn
~Jqmen liM!Is Wi111WQIJ1ate diet. ~. ;m wei!t1l nwcuon 11 CMliWel!tl pa1ien1s, ;m m11ea1 Olher
t.l1dei1jing ii1!dcaiiJOOierns (see ta:ATKlNS MD QJ«:AllJSE). Pate'IIS stcU!II! atMsed 10 i1foon SIJlseqJert
~ r:llle II'« use r:ll.FITCJI a~~~~ ageRs.

Joroer.fved aaM!-

INDICATIONS AIKJ CUNICAL USE
l.FITCJI (ala'laslatl1 cab.ml Is i'dcaled as .., ~ mdiet. at 1eas1 eopvaieni1D lhe Arllesic3l Him AssoCiaDon
INIAl Step 1 diet, b-Ile reQ.aon ct elevated m dUeslerol. ~ . l..ll_.C. TG ;nj ~ 8 {IIJo ~ 11
~ arll dyslipdernc ani!ms, when respc:nse m diel arll Olher 1o pan~ measlfl!S atre has
been mdecJ,iale, rrui1g.
• Prmary h)peictDeseoleiilia (T)lle laj,
• CciTtw1ed
~ (T)lle lq, ill:t.dr9 fanlaj a:mnd hJpeilpden1a. ~fl ........
d1llesllra a ri!tJanjes a-e lle lip<l abrmnalily r:l an:em.
· ~lAl!ileioa (T)lle .
· ~(T)lli!IV);

-

• Flrnlal hJIBddS8ce •oa ~ ;m ~· Fa IDTlilz)9Ws f<mial hJIBddS8ce•oa. l.FITCJI
stcU!II! U98d as.., ~ '> natmenes SLd1 as I.Jl_ aP1eres15. a as ~ I SLd1 natmenes .., ra
1'1 dhcalllials, l.FITCJI (1omIll ~ sqili:anltt I1'IJlMld lip<l JJo1ies in palienls Wl1h a Wide vniY r:l
~ ;nj dyslipdernc ardilms. 1'12 OOSiHeslmSe Slides 11 --~ ~ palienls
(FteODson Types 1a ;m ti l.FITCJI i1!0ad te 1ew1s r:1 m clr:ilesll!m (2!}-45'Aol. I.Jl_ P9-fiO"l. ape 8 1325011.TG (1 9-3~ arll i'creased lwj1 dersti 1iJqmen clr:ilesll!m JQ-Q 1ew!ls 15-!W.l ~ i8IIXJISI!S
wee actoENed 11 pal8llS..., heleroz)9lus trTilial hJIBddS8ce•oa. oon-trTilial lams r:1 hJIBd"*"*-ce•oa.
CXI1'Ill1ed hjpeifpOma, ill:t.dr9 fanlaj a:mnd ~ ;nj palienls
IDl-i1st.tn di!pinlerl clabeles
melilus. i'1 pa!lei1IS Willl ~del IW (T)lle IV). l.FITCJI (10 tl Ill mg daillj i1!0ad TG (25 - 56'4) nll..ll_.C
1e1ie1s (23 - ~ · 01)tmaoos. wl1ch ctaacleri2l! Types I arll V.teYe ra been measond 11 dhcal Slides 11 pate1S
Wlf111{11TG1ew!ls l>11 ~·
1'1 <11 ~lallel Sl1ltf 11 pallei1IS Wl1h ~.....,..,oa (T)lle 1). l.FITCJI (10m Ill mg dal)l i1!0ad m.c
(40-~. TG (40-56'4) arll lll.C + \til..C 1ew!ls (34·58'11.)
1'1 <11 qli!O lallel Sl1ltf 11 pate1S ..., hoinoz)gcliS tm11a1 hJIBctDesece •oa fHl LI'ITOR (10 m Ill mg dallll
i1!0ad iliiBi l..ll_.C 1ew!ls !22"j. 1'1 a pb S11Jtt, l.FITCJI!ll"'!VdaY !1-.-l a iliiBi I.Jl_.C ~ r:l ~lor
pal8llS ra on plasiilal)heii!SIS arll ct 31 " lor patients wile iXI1IIlJed plasrni\lei!SIS. AiliiBi I.Jl_.C ~ ct
35'11. was <tJserved 11 receptt def8CIM! pa!lei1IS arll r:l19llo 11 receptt negatNe pa!lei1IS (see PHAAMA<Xl.OGY,
CJncalsndes)
Fa more delals on elllca:y resUis 1]11 ~ classdlcalm arll pooled data Ill' Frah:lcson types, see
PHAAMA<Xl.OG'(, CJncal Sldes.
Pnor '> ilballlQ lherapy
l.FITCJI. searo.y auses stcU!II! eDJied lor eleYato1s 11 pasma lip<lliM!Is (e.g
JXDIY aJ1Iroled clabeles melilus, hjpoCt1)<odsm, l1l!ltiOOC syrOome, ~ obsliu:IMl Mr dsease, ;nj
<*:dlolsm). ;m a lip<l proQe perforned m nmue m dDesli!ra. I.Jl_.C. tO. arll TG. Fa pate1S
TG
<4.52 illlD\. (<400 IT1!Ytl).l..ll_.C calli! esll1l2!ed l.iSI1g lhe folowr1g I!CJJ3IIon:
I.Jl_ (!!rndA) ; m.c - (~ 37 l (TG) + tO. -QJ
I.Jl_ (in!Yd) ; m.c - (102 l (TG) + tO. -QJ
Fa paDei'IIS Wl1h TG 1ew!ls >452 illlD\. (>400 ~Ills I!IJ.'IIOi IS less acruale ;nj l..ll_.C an:8"8aaD1S
stoJd ll!measond ii'ecllya 1]11 ~
COifTRAJNOICATIONS
~ '> ~ CXI!'!l0'8t dills medca1m
fJcM Ml' ilseese a ..-...plan!d perSIS1I!nl eleYations r:l senrn ll1mr1WlaseS l!lll8edi1g 3 limes lhe l«B' inll ct
ramal (see l\ltfliSl
f'nl!ral:y ;nj laaaiJon (see ~
WARNINGS

.c

-c.

.c
.c

Tl'e use r:l tt.1G-CM ra1Jclase l't1b1os has been assoaaled Wilh SMre ~· i1ctdng ~ wl1ch
may Ill more frecr,Jert when h!y a-e oo-acirnslered Willl ciugs 111a1 rhbt lhe cyllCtrane P-450 enzyme sys11m
AkJvasla!rliS mecald2ed 1]11 cyllCtrane P-450 idJrm 3A4 arll as SLd1 may f1l8'acl Wilh ageniS 1hat rhbt Ills
enzyme. (See WNfH>S, '-tJSde efteds ..-.:1 I'AECAliTnlS, Drug l'1lel3cOons arll ~ P-450-mldated

i'1Eraclionsl
llepllic Eflecls
1'1 cfncalll1als, perSIS1I!nl i'aeases 11 senrn ll1mr1WlaseS ~ter ltall!vee trnes lhe l«B' liml r:l namal
oaured 11 <1" r:l palienls wile receM!d l.FIT!R When lhe dosage r:ll.FITCJI was il!Oad. a when iiDJ treatmert
was il1ll!ri\4XIld a ilsaJntn.ed. senrn ~ lew!lslt!Wled mpnSealmi!lt 1ew!ls. Tl'e i'aeases were
generaly ra a5SlCiated Wlf1 )alldce a~ cfncal "!JJS a ~- Mosl pabenls aJ1RJBd W8almei'f Wlf1 a

- l b s e r:ll.FITCJIWI!holA dhcaiSil(JJI!Iae.
lMJ l!rdm l!:jiS :tn.*l be gertgnre;! bebJ! !he Dna!QJ d mtrne!j, ;nl !llllbly lt!ereat!!J. Specill atll!f1lDi
stcU!II! pad m pa!lei1IS wile dew!qJ elevated senrn ~ 1ew!ls. arll 11these paiJeniS iTiiBSiflm!l'll
stcU!II! repealed prtlll1llly arll lhen priJrmed more frequenlly
Hincreases in alrile Mlinolransfeme (All) 01 aspaltale amillllransfllase (AST) show evidalce of
~ particulal1y if IIIey lise to greater than 3 times llle lmit ol normal and . . persiAonl,
111e dosage should be reduced or 111e drug discontinued.
l.FITCJI stoJd Ill U98d Wilh caJIOI111 pate1S wile aJI1SliTe s.tJslarlial CJ,ki11llleS r:l alatd .ro<a teYe a past
IIsby r:1 Ml' disease. fJcM Ml' ilseese a ..-...plan!d r.r&lnWiase elevallons a-e w liMd:aluiS m lhe use r:l
l.FITCJI; - SLd1 a anitlon stoJd ~ cb'l1g lherapy, lhe iiDJ stoJd Ill ilsaJntnJed
·~

wr•• CA!Oin19n.18161 489-502

Qmrt klng-11!m1 dala fnm dhcai1Jials

oo ra ideate .., ad¥ine elfecl r:1 aarvastllll on lhe ll.mrllens.

~
SI!Ji!i3t decreases 11 crtUalr1g ~ -

11 pabenls 1reated Willl amaslalll..-.:1 Olher
teYe been
<tlserved. Tl'e dhcal SIIJlifi3a r:1 a jXJIIJ11lal b:lg-lem1 SlalllflU:ed defiaelq r:1 ~has ra been
establshed. l has been iepa1ed 111a1 a decrease i'lll1)'0C3lial ~ leYels cru:llead ID lrpared C3liac
flJaon , pall!i'IIS
bonlerh aJV!Siil'8 hla:1 laUe (see saECT8l B8.llGIW'H'I).

Elll!c1 on l..lpopro!!!iJ tal
in some patients lhe beneficial elfecl r:llowenld m c:holeslerol..-.:1 I.Jl_ 1ew!ls may Ill pa1ly - I l l ' a
an:omilant inl:rBase , lll(allew!ls.liili
Is olltlined, l is suggesU!d, wt1ere feasillle, 1hatllli!IISll!l1lel'iiS r:l serum 41(a,) Ill lllowed 141 11 palients placed on aDv.lstltllltoerapy (see saECT8lllllLCGIW'HI').
llvpo!•!lilllllb
MllllPM!II ~ SjiOome has been repaaj
Olher tt.1G-CM ra1Jclase ~ wl1ch has il'li1ided
1 a more r:llhe !tllowing feallJes: ~ <l1giOil(lema, ~ eryl!lernan.s-1<2 syntome, polymyalgia
i!lelrnatica, vasa.ttis, llJ1Ui. 1lron'tlocylcpe lel.i<llpona.llerrdyli: <l1t!ll1ia. posiliYe NIA. ESR roeas..
eosrqto1a, ¥hillS. malgia, il1lClrla. as1hena, ~. few<. ellis, ll!mg, malaise, djs!rea. DOC
ep&1ermal ~. EI)JheJm
' ill:t.dr9 Slew!ns-.lmol syrOome AlltaJ1t ., daa! ~
syntome has ra been desalled as su:h, LI'ITOR stoJd Ill ilsaJntnJed it ~ IS SlJSili!CII!d.

llrther""""'"""'

.c

UseinPrtcr!ancy
UPITOR Is c:onliaildic:aled cUing pngnancy (see COfiT1WNDICAJ10
AlherosderosiS IS a c11onc process arll cisca1truallo1 r:l ~ ciugs cb'l1g ~ stcUl teYe
I1'!Kt on !he ClJIXI1l! ct klng-lem11herapy r:1 prmry h)lleid..,...ce•oa. OrJies1Billnt ~ palJcls r:1
bos)mesiS a-e essenDal W'llQU1IS lor felal ~ fR:ldro Sjl11lleSIS r:l SI800s ..-.:1 eel
i11i!!iDalesl Since tt.1G-CM ra1Jclase lrtilGas decrease synlhesis ;nj jXl6Sby lhe S)<llhesis r:l Olher
txoklgicaly aciM! Slbscn:es derMld fnm · h!y may caJSe tam 1D lhe !eaJS when U1nstered '> IJI!gl&twanen

There a-e oo data on lhe use r:ll.FITCJI cb'l1g ~· l.FITCJI stoJd be acirnslered m wanen r:l ~
age aty when SLd1 pabeniS a-e h9tt ldcely '> an:8i\'e ;nj teYe been lriamed r:llhe jXJIIJ11lalllallrds. ~ lhe
~ becomes jlri!!J8t wlile lal<r1g l.FITCJI, !he iiDJ stcU!II! ilsaJntnJed ;nj lhe pallert awiSed r:llhe
jXJIIJ11lal nsk '> lle fellS.

1'1 iaiS, ll'il< txn:e'1llmms r:latavasta111 a-e SiiTG m 11ose 11 plasma liS ra kriMil-lhiS iiDJ is e>mlild
11 ll.mr1
Because r:llhe JX)Iel1llal lor ad¥ine reaams 11 iUSII1Q mns. wanen ~a~q l.FITCJI stcUl ra
lreasl·!eed (see~

flllilll:iU!H

TrealmiJt l!lijliiBlCe 11 a peoialli: ~ IS lmitsd m006es ct l.FITCJI141 moo II1!VdaY lor 1 year 11 8 pa!lei1IS
hoinoz)gcliS trTilial hylbct...,.ce•oa. No cfncal a blx:hei11ical alromaities wee iepa1ed 11 these

Treamn eoper~erre 11 acUis 70 years a older

-221) wntt 006es r:ll.FITCJ1141m !llll'l!)'day has den'li:l1sralad
1hat lhe safely ;nj elfeaNeness r : l - 11
IJQIUatmw.r; SiiTG '> lhat r:l patienls <70 years r:l age.
Phal• •a::d<III!IIC ewkJallon ct atavasta111 11 s.qects <Nfif lhe age r:l65 years indicates .., n:reased ALC. P& a
pracaJIOIBy measue. lhe boesllbse stoJd Ill acirnslered ·
(see PIWfMCQOGY, ttmr1
Plana::doietiCS; saECT8l B8.llGIW'H'I).
f!enallnsuf!!ciency
Plasma an:8"8aaD1S ;nj I.Jl_ lowemg efficacy r:ll.FIT(Jiw.r; sf'own '> Ill srnlar 11 palienls will iT'Cderate
renalm.tfioercj 00111800 ..., pal1eniS Willl ramal renal flJaon ttMeoe', Sill! 5eleal C2llS r:l ~
teYe been ~ 11 paDei'IIS wit1 a IIsby r:l renal rWfiaercy r:l tno1own seventy, as a pracaJiiliBy rneasue
;nj pendng lr1te' l!lijliiBlCe 11 renal ilseese, lhe boesllbse {1 0 ~ r:ll.FITCJI stcU!II! U98d in these
pa!lei1IS. SinD JlecaJDlS <WY 11 paDei'IIS Wi1l1 SMil! llJ1III rWfiaercy peetili'1e dlmn:e <30 rrUnw1
(<0 5 ntlsec)J, lhe boesl dosage stcU!II! U98d ;nj fl1llemen1ed caJIIOUSiy (see W/liHHiS, '-tJSde Efleds;
I'AECAliTnlS. Dn.g ~
Refer also k1 DOSAGE MD ADMNST'RAlXlN.

.c

tMl-CoA i8il.aJse rt1bDs l11i!lfere..., ctaes~era S)<lhesiS ;m as su::11 mil' JhecJell::aly tilt aaera ardl:r
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CHLAMYDIA PNEUMONIAE:
A POSSIBLE CAUSE OF
ATHEROSCLEROSIS
By Sandy Widder

INTRODUCTION
hlamydia pneumoniae is a Gram negative obligate

C

intracellular bacterium. The organism has a biphasic
life cycle consi ting of a mall, den e elementary
body and a larger, metabolically active cell called the
reticulate body. The elementary body i the infectious
form of the agent and is u ually tran mitted between
human via aero ol drop . The reticulate body i the
vegeta ti ve fo rm and divide via binary fi ion to form
inclu ion bodies in the ho t cell. ' C. pn eu moniae is
re pon ible for a variety of re piratory yndrome , uch
as: pneumonia, pharyngiti , bronchiti , a thma and
chronic ob tructive pulmonary di ea e. 2 C. pneumoniae
infections are common and it i e timated that 50- 70% of
adult are eropositive. 1 In recent year , thi bacterium ha
been identified a a po ible ca u e of athero clero i .
Athero clero i i the principal underlying cau e of
coronary artery disea e. The athero clero i develop a a
re ponse to injury to the endothelium and mooth mu cle
of the arterial wal1. 3•4
Endothelial injury lead to the adherence of platelet
and acti vatio n of macrophage which migrate t the
subendothelium.3•4 The macrophage inge t low d n ity
lipoprotein and become foam cells.H 5 Relea e of growth
factor , by the macrophage and platelet , lead to the
proliferation of smooth mu cle cell and ecretion of
extracellular matrix.3•4 The earlie t le ions are fatty treaks
which in turn develop into fibrou plaque (a fibrou cap
s urround ing a lipid rich core), and eventually become
calcified Y The e athero clerotic plaque decrease arterial
lumen diameter and may lead to total ob truction. If th ere
i ulceration or rupturing of the plaque, a thrombu may
form a a re ult of platelet adherenc and aggregati n. If
the thrombu continue to increa e in ize, the already
narrowed lumen may become partially or fully blocked,
thu precipi tating i chemia. 3.4 It ha been ugge ted that C.
pneumoniae infection of endotholelial or smooth mu de
cell of ve el wall re ult in local inflammation and
fibro i and ubsequent atheroma formation. 6 Chronic
infection with C. pneumoniae may also timulate the
production of pro-inflammatory cytokine , thu increa ing
the ri k of cardiova cular di a e.

ABOUT THE AUTHOR
Sandy Widder is a second-year medical student at the
University of Western Ontario who previously completed
an HBSc in zoology at the University of Calgary.

54

INFECTION WITH C. PNEUMO IAE AND
ATHEROSCLEROSIS
C. pne umonia e fir t became associated with
athero clerotic di ea e when tudies demonstr a ted
increa ed titres of immunoglobulin G (IgG ) and IgA
antibodie in the erum of male who had coronary artery
di ea e or who uffered acute m yoca rdial infarction ,
compared to control .
Saikku et al., demonstrated that tho e individual w ho
po e ed elevated titre of antibodie had twice the ri k
of coronary ar tery di a e .9 In a ddition to
eroepidemiological tudie , oth r experiment h ave
found C. pneumoniae within atheromatou le ion via
irnmunohi tochemi try and polymera e chain reaction 10,
electron micro copy", and culturing technique .12
The pre ence of C. pneumoniae in a th ero cle roti c
le ion , however, doe not produc enough evidence to
indicat a di tinct role, and there i debate a to whether
the pre nee of C. pneumoniae i cau ative, contributory, or
merel y coincidental. Animal tudie have contribute d
greatly by providing further evi dence on the role of C.
pneumoniae in the d evelopme nt of athero clero i .
Laitenen at el. , u ing ew Zealand white rabbit ,
demonstrated that after intra-na al or tracheal inoculation
of C. pneumoniae, 2 /3 demon trated a thero clerotic-like
change in the aorta, while no le ions were found in the
control . 13 Additionally, trea tm e nt with antibiotic
following infection of rabbit prevent the development of
atheromatou le ion . It ha a1 o been demonstrated that
C. pneumoniae accelerate the athero clerotic process in the
aortic arche of apolipoprotein-E deficient mice. 14
CLINICAL TRIALS
The po ibility of C. pneumoniae producing arterial
inflammatory change ha Jed to everal clinical tri al
utili zing macrolide antibiotic th e rapy a a mean of
treating athero clero i . In rabbit , weekly treatment with
azi thromycin after expo ure to c. rneumoniae, prevent d
the acceleration of athero clero i .1 There have also b en
hum an clinical trial which demon trated a fivefold
reduction in ad ver e cardiova cular outcome in patient
receiving azithromycin 15, and a reduction in future cardiac
event from 10% to 1% u ing roxithrom yc in . 16
Unfortunately, the number u ed in the human clinical
trial we re mall, and ther fore the re ult mu t be
interpreted with orne caution.2
CO CLUSION
Although a direct cau a l relation hip ha not b en
e tabli hed between C. pneumoniae and athero clero i ,
recent cientific evidence ha trengthened the likelihood
that C. pneumoniae may initiate or wor en athero clerotic
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di ea e . The re ults of clinical tr ials using macrolide
antibiotics have been especially encouraging; however,
further re earch is needed. There have not been any large
clinical trials corroborating athero clerotic improvement
w ith antibiotic . In addition, one needs to e tabli h that
the optimistic re ults are not the consequence of drugs
ac ting in a non-antimicrobial fashion on other
inflammatory mechanism .2
Finally, one must look at the consequences of using
antibiotics within the community; the wide pread u e of
antibiotic may electively increa e drug-resistant bacteria.
Should C . pneumo niae be a n infectiou cau e o f
a the ro clero i , one would be able to identify and trea t
tho e at ri k. In the future, one might be able to eradicate
a thero clerosis by means of a simple pill!
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azithromycin in male survivors of myocardial infarction. Circulation 1997;
404-406.
16. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mau tner B for the ROXIS
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THERAPEUTIC MYOCARDIAL
ANGIOGENESIS: PROSPECTS FOR
GENE THERAPY
By Warren Ball, BSc., MSc. and David G. Almond, MD, FRCPC

INTRODUCTION
schemic heart disease remains the leading cau e of
mortality and morbidity in the Western world .
Therapeutic approaches to the management of patients
with chronic myocardial ischemia are currently aimed at
reducing disease progression via risk factor modification,
reducing m yocardial oxygen demand and cardiac events
with medication or increasing blood s uppl y to
compromised m y ocardium by percutaneous coronary
intervention (PCI) or coronary artery bypass surgery
(CABG). However a significant portion of patients are
refractory to medical therapy and are not candidates for
PCI/ CABG . The growth in our understanding of
molecular signaling pathways in blood ves el formation
has led to research aimed at stimulating growth and
development of new collateral vessels that will form
endogenous bypass conduits, termed therap e utic
angiogenesis. This review outline the impetus for
angiogenesis in the myocardium and will describe the
molecular and cellular events of angiogenesis, including
the key regulatory angiogenic factors. Finally, a the
ability to induce myocardial angiogenesis would have
dramatic impacts in cardiovascular medicine, progres
into the field of therapeutic angiogenesis will be
summarized.

I

Myocardial Requirements for Angiogenesis
The three primary stimuli believed to stimulate
angiogenesis are: 1) mechanical factor 1, 2) hypoxia2, and
3) inflammation3 . Mechanical factors, such as increased
shear stress associated with increased blood flow, may
induce angiogenesis by disrupting the endothelial surface,
resulting in the release of proteases and I or angiogenic
factors.! The homeostasis of myocardial oxygenation is
regulated within narrow limits by moment-to-moment
adjustments in coronary artery tone, which in turn
controls blood flow in direct proportion to cardiac oxygen
demand.4 This is true even under conditions of stre s, for
example during exercise or in early stages of cardiac
disease. However, the vasodilatory reserve of coronary

ABOUI' THE AUI'HORS
Warren Ball is a second-year medical student at the
University of Western Ontario. Prior to entering medical
school he earned an Honours BSc. in Life Sciences at
Queen's University and an MSc. in the Cardiovascular
Science Collaborative Program at the University of Toronto.
David Almond is the Director of Invasive Cardiac Services
of the London Health Sciences Centre and an Assistant
Professor of Medicine at the University of Western Ontario.

56

arteries is limited and, particularly in the face of severe
atherosclerosis, when oxygen demand exceeds supply,
hypoxi a ensues, impeding m ocardial function.
Fortunately the heart is equipped with a long-term
homeostatic mechanism for maintaining myocardial
oxygenation in the face of hemodynamic or metabolic
stres es; chronic hypoxia triggers neovasculari zation. 5
Inflammation al o repre ents an important modulator of
myocardial angiogenesis. Following infarction,
myocardial necrosis is accompanied by the influx of
lymphocytes and macrophages with subsequent release of
angiogenic factors. 6 The e mechanisms are by no means
mutually exclusive and the continual interaction of each
likely occurs in vivo.
Cellular Components of Angiogenesis
A number of components of the stable vessel are
potentially involved in active neovascularization. 7 Most
prominent are the endothelial cells (ECs). Once thought to
be passive liners of the microvasculature, the e cells are
now recognized as a composite active endocrine organ.
Pericytes sit adjacent to the endothelium and contribute to
the regulation of vessel ize through adjustment in
muscular tone and may check the proliferation of ECs.7
Providing structural integrity to the thin walled
capillary are the basement membrane (BM) and the
extracellular matrix (ECM). The arrangement and
composition of the ECM appears to be vital to the
angiogenic response.7 For example, collagen modulate EC
proliferation and motility, while heparin sulphate
proteoglycans (HSPGs) bind various growth factors,
thereby serving as a repo itory of an~ogenic modulators
in anticipation of appropriate stimuli. Macrophages and
platelets may al o contribute to angiogenesis, releasing a
host of factors capable of modulating the angiogenic
response.
Angiogenic Growth Factors
Early investigative work into the mechanism of
angiogenesis arose from oncology research, as it was
observed that tumors could be implanted into an
avascular region, such as the corn a, and induce the ingrowth of new capillarie . Thus, the impetus became the
identification of the relea ed diffusible activators capable
of stimulating the relatively quiescent vasculature to
proliferate. A number of potent angiogenic factors have
been discovered, including ba ic and acidic fibroblast
growth factor (bFGF and aFGF), vascular endothelial
growth factor (VEGF), transforming growth factor-beta
(TGF-~) 9 • 11 , insulin-like growth factor-1 (IGF-1) 12,
hepatocyte growth factor (HGF) 13•14, tumor necrosis factoralpha (TNF-a) 15, platelet activating factor (PAF) 13, nitric
oxide ( 0) 16' 17, adenosine 1 20, and angiopoietin21 .
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An Integrated View of Angiogenic Regulation
A number of different stages have been proposed for
the process of angiogenesis 7•22 ; however, in reality
angiogenesis is a cascade of overlapping events; any
division therein is mainly didactic. Figure 1 depicts a
speculative cascade for the molecular control of
angiogenesis based upon the evidence accumulated to
date. A step-by-step description of this diagram follows:
1. An initiating stimulus, such as hypoxia or ischaemia,
is required to activate the quiescent vasculature.
2. An upregulation of EC VEGF 23.24, bFGF25 and ()26•27
gene expression ensues.
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5. The angiogenic factors released from the ECM, ECs
and HSPGs, in addition to co-factors (heparin and
plasmin) provided by the extravasation of plasma,
provide the chemotactic impetus for EC migration
away from the vessel wall and into ischemic
myocardium. ECs subsequently differentiate, change
shape and adhere to one another to form the lumen of
a new capillary. 7
6. VEGF, bFGF and NO are chemotactic for
macrophages I monocytes and induce these cells to
release of a host of angiogenic modulators .
Fibroblasts, too, potentiate EC proliferation and
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Figure 1: Integrative model of myocardial angiogenesis

3. These factors act via autocrine and paracrine
pathwa ys to : (a) increase the permeability and
dilatation of the ve el wall, (b) induce the relea e of
proteolytic enzymes 28 •29, including serine proteases,
urokinase-type and ti ue-type plasminogen
activators (uP A, tP A), matrix metalloproteinases, and
collagenases which dissolve the local BM and ECM
and (c) timulate EC motility.
4. (a) The degredation of the ECM also releases
(a ctivate ) sequestered VEGF and bFGF bound to
HSPGs in the ECM. (b) In the heart, cardiomyocytes
may release adenosine, VEGF, bFGF, and 0 in
respon e to injury, while increases in blood flow
(shear tress) and oxygen consumption in normal or
border-zone tissue surrounding an infarct may also
stimulate the relea e of angiogenic factor .

7.

8.

migration by releasing HGF into the extracellular
milieu and initiating the in situ biosynthesis of PAF,
VEGF and HGF itsel£.13
In addition to their structural role, pericytes may
activate TGF-j3 31 , which subsequently inhibits EC
proliferationll and promotes differentiation and
formation of tubules32 • The e tubes fuse and coalesce
into loops and blood circulates through the new
vascular bed. Only now does de novo BM synthesis
begin, and as a re ult the immature vessel is initially
relatively leaky.
IGF-1 also contributes to the differentiation and
morphogenetic pha es of angiogenesis by shifting the
p~oteolytic balance back to homeostasis and, along
With TGF-j3, by stimulating the fibroblast synthesis of
BM / ECM components. 10
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Fibroblasts and pericytes are attracted to the forming
vessel, secreting matrix component and providing
structural and functional support? Given its apparent
role in vasculogenesi , it has been uggested that
angiopoietin ma y be involved in the control of
pericyte proliferation and migration in this stage of
angiogenesis. 21
The angiogenic cycle is complete.

Therape utic Angiogenesis
In the heart, the extent of coronary collateral
vascularization (blood flow) is a determinant of infarct
size, the amount of surviving viable myocardium and,
thereb y, prognosis in ratients suffering an ac ute
myocardial infarction. 3 However, often thrombus
formation proceeds faster than collateral development,
which may require days to weeks. 34 Therapeutic induction
of m y ocardial angiogenesi immediately follow ing a
myocardial infarct offers the hope of minimizi ng or
preventing the re ultant cardiomyocyte cell lo s, fibro i ,
lo s of function, wall thinning and, ultimatel y, heart
failure. Even more efficacious would be therape utic
induction of coronary collateral de ve lopment in the
ischaemic myocardium of patients with coronary artery
disease before progression to infarction. To date, re arch
ha focused on the most prominent of the identified
angiogenic growth factors in the developme nt of
therapeutic angiogenic strategies- VEGF and the FGF .
Evidence that administration of bFGF35 and VEGF36
could therapeutically induce angiogenesi s was first
accomplished in a rabbit model of hind-limb isch mia.
Extending this work to the myocardium, intracoronary
administration of bFGF37 of VEGF wa shown to enhance
collateral perfusion and m yocardial vascular density in
re pan e to myocardial ischaemia in a canine m odel.
Similarly, exogenously administered bFGF improve
coronary flow and reduce infarct ize in compromi ed
porcine myocardium 39 • However, de pite the efficacy of
systemic pharmacological intervention 40 •41 , th re i
concern over ob erved sy temic activity of admini tered
growth factor peptides.
Gene therapy may circumvent thi by providi ng
continuous, local expre ion of angiogenic agents.
Potential delivery vectors include plasmid , viral v ctor
(adenoviru es or herpes implex viru e ), or cells. Again
utilizing the rabbit model of hind-limb i chemia, I ner'
group has demonstrated augmented collateral
development 42 following percutaneou application of
plasmid VEGF165,which had been applied to a hydrogel
polymer coating of an angioplasty balloon 43 • Use of an
adenoviral vector expre sian VEGF ha al o been hown
to improve mJ'oc ardial perfusion and function in a
porcine model.
The encouraging re ults in animal models have
resulted in the initiation of clinical trials of therapeutic
angiogenesi . Proof of concept for the clinical ben fit of
angiogenic growth factor was initially documented in
patients with critical limb i chaemia . 45·~ 6 Recently, aFGF
ha been used for the fir t time in patient undergoing
elective CABG. 47 The growth factor was injected into the
myocardium distal to an internal mammary artery - left
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anterior descending (LAD) ana tomo is and close to the
LAD in a region containing additional steno es of the LAD
or one of its diagonal branche . Angiography twel ve
weeks later demonstrated capillary fo rmation around the
site of injection prouting from the proximal part of the
coronary artery and rejoining the di tal parts of the ve sel.
Isner ha also undertaken a pha e I clinical tria] evaluating
therap utic angiogene i in patients with severe i chaemic
cardiac di ease who are not candidates for mechanical
reva cularization, including tho e with occlu ion of
vessel too mall to be bypassed, those without conduits,
and tho e who are not surgical candidates becau e of
concomitant di ease. However, thi tudy evaluates the
safety and efficacy of direct injection of naked plasma
VEGF D A as ole therapy for evere (functional class 3
or 4) exertional angina. Early result from five patient
reported that all patient experienced marked ymptom
improvement and I or objective e idence of increa ed
myocardia] perfu ion, as evaluated by angiographic and
single photon emis ion computed topography (SPECT)se tamibi tudie , between 30 and 60 day following the
procedure . Similarly, bFGF and VEGF, deli vered by
intracoronary injection, have entered into a pha e I trial in
ischaemic myocardium not amenable to CABG.6
While early results suggest that application of
angiogenic growth factors to the myocardium i safe and
ma y lead to decrea ed symp tom s and increased
myocardial perfusio n in elected patients, significant
question remain. Optimizing the anatomic site, number
and do e of intramyocardial injections will require further
work. The appropriate formulation or vector al o remains
to be determined. Recombinant VEGF protein has al o
shown to be efficacious for the induction of limb and
myocardial angiogene is in pre-clinical and preliminary
clinical inve tigation 47 and the adenoviral VEGF vector,
shown to increa e myocardial perfusion and function in
porcine m yocardi um, is now being tes ted in human
subject 44 •
Perhap mo t ignificantly, minimally in va ive
method of growth factor introduction will need to be
developed to permit proper scientific tudies that include
randomization of human subject ver us placebo. Current
clinical studie involving VEGF require a minithoracotomy. The availability of a catheter ba ed y tern to
deliver reliable percutaneous m yocardial gene deliver~
may solve thi i ue and is currently under inve tigation4 .
Recent work has also inve tigated the pericardia! space as
a potential site for angiogenic factor delivery and I or
expre ion.50..s 1 Cardiomyocyte transplantation into carred
myocardi um ha already been hown to re tore heart
function in rats 52 and, in combination with gene therapy,
offer a means of replacing fibrou car with functional
cardiomyocytes while simultaneously inducing
angiogene i to alvage surrounding viable myocardium
and ensure adequate oxygenation to the transplanted cells.
Summary
Adequate blood upply is a condi tion for myocardial
survival and function. Thu , va cular growth is under
tight r gulation by a multifactorial ca cade balancing the
initiation and down-regulation of angiogene i . The
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pre ence of growth factor in the myocardium alone is not
s ufficient to permit angiogenesis; additional stimulichemical, molecular, or mechanical-are required .
Re earch ha demonstrated that the addition of pecific
growth factors can initiate coronary collateral
development in the pre ence of m yocardial i chemia .
However, it remain to be full y elucidated whether
angiogenesis can be efficaciou ly induced through the
introduction or up-regulation of a ingle vital growth
factor or whether the altered expre ion of multiple factor
i necessary to adueve therapeutic result . Thus, future
tudies must be aimed at e tabli hing the optimal
angiogenic factor(s), dose and route of administration for
extrapolatio n to the clinical etting. Gene therapy i
currently the focu of therapeutic angiogenic re earch and
re ult from early clinical trials offer the promi e of
minimally invasive myocardial reva cularization for
patient with evere i chemic heart disea e.
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A LITERATURE REVIEW OF
EXTRAHEPATIC BILE DUCT CANCER
By A.K Sahajpal and W. Davies MD

Introduction
xtrahepatic bile duct (EHBD) carcinoma is an
uncommon malignancy with overall five year
survival rates less than 5% 1• Le ions are frequently
mall, making diagnosis difficult, and they are often
locally invasive at the time of presentation making
re ection irnpo sible2 • Tumour usually spread within the
bile ducts and, locally, they may invade the hepatic artery,
portal vein and liver parenchyma 3 . Surgical resection
offers the only chance for long-term survival 1• 11 • Surgical
cure and prognosis are based primarily on the stage of the
tumour at the time of diagno is. Anatomical location of
the lesion, morphological type, and grade of the tumour
al o affect prognosis4 • Overall, the five year survival with
urgical re ection is less than 30%.
These tumours arise from epithelial cells lining the
major extrahepatic bile ducts. The majority of tumours
appear histologically and microscopically similar 5 .
Generall y,
tumours
are
mucin-producing
adenocarcinoma . Three anatomic divisions are recognized
for tumour cia ification: (1) Upper third, involving the
hilar region and confluence of right and left hepatic ducts this type of EHBD tumour is also known as a Klat kin
tumour; (2) distal to the junction of cystic duct and the
uperior border of the pancrea (middle third); and (3) the
lower third at the distal end of common bile duc:f- 11 •
Location of the tumour i responsible for differing
survival rate 4 11 • Lesions of the distal third are most often
curable with re ection, whereas Klat kin tumours (upper
third lesion) are often invasive and uruesectable at the
time of g_resentation, and have low survival rates with
re ection 11 • Unfortunately, the confluence of the hepatic
ducts c_onstitut~ the location of argroximately one-half of
all malignant bile duct cancer 6- 10•1 • •
Morphologic subtypes include papillary I polypoid,
a nd clerosing tumours . These lesions can be well,
moderately, or poorly differetiated 2• Papillary lesions have
a significant long-term survival advantage compared to
clerosing lesions 11 • In EHBD cancers, local invasion,
ly mph node metastases and the status of the surgical
margins are primary factors affecting prognosis 28 •
The etiology of EHBD cancers is not well defined 29.30.
A link between gallstones, gallbladder di ease and bile
duct cancers has been observed 29 • In addition, biliary
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enteric anastomos i , inflammatory bowel disease,
choledocal cysts, and smoking have also been shown to
increa e the risk of bile duct cancers in both men and
women. Other factors uch as unsaturated fat intake, bod
we ight, and alcohol show only a weak correlation .
Associations between cancer of the bile duct and
ulcerative colitis (UC) have been observed 35 • A tudy by
A~ "':' ari et a/ 35 reviewed thirteen patients at the May o
Clinic between 1935-1973 with documented association of
UC and bile duct cancer. Onset of bile duct cancer was
insidious in each ca e. Common presentation for these
patient wa fatigue, anorexia, and weight loss followed
by dark urine, pruritus, jaundice and acholic stools35 . The
incidence of bile duct cancer in patients with UC been
reported as between 0.4% -1.4%35 . At onset of cancer, mo t
patients had mild to moderate periodic exacerbations of
UC with one having no symptoms35 •
Presentation and D iagnosis
Patient typically pre ent with painless jaundice and
weight loss. Clinically the e patients present with cleral
icteru , jaundice, dark, tea-coloured urine, and claycoloured stools. As ductal obstruction worsens patients
develop pruritu , hepatomegaly and are at risk for
developing a cending cholangitis. If the tumor is confined
to right or left branche and occluding the lumen, jaundice
may not be present, delaying symptoms and pre entation
longer5•31• Early diagnosis is crucial to survival 13 • Initial
inve tigations after a complete history and physical
examination include appropriate blood work which
should include liver function tests.
Once a pattern of obstructive jaundice ha been
identified, abdominal ultrasound is the most effective
initial radiologic investigation. Ultrasound will
demonstrate a dilated intrahepatic biliary tree and,
depending on where the primary tumour is located,
dilation of the extrahepatic bile ducts to the level of the
~umour. At this stage, the differential diagnosis may
mclude: choledocholithiasis, benign bile duct stricture ,
sclerosing cholangitis, and pancreatic neoplasms. Imaging
of the EHBD can be achieved by perfoming either
endo copic retrograde cholangiopancreatography (ERCP)
or by percutaneous tran hepatic cholangiography (PTC).
At the time of ERCP or PTC, the obstructed bile duct can
be tented or drained to allow for decompression of the
obstructed biliary sy tern. A sub equent CT scan should
be done to help stage the tumour (rule out distant
metastases, and evaluate the extent of local invasion). In
some centres, hepatic arterial angiography is used to
assess local vascular invasion which may preclude
surgical intervention. If the EHBD cancer is not re ectable,
palliation can be obtained with a PTC drain or an ERCP
placed drainage stent? 2·34
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Management
The mean survival for patient for untreated EHBD
cancer i 3-6 months ·36 • Chemotherapy alone has had
little role in the treatment of EHBD tumours for curative
or palliative management!. These tumours unfortunately
do not respond to any great degree to currently available
chemotherapeutic agents. Radiotherapy can increase
length of survival, q u ality of life, and shows benefit in
patients with previous curative or palliative surgery 1. It
may al o benefit patients with local recurrences 1. The use
of high dose radiotherapy is a feasible therapeutic option
for the management of EHBD cancer. Radiation therapy
can be delivered by external beam or intraca itary
radiotherapy via a PTC drain37.5 1_
Indications for use of radiation treatment include: (1)
adjuvant therapy following complete resection; (2)
palliative radiotherapy for patient with positive margins
or local recurrence following surgery; and (3) palliative
t reatment of nonresectable advanced tumours 1 •
eoadjuvant chemoradiation for EHBD cancer can be
used preoperatively 36•38 • Proponents of this approach
believe some tumours may be decreased in ize to allow
for re ection and theorize that the neoadjuvant approach
may improve s urvival. Few data exist to support this
approach at present.
The ide effect of radiation treatment for EHBD
cancers are variable and most complaints are related to
irradiation of inte tinal epithelium 1• Diarrhea, nau ea and
vomiting are commonl.
The pri n ciples of su rgical management of HBD
cancers in~olve~ comp~ete en bloc re ectio~ of the prim~
tumour With histologtcally proven negative margins · .
Management based on anatomical location is as follows:
(1) upper 1/3 (Klatskin tumour), resection of bifurcation of
bile duct +I- as ociated hepatic resection; (2) middle 1 I 3,
may
be
amenable
to
local
resection
or
pancreaticoduodenectomy (Whipple procedure); (3) distal
1/3 of biled duct, pancreaticoduodenectomy. The aim of
surgical palliation is to relieve biliary obstruction, thereby
decompre ing the biliary tree39 • This i accompli hed by
performing a biliary enteric bypass.
Surgically placed U-tubes have been used in the pa t
to palliate patients, but are used much le s frequently than
PTC drain or ERCP-placed stents 3•39 . Percutaneou
techniques have associated problems. Mortali~ may reach
up to 25-31% and infection is also a concern 1• External
catheters lead to the loss of fluid and electrolyte a well a
bile constituents3 • They also provide a portal of entry for
bacteria leading to cholangitis, epticaemia, and liver
ab ces e 3 . Ca theters require daily care, dressing and
irrigation. If obstructed they can be changed with ea e and
may be u ed as a portal for intracavitary radiotherap .
Mortality rates for percutaneous and endoscopic palliative
procedure have been estimated at 15-33% for 30 day po t
procedure 6•22 •23• 42 • This is imilar to the perioperative
mortality rate for surgical palliative bypa s.
Palliative surgical decompre ion of biliary
ob truction in patients with unre ectable EHBD cancer
involve Roux-en- Y biliary-enteric ana tomose . The
location of the bypa depend upon the origin of the
primary tumour. The bypass can be performed both intra-
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and extra-hepatically. The intra-hepatic approach
commonly employed i the " round ligament" approach
(segment ill approach) to the ducts of the left lobe lateral
to the ligamentum teres39 •
Guidelines for the choice of a decompression
procedure include: (1) general condition or health of the
patient; (2) effectiveness of the procedure with re pect to
quality I duration of survival; (3) associated
complications 17 . Regardle s of the procedure employed,
the goal of palliation i the relief of ;ymptom of
ob truction -jaundice, pruritu , malai e, etc1 .
Surgical re ection can be accompli hed with
acceptable operative mortality and morbidity with respect
to length and quality of life 6•12- 17• The key to ucce ful
surgical management of EHBD cancers is early and
accurate preoperative diagno i 13 • Invasion of the hepatic
artery, portal vein and di tal metasta e are the u ual
reasons makin§ the e tumous nonresectable at
diagno i 3' 13' 1731.38.3 • Contraindications to re ection include:
(1) regional/ distant meta ta e ; (2) bilateral intrahepatic
spread beyond econd order ducts; (3) inva ion of the
main trunk of the hepatic artery; (4) inva ion of the main
trunk of the portal vein9•13•17•43• 44•45.
A tumour is considered re ectable if it is localized to
the bile duct. Procedure for radical urgery are
individualized and preoperative mapping with PTC and
ERCP are crucial to plannirlg. If resection is performed a
margin of 1.5 em from the edge of the tumour e pecially
on the hepatic side i recommended 46 .
Postoperative complication include ana tomotic
leaks, wound infection, bleeding, intra-abdominal ab ce s
formation, sep is, pancreatitis, and portal vein
thrombo is 13• As a result of improved surgical technique
and po toperative management of patients, the
po toperative mortality rate has decrea ed . The
perioperative mortality rate depends upon the extent of
the surgical resection, but range from 2-5%47.
Liver transplantation as a form of management i not
an effective treatment for the management of EHBD
cancer. It has been e timated that up to 0% of transplant
patient died or manife t di ea e recurrence within one
ye~· 2+27 • In the literature, there have been a few report of
curative surgery with liver transplantation for hilar
carcioma with adequate long-term urvival, if margins
are clear and lymph node are negative .49 . At pre ent, thi
i still not an accepted therapeutic option and is
considered experimental.
Conclusion
Extrahepatic bile duct cancer are rare neopla m with
overall five year urvival rate less than 5%. En bloc
surgical re ection with negative hi tologic margins offer
the only chance for cure. Even with surgical re ection, 707~% of patient~ develop tumour recurrence and ultimately
die from the di ease. onre ectable patients can be treated
palliatively with PTC drainage of the obstructed bile duct
or via ERCP placed tent . Adjuvant radiotherapy via
external beam or intracavitary radiotherapy may improve
urvival. Palliative radiotherapy may slow progre ion of
the tumour and minimize a ociated ymptom . Although
extra-hepatic bile duct carcinoma are rare, they should be
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con idered in the differential diagno is of p atient who
pre ent with ob tructive jaunctice.
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CURRENT OPTIONS IN LOCAL
BREAST CANCER TREATMENT
By Helen Lewandowski

INTRODUCTION
reast cancer is the most common malignancy in
women 1, and the mortality from this disease is
second only to that of lung cancer as a cause of death
among women2 • In the general population, an individual
woman' s lifetime risk for developing breast cancer is one
in nine 1• These numbers are staggering to many women,
for whom breast cancer often carries powerful emotional
connotations aside from its medical consequences. This
disease is particularly frightening because it runs an
insidious course. The preclinical, prediagnosis stage of a
breast tumour's history and the clinical phases after initial
treatment are often measured in decades 3 . Breast cancer
has an essentially fixed rate of recurrence for 15-20 years
after initial treatment. This is in marked contrast to most
other cancers, for which a 5-year survival can be
considered a cure4 •
Patients diagnosed with breast cancer and their
clinicians are faced with multiple treatment decisions5 .
These include combinations of surgery, chemotherapy,
radiation therapy and hormonal therapy. The choice of
treatment decisions in breast cancer is largely guided by
tumour stage at the time of diagnosis, and patient
preference . Breast tumours are staged according to
tumour size, presence of nodes or distant metastases, and
whether the tumour is inflammatory or ulcerates the skin
(see Table 1). In patients with less advanced disease,
surgery is still the mainstay of treatment. However,
surgery in patients with advanced systemic disease is
limited. Radiotherapy and hormonal manipulation are of
considerable importance to treat or palliate si t es of

B

TABLE 1- Staging and Prognosis of Breast Cance~
Stage

Description

5-year survival

stage 0
stage 1

in situ carcinoma
primary tumour <2cm,
negative axillary lymph nodes,
no distant mtastases
primary tumour <2cm
and positive axillary lymph nodes,
or primary tumour 2-5cm
with negative nodes
tumour 2-5cm and positive
nodes, or tumour >5cm
and negative nodes
tumour >5cm with ipsilateral
axillary nodes or
fixed lymph nodes
internal mammary lymph nodes,
or tumour extending to chest wall
and ulcerating the skin
distant metastases

95%
85%

stage 2A

stage 28

stage 3A

stage 38

stage4

64

75%

65%
50%

41%

10%

metastases 1• This article focuses on current issues in the
local treatment of breast cancer, and how it should be
timed in relation to systemic treatments.

LOCAL TREATMENT OF BREAST CANCER
Historically, the evolution of local treatment has
mirrored the prevailing theories on the spread of breast
cancer. At the turn of the century, Halsted popularized the
radical mastectomy, which involves en bloc resection of
the breast, overlying skin, underlying pectoral muscles
and axillary contents6 . This was based on the belief that
tumour spread occurs in an orderly fashion by direct
invasion and through lymphatic channels. The goal of
brea st cancer surgery was to remove the maximum
amount of breast tissue and axillary lymph nodes in order
to fully eradicate the tumour. This policy remained
unquestioned dogma for several decades until patient
survival analysis in the 1950' s and 1960's demonstrated
that this radical surgery was not improving patient
survival 5 . The realization that failure after surgery was
more often due to systemic dissemination of tumour
before surgery than to inadequate local sur?ery cau ed a
shift towards more conservative approaches .
Currently, there are several surgical options available
to patients with operable tumour. In patients with ductal
carcinoma in situ, these include simple mastectomy and
breast-conserving surgery (BCS) without axillary node
dissection. Patients with invasive stage 1 and 2 cancer
have a choice between BCS with axillary lymph node
dissection, and modified radical mastectomy (MRM).
Simple mast ctomy involves a resection extending from
the clavicle to the costal margin and from the midline to
the latissimus dorsi . The entire axillary tail and the
pectoral fascia are completely removed . The skin is
excised and skin flaps are similar in thickness to those in a
radical mastectomy. However, the axilla is not invaded
and axillary nodes are not remo ed. Modified radical
mastectomy consists of removing the breast, nippleareolar complex and dissection of axillary lymph nodes. In
contrast to radical mastectomy, the pectoralis major
muscle is spared. Rarely, the pectoralis minor muscle may
be removed to facilitate dissection of the higher level
lymph nodes. Breast-conserving surgery for invasive
cancer includes lumpectomy and quadrantectomy, and
consists of resection limited to removal of the breast
tumour with a margin of normal breast tissue. Axillary
dissection is performed and the patient receives postoperative adjuvant breast irradiation. All these procedures
can be performed on an outpatient basis with few
complications, few readmissions, and good patient
acceptance 7 • Issues which patients and their clinicians
must address include the choice of mastectomy versus
BCS, the role of axillary dissection, and the timing of
chemotherapy relative to surgery.
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MAS TECT O M Y VERS U S BREA ST-CO N SERVI N G
SURGERY
Initial treatment for women with stage 1 or 2 breast
cancer is surgery. The option available are modified
radical mastectomy and breast-conserving surgery.
Evidence from six prospective randomized controlled
trials has shown that removal of the tumour followed bl
radiotherapy results in similar survival as mastectomy .
Without particular reasons for electing mastectomy, the
choice between BCS and MRM is made according to
patient preference. The goal of BCS is to provide
atisfactory cosmetic results without compromising local
tumour control or survival compared to l'vfRM'l. However,
there are conditions in which mastectomy is favored. It is
indicated for diffuse-appearing microcalcifications on
mammography, multiple tumours in different breast
quadrants, failure to obtain tumour-free margins, and if
radiotherapy is contraindicated. Contraindications to
radiotherapy include physical disabilities preventing its
u e, a history of therapeutic irradiation of the breast or
chest, treatment during the first or econd trimester of
pregnancy, scleroderma and SLE . BCS is also not
recommended in the presence of a large tumour / breast
ize ratio or a large breast size5• In addition, there are risk
factors for local recurrence following BCS. These include
extensive ductal carcinoma in situ, young age, multiple
tumours and high nuclear grade of tumour. Local
recu~rence may lead to hi~h patient anxiety and may
reqwre salvage mastectomy . In the e patient , the risks
and benefits of mastectomy versus BCS should be
carefully weighed on an individual basis.
In addition, the option of breast reconstruction after
mastectomy should be di cus ed with the patient before
any definitive surgery. Breast reconstruction techniques
include silicone gel implantation beneath the pectoralis
major muscle, and the use of m y ocutaneous flaps to
transfer skin, fat and muscle from distinct parts of the
body. Currently, the most commonly used flaps are the
latissimus dorsi and transverse rectus abdominis (TRAM)
m yocutaneous flaps 3 . Regardless of the technique u ed,
the goal of breast reconstruction is re-creation of the breast
mound . The main indication for this procedure is the
patient's desire to have it performed . The only true
contraindications to breast reconstruction are significant
comorbid conditions that would interfere with the
patient's ability to tolerate a longer operative procedure in
the ca e of immediate reconstruction, or additional
procedures in the case of delayed reconstruction3 .
AXILLARY DISSECTION
The appropriate treatment for the axilla remains
controversial. Although Halsted' s principles promoted
extensive axillary dissection, more recent evidence has
questioned the impact of axillary dissection on survival. A
trial by the ational Surgical Adjuvant Breast Project
howed that radical axillary dis ection did not positively
affect survival in patients with stage 1 and 2 breast
cancer 10 . Axillary dissection is also as ociated with
ignificant surgical morbidity . Possible complications
include post-operative infection, pare thesias, alterations
in houlder mobility and lymphedema. However, the
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presence o r absence of metastatic involvement of the
axillary lymph nodes is the strongest prognostic factor for
patients with primary invasive breast cancer. In addition,
extensive axillary dis ection is associated with greater
reduction of recurrence risk in the axilla than sampling
only a few nodes 11 • Thus, the decision on whether to
remove axillary nodes and how extensively to do so
requires balancing expected health benefits versus side
effects.
Currently, there exist clinical guidelines for axillary
dissection 11 • These are that removal and pathological
examination of axillary lymph nodes should be standard
procedure for patients with early invasive breast cancer.
For accurate staging and to reduce the risk of recurrence in
the axilla, level 1 and level 2 nodes should be removed.
Level 1 nodes are tho e situated lateral to or below the
lateral border of the pectoralis minor muscle. These nodes
receive most of the lymphatic drainage from the breast.
Level 2 nodes are situated deep to the pectoralis minor
muscle and receive lymph from Ievell nodes and and also
some drainage directly from the breast.
After axillary dissection, irradiation of the axilla
should be carried out with caution. Omission of axillary
dissection may be con idered when the risk of axillary
metastases is very low or when knowledge of nodal status
will have no influence on therapy. Recently, attention has
been focused on the technique of sentinel
lymphadenectomy to identify node positive patients 5 •
The e involve the use of markers such as vital blue dye
and techneti u m-labelled sulfur colloid to identify a
sentinel node that drains lymph from the tumour area. If
the entinel node has no evidence of metastatic breast
cancer, complete axillary dissection can be avoided. If the
node is positive for metasta es, axillary dissection should
be performed. In a study of 62 patients, the sentinel node
wa s identified successfully in 92% of cases and was
positive in all patient found to have metastatic disease.
There were no skip metastase 11 • As this techniq u e is
refined, a significant amount of axillary dissection and
surgical morbidity may be avoided in the future.

TIMING OF SURGERY AND CHEMOTHERAPY
Traditionally, chemotherapy has been used as an
adjuvant therapy following surgical resection in breast
cancer . However, neoadjuvant or preoperative
chemotherapy has been commonly used in treating
variou cancers, including breast cancer 12 • The rationale
underlying this is that treating metastases at the earliest
possible time may avoid rapid growth of metastases after
treatment of the primary site and may prevent emergence
of resistant clones. Decreasing the size of the primary
tumour may make unre ectable tumours resectable, may
make organ /?reservation more likely and may improve
local control . This approach is mainly used in women
diagnosed with stage 3 breast cancer. This includes
patients diagnosed with stage 3A disease, which is
generally considered operable, and stage 3B disease which
is inoperable. Patients with inflammatory breast cancer are
als~ included in stage 3B disease. This subgroup of
patients has a particularly poor prognosis, and is
characterized by tumours with a rapid onset of erythema,
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edema and ridging 13•
Women with stage 3 breast cancer are a complex
group in terms of treatment. Currently, multidi ciplinary
therapy is the treatment of choice for the e patients. The
accepted strategy is primary or neoadjuvant
chemotherapy followed by either surgery, radiotherapy or
both. Most patients achieve a respon e to chemotherapy
that results in downstaging of the tumour. With the
multidisciplinary approach, 5-year survival rates are 3060%, compared to 10-20% for local therapy alone 13 • In one
study, patients with stage 3 breast cancer including
inflammatory disea e were treated with chemotherapy
followed by surgery and additional chemotherapy.
Patients with inflammatory brea t cancer or
supraclavicular nodes also received adjuvant
radiotherapy. Overall 5-year survival was 56%, and wa
affected by stage (3A or 3B), presence of inflammator:f
breast cancer and the number of positive nodes 1 •
However, it i not clear that the apparent improvement in
outcomes resulted from the use of neoadjuvant
chemotherapy as much as the use of chemotherapy itself.
In another report, the addition of chemotherapy after
radiotherapy and surgery in patients with stage 3 breast
cancer improved 3-year survival from 57% to 90%, and
this difference remained highly significant at 5 years 12 •
Therefore, neoadjuvant chemotherapy has not been
shown to improve survival when compared to adjuvant
chemotherapy for stage 3 breast cancer. However, the u e
of neoadjuvant chemotherapy may decrease the tumour
size and thereby reduce the scope and difficu l ty of
surgery. In one stud y, patients with locally advanced
brea t cancer deemed unre ectable with primary w ound
do ure underwent 8 weeks of infusional 5-fluorouracil
and radiation therapy. 73% of patient had an objective
clinical response and all were able to undergo MRM with
primary wound closure 14 . Additionally, the use of
neoadjuvant chemotherapy reduces the likelihood that
skin grafts or complex reconstruction will be required, and
may decrea e the inten ity and morbidity of irradiation
needed to treat the brea tor che t wall 12 •
The use of neoadjuvant chemotherapy in stage 3
breast cancer gave rise to the idea of applying this
approach to patients with earlier stage, operable brea t
cancer. This was based on
tudies showing
"micrometa tases" in the blood and bone marrow of a
significant number of patients undergoing surgery for
early tage breast cancer 15 • It was felt that if the e are
treated earlier, there is the potential for higher cure rate .
However, the use of neoadjuvant chemotherapy for
patients with operable breast cancer i controver ial. It
may achieve significant tumour regression but the
primary goal of improving survival has not yet been
clearly demonstrated 15 • At this stage, neoadjuvant
chemotherapy for operable brea t cancer i still considered
investigational.

constitute es ential aspect of treatment. Several urgical
option are available to patients and their clinicians. The
choice between mastectomy and BCS should be based on
tumour factors and and patient preference following a
thourough di cussion of the e options. Following surgical
treatment, the need for adjuvant chemotherapy and I or
radiation therapy must be determined based on tumour
characteristics such as stage, grade, hormonal status and
patient characteri tics uch as menopausal statu s and
previous m dical hi tory. By weighing these factors
carefully, breast cancer treatment may be optimized for
patients on an individual basi .
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CONCLUSION
The current management of brea t cancer require a
multidi ciplinary approach involving surgical, medical
and radiation oncologists. This field is constantly
evolving. Local and systemic treatment mod a lities
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RECENT ADVANCES IN
UNDERSTANDING MELANOMA
By Benjamin Barankin and Lyn Guenther MD

educing melanoma mortality i an important public
health goal for dermatology, and as a result, has
been intensively tudied from an epidemiological
point of view. 1 The recent literature on melanoma will be
di cus ed.
Melanoma i a malignant di ease ansmg from
melanocytes. Melanocytes produce melanin, which
generate a brown skin color. Skin cancer is the most
commonly diagnosed cancer in the United State and
Canada (more than 63,000 Canadian will develop kin
cancer each year); anyone born today has a 1 in 7 risk of
developing skin cancer during his/her lifetime. 17
Although the incidence of melanoma is lower than other
type of skin cancer, it i the mo t erious form of skin
cancer and has the highest death rate. 3 In 1996 in the
U.S.A, there were an e timated one million ca es of kin
cancer; 5 percent of tho e were melanoma and caused 75%
of kin-cancer death _3 In 1999, a 6% increa e in melanoma
incidence is expected which will mean that 44,200
American will be diagno ed this year (3200 in Canada),
with approximately 7,300 deaths attributed to melanoma. 3
In Ontario, there are approximately 1400 people
diagnosed with melanoma (men > women) each year with
approximately 300 deaths per year. 16 A disturbing trend is
that the incidence of melanoma in Canada ha doubled
during the past 20 year .17 Clearly, more need to be done
in terms of education and prevention. According to Dr.
Ja on Rivers from the University of British Columbia, the
increase in the age-specific incidence for melanoma has
tabilized for women, especially for more recent birth
cohorts, but in men the rate i till increasing. 26 Table 1
provides skin cancer statistics and trends in Canada.
Melanoma occur among all racial and ethnic group .
It i more frequent in re ident of areas of high ambient
solar irradiance, more frequent in un ensitive people and
occur with highe t density on body site expo ed to the
un. In addition, melanoma ha been hown to be more
frequent in people with intermittent high sun expo ure.2
The u eful acronym for identifying a possible melanoma is
de cribed in Table 2. The incidence among dark skinned
ethnic groups i 1 per 100,000 per year or les , but among
light- kinned people has been measured as high as 50 per
100, 000. 1 In common with most cancers, melanoma
incidence increases with age. However, in Cauca ians, it i
relatively more common in young adult than most other
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Canadian Skin Cancer Statistics &Trends

• Half of all new cancers are skin cancers
• Approximately 63 ,000 new cases of skin cancer will be
diagnosed this year in Canada
• Approximately 3,200 new cases of melanoma will be diagnosed
this year in Canada
• In 1998, 740 deaths were attributed to malignant melanoma
• The incidence of melanoma doubled among the white population
between 1973 and 1991
Table 1: Skin Cancer in Canadians

cancers. In fact, in the U.S.A, melanoma is more common
than any noncutaneous malignancy in the 25 to 29 year
age group, and it accounts for more years of life lost per
case among adults than any major site other than
testicular cancer. 3 As well, a gender difference in
melanoma location exi ts; that is, women have an exces
of melanoma on the legs, and men have an exces of
melanoma on their ear , calp and especially the posterior
trunk .U 5 In 1996, a study in the Journal of Cutaneous
Medicine and Surgery found that men and women had a
similar anatomic distribution of painful sunburns, and
since the anatomic distribution of melanoma differ , "it
would appear that factors in addition to sunburns in
adults account for the differences in the anatomic
distributions of melanomas in men and women." 15
Unawareness of Melanoma
A high proportion of U.S. residents are unaware of the
dangers of melanoma . Forty-two percent of those
surveyed had no knowledge of the disease, with the level
of awareness lowest among people ages 18 to 24 year .
The survey also found the level of melanoma
awarene s to be directly related to levels of education and
income. Of those with annual incomes of less than $20,000,
60 percent reported they did not recognize the term
The ABCD's of Melanoma

Asymmetry-<>ne half doesn't match the other half.
Border irregularity-edges are ragged, notched or blurred (not well
circumscribed).
~lor-color is not uniform. Shades of tan, brown and black are
present; red, white or blue may also be present.
Diameter-more than six millimeters.
Other Warning Signs of Melanoma:
• change in the size, shape, or color of a mole
• oozing or bleeding from a mole
• a mole that feels itchy, hard, or tender to the touch
Table 2: Principles in detecting skin cancer '
Source: American Academy of Dermatology
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melanoma. Only 31 percent of tho e with annual incomes
of $75,000 or more reported no knowledge of the disea e.3
It is likel y that many Canadians would be similarly
unaware of melanoma.
UV and Melanoma
The two types of ultraviolet radiation that reach the
earth from the sun are ultraviolet A (UV A) and ultraviolet
B (UVB). UVB has long been a sociated with sunburn,
while UV A has been recognized as a deeper penetrating
radiation. Scientists have long suggested that there may be
an association between UVA radiation and malignant
melanoma. 3 The wavelen?th of tanning parlors is UV A.
Both tanning parlors 22•23•2 and PUV A (Psoralen & UV A
rays) 25 increa e the ri k of melanoma. It is only r cently
that UVB rays have achieved similar tatu in causing
melanoma. In the recent study in the May 1998 issue of the
American Journal of Pathology, 158 human ne w born
foreskin grafts on immunodeficient mice were treated
with
a
chemical
accelerant
7, 12dimethyl[a]benzanthracene (DMBA) alone or UVB alone,
or UVB combined with DMBA, or nothing. The grafts had
had no prior sun exposure. Twenty-three percent of the
grafts treated with only UVB, and 38% of grafts treated
with the combination of DMBA and UVB, deve loped
abnormal pigmented lesions including one human
malignant melanoma within 5-10 months of exposure.
Untreated human skin xenografts were unchanged, and
those receiving only DMBA had very minor changes in a
few grafts.
Sun Awareness
Efforts to educate people about sun protection have
resulted in an increased awarene s that sun expo ure is
dangerous. In a study released in 1997 by the American
Academy of Dermatology, a decline in the attitude that
having a tan was healthy and an increa e in the reported
u e of unscreen by adult (35% in 19 6 to 53% in 1996)
was noted.3 Unfortunately, during the arne decade, the
UV exposure of adults, as measured by sunburning (30%
in 1986 to 36% in 1996) also increased, a did the regular
use of tanning beds (2% in 1986 to 6% in 1996).3 The risk
factors for developing skin cancer are listed in Table 3.
Sunscreens Increase Cancer?

• blond or red hair
• blue eyes
• Caucasian
• changed/changing mole
•
•
•
•

congenital mole
fair complexion
freckles
immunosupression

• melanoma in first-degree
relative
• one or more large or
irregularly pigmented lesions
• personal history of melanoma
• severe sunburns in childhood

• inability to tan

Table 3: Risk factors for skin cancet
Source: Centers for Disease Control
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Recent controversy over the role of sunscreens in
preventing melanoma has raised que tions about the u e
of the e agents. There is concern among some
dermatologist that unscreens alone do not protect
against melanoma. Sunscreen might unfortunately lull
you into a fal e ense of security, making you feel that you
can stay out much longer than you should. Unfortunately,
some individuals with the belief that sunscreen provides
sufficient protection, may ignore other sun safety
behaviors that could provide additional protection.
Sub equently, these same individuals may ignore
suspiciou marks or lesions as potentially dangerous
becau e the feel that sunscreen alone provide all the
protection they need. 3 Historically, the sunscreens used in
the pa t offered poor longer wavelength UV A protection
which may have also played a role in melanoma rate not
falling with increased sunscreen use . Use of these
sunscreens may have increased the long UV A exposure if
sun exposure increased since the suncreen decreased
burning. There is actually little evidence that protection
again t the sun protects against melanoma, but this issue
is difficult to study epidemiologically.2 Clearly more
research into thi matter is nece ary.
Self-Examination
According to a study published in the May, 1998
Journal of the A merican Academy of Dermatology, people are
more motivated to examine their kin for skin cancer if
they have had di cu ions with doctors and if they think
they are at hi~h risk for developing melanomas and other
skin cancers. It is estimated that skin self-examination
(SSE) may reduce mortality from melanoma by 63%.
Eighty-one percent of tho e surveyed who talked to a
health care orker were doing SSE compared to 35% who
were practicing SSE but had not talked about sunning
with a doctor or nur e. SSE was reportedly performed 1.5
time more often by women than men, with white persons
performing SSE 1.7 times more often than other races.
Some education beyond high school also increa ed the
practice of regular SSE. Thus, there is clear evidence for
the n ed for prevention through skin self-examination in
melanoma. Thi will both ease its economic burden, and
more importantly save live .
Relating Melanoma Risk to Nevi
Recent r search has found that the risk for melanoma
wa trongl related to the number of small nevi, large
non-dysplastic nevi, and clinically dysplastic nevi. In the
absence of d splastic nevi, increased numbers of small nevi
were a sociated with an approximately 2-fold increased
risk, and increased numbers of both small and large nondysplastic nevi were associated ith a 4-fold increa ed
risk. One clinically dy plastic nevu was associated with a
2-fold increased ri k, while 10 or more conferred a 12-fold
increa ed risk. As well, there is an estimated 81.6%21 to
100%19 lifetime risk of melanoma in a person with familial
dysplastic nevi who ha two relatives with melanoma. 19 In
regard to congenital nevi, they appear to significantly
increa the risk of malignant melanoma if they are large
(= 20cm) .3.2° The reported risk in patient with large
congenital nevi varies from 3.8% -18%. 20
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Genetic Testing for Melanoma?
It has been hown that approximately 8 to 12% of
melanomas appear to be inherited in an autosomal
dominant fashion. A French tudy published in the
October 1995 issue of the Archives of Dermatology
concluded "a familial investigation should be performed
for each pat~ent wi th cutaneous malignant melanoma
(CMM), particularly when he or he exhibits phenotypic
ri k factors for CMM such a red hair and atypical
moles." 13
Furthermore, th ere is now trong evidence that
germline mutation of the CDKN2A gene on chromo orne
9p21 predispo e to melanoma in a sub et of melanomaprone familie . A tudy published recently in the Journal
of Cutaneou Medicine and Surgery concluded "the
identification and subsequent surveillance of unaffected
individual who have a genetic predi position to
melanoma may lead to the detection of early (curable)
melanomas and to a red uction in mortality." 10
Cost of Treating Melanoma
A recent tudy in the U.S. found that the annual direct
co t of treating newly diagno ed melanoma in 1997 was
e timated to be $563 million. Dr. Ja on River from the
University of British Columbia noted tha t the Canadian
figure i unknown, but estimated it to be 5-10% of the
American co t. 26 The American study broke down the cost
of treating each stage of the disea e and found that Stage I
and II disea e each comprised about 5% of the total cost;
stage Ill and stage IV disease consumed 34% and 55% of
the total co t, respectively. About 90% of the total annual
direct cost of treating melanoma in 1997 was attributable
to less than 20% of patients (those patients with advanced
di ease, that is, stage III and stage IV). The study
concluded that "in addition to the potential urvival
advantages, aggre sive primary prevention through sun
protection and intensive screening to enhance earlier
detection sho u ld reduce the economic burden of
melanoma care." 5
Laboratory Tests And Imaging for Melanoma
There i an ongoin g controversy abo u t the use of
laboratory and imaging studie for baseline and for
follow-up evalua tion to detect malignant melanoma
(MM) metastases. Some argue that no laboratory te ts or
imaging studies hould be routinely ordered for patients
who exhibit no evidence of metastases on history or
physical examination. However, CXR screening may be
sugge ted since it detects about 5% of metastase which
would have been classified clinically as AJCC (the
American Joint Committee on Cancer) stage I or II MM.
LDH levels, which are inexpensive, are routinely ordered
b y orne physicians because metastases have been
infrequently detected in asymptomatic patients. Some
physicians also consid er computed tomography (CT)
scans for patients who have thicker primary MM; CT of
the c:hest sho~ d be considered e recially if the patient has
cerVIcal or axillary adenopathy. 1 The final position from
the Guidelines for th e Management of Cu taneous
Melanoma i that "extensive investigation for systemic
metas tases in patien ts with primary melanoma is not
U. W .O. Medical Journal 70 (1 )
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recommended" and that " inve tigation s u ch as CT,
ma~_etic resonance imaging (MRI) cans, and positron
enusswn tomography (PET) scans should be utilised only
where specific symptom suggest the pre ence of
meta ta es. 9
Advances in Melanoma Therapy
The improvement of treatment options and urvival
rates for melanoma patient is an important health care
concern as melanoma is the tenth mo t common type of
cancer in Canada.1
Several advance in the evaluation of regional lymph
node , adjuvant therapy and genetic immunotherapy for
the treatment of malignant melanoma have improved the
treatment options for patients, as well as the five year
survival rate for many patients according to a study in the
May 1998 issue of the Journal of the American Academy of

Dermatology.
The evaluation of regional lymph nodes has proved to
be an important predictor of the long-term ou tcome. In
patients with nodal metastase , the actual number of
di ea ed node i the mo t important factor for the
prognosis and overall urvival. Selective node dissection
(which focu es on the main, or entinel, node) may be
u ed to determine the condition of the entire grou p of
nodes.9 Another evaluation of the regional lymph nodes,
intraoperative radiolymphatic mapf,ing, increase entinel
node identification to 99 percent. Both of these options
are still controver ial, and confirmation is needed.
The most significant prognostic factor for melanoma is
di ea e stage at presentation. While AJCC stage I and II
melanomas (localised disease) have five year survival
rate of ~ 85%, the rate for tage IV (metastatic) disea e is
less than 5%, with median survival time of 6-10 months. n
Becau e of the poor progno i of tage IV disease, clinical
trials of adjuvant therapy are underway. A promising but
controversial adjuvant therapy involves interferon alpha
2b ~hich may improve the long-term survival rates of
patient . A study publi hed in the January 1996 issue of
the Journal of Clinical Oncology hawed that "IF alpha
2b wa the first agent to show a significant benefit in
relap e-free and overall survival of high-ri k melanoma
patients in a randomized controlled trial." 14 However, at a
recent conference addressing the issue, it was noted that
only high dose interferon therapy (as opposed to low
do e) may have potential benefit, but that at present, since
clearly more re earch is needed, there is no standard
therapy for high-risk melanoma patients. n
Genetic immunotherapy focuse on application of
gene therapy as it applies to immunotherapy ba ed upon
the understanding that melanoma appears to be an
immunoresponsive di ease. One approach to gene therapy
involves genetically modifying tumor cells to make them
more immunogenic. Another approach involve the
injection of foreign genes directly into the tumor in an
attempt to impact the immune response to the tumor.
Due to the inconclusive evi d ence tha t adj u vant
therapy is beneficial for persons with melanoma, the
Guidelines for the Management of Cu taneous Melanoma
recommend referral to a melanoma centre for adj uvant
therapy such as immunotherapy, chemotherapy or gene
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therapy in patients with melanoma > 4mm in thickne
and / or wi th involved node , whose progno is is poor.9
Melanoma is certainl y one of the mo t s tu died
condition in Dermatology, and with reason. Wi th the
promising research into it treatment and prevention, we
hope to ee declines in the incidence and imp r o ved
urvival in the near future .

25. Stern RS, icl1ols KT, Vakeva LH. Malignant melanoma in patients treated
for psoriasis with methoxsalen (p ora/en ) and ultraviolet A radiation
(PUVA): The PUVA Follow-Up Study. N Eng/ J Med 1997;336:1041-5.
26. Rivers ]. The Un iversity of British Columbia. Personal Communica tion,
February 11, 1999.
Q
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CARDIOVASCULAR MANIFESTATIONS
OF RHEUMATOLOGIC DISEASES:
A REVIEW
By Dan Hackam BSc, Editor-in-Chief
great variety of sy temic di ea e and yndrome
di play cardiova cular manife tations, and among
these, the rheumatologic di eases figure
prominently. Such effect range from the trivial and the
benign, such as most pericardia! effusion occurring in the
context of collagen vascular diseases, to the severe and
life-threatening, eg myocardial fibrosis occurring in
cleroderma. 1 This review erves to briefly highlight the
cardiac con equences of orne of the more common
rheumatoid conditions.
Sy temic lupu erythemato us (SLE) is a multisy tern
di order in which tis ue are damaged by autoantibodie
and immune complexes2 The va t majority of case occur
in women in their child-bearing years. The disorder has a
prevalence of 20-50 cases per 100,000, and is more frequent
in blacks than in white .
Pericarditi i the mo t common cardiac manife tation
of SLE, and occur in two thirds of patient . It is generally
benign, sometime associated with pericardia} effusion ,
and rarely lead to tamponade or constrictive pericarditis.
If not evident from the clinical background of SLE, the
diagnosis can be made by the pre ence of lupu
erythematosu cells or a titre of antinuclear antibodie .
Valvular insufficiency is a rare consequence of SLE and i
a result of Libman Sachs endocarditis, which may lead to
sy temic emboli. Myocarditis may result in conduction
abnormalitie , heart failure, or udden death.
The antipho pholipid yndrome is a well-known ub t
of lupus and is associated with valvular dysfunction, a
tendency towards thrombo i , myocardial infarction (MI),
pulmonary hypertension. and cardiomyopathy. MI occurring
in a lupus patient may be due to this prothrombotic tendency,
or may be the result of lupu vasculiti , chronic steroid
treatment, or coronary athero clerosis. Anticoagulation i
recommended with high dose coumadin treatment, aiming
for an INR between 2.5 and 3.0.
Rheumatoid arthriti (RA) i another multisy tern
di ea e with diverse multiorgan effect , the sine qua non
being an inflammatory synoviti that chiefly affect the
peripheral joints. 3 The prevalence of thi disorder is
approximately 0.8%, with a female:male preponderance of
3:1. RA may affect any part of the heart, with pericarditi
again being the mo t common cardiac complication (1050% of RA patients); it is particularly prevalent in tho e
patient with ubcutaneous nodules. Coronary arteriti ,
occurring in up to 20% of patients (ba ed on autop y
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tudie ), may infrequently result in the occurrence of MI
or angina pectori . Myocarditi and valvular insufficiency
are further, rare complications.
Raynaud's phenomenon can be defined as episodic
ischemia of the finger or toes occurring in the context of
expo ure to cold weather or objects .~ It may be primary
and idiopathic, in which ca e it is known as Raynaud's
disea e, or may be econdary to an underlying disease,
medication, or other process. Raynaud's disease has a
female :male preponderance of 5:1, with a peak onset
between the age of 20 and 40. The disorder is associated
with primary pulmonary hyperten ion and coronary
va o pasm (also known as variant angina).
Scleroderma is a multiorgan disease typified by fibrosis
of the kin, blood ve els, and viscera. 5 Cardiovascular
complications are frequent in the diffuse cutaneous
systemic dero i ubset, and rare in the more limited form
of scleroderma. The e manife tations include pericarditis,
heart failure secondary to hypertension or cor pulmonale,
and arrhythmias. Left- ided heart failure occurs in up to
30% of patients with diffuse cutaneous scleroderma.
Ankylosing spondyliti (AS) is an inflammatory
di order that characteristically affects the axial skeleton,
starting in the 2nd or 3rd decade of life. 6 The male:female
preponderance is 3:1. The two cardiovascular effects of AS
are aortic regurgitation and conduction defects. In a small
percentage of patient , all three layers of the aortic valve
and proximal thoracic aorta are thickened and scarred,
re ult:ing in aortic insufficiency. The frequency of both the
valvular abnormality and the conduction defect increase
with the duration of the di ease.
In do ing, the e cardiovascular manifestations are by
no means the commonest effects of rheumatological
disorder , but when they occur, they may be devastating
to the patient. It is therefore important that the noncardiologi t have a good grasp of these complications, in
term of natural history, diagno i , and management.
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reactions reponed during therapy were of mild·to·moderate severity.
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NORVASC
famlodipine besylate)
Tablets 2.5, 5 and 10 mg
Antihypertensive-Antianginal Agent
ACTION AND CUNICAl PHARMACOLOGY
NORVASC (amlodipine besylate) is a calcium ion influx inhibitor (calcium entry blocker or calcium ion anugonist).
Amtodipine is a member of the dihydropyridine class of calcium antagonists.

INDICATIONS AND CUNICAl USE
llyporteosioa
NORVASC (amlodipine besylate) is indicated in lht treatment of mikt-to-moderate essential hypen.ension
NORVASC should normalty be used in those patients in whom treatmem with diuretics or beta-blockers was found
ineffective or has been associated with unacceptable adverse effects. NORVASC can be tried as an initial agent in
those patients in whom the use of diuretics and/or beta·bktckers is contraindicated or in patients with medical
conditions in which these drugs frequently causa serious adverse effects. Combination of NORVASC with a
diuretic. a beta·IOOcking agent. or an angiotensin converting enzyme inhibR:or has been found to be compatible and
showed additive antihypertensive effect.
Cluooic Slo~le AllfiN

NORVASC is indicated for the managemem of chronic stable angina (effort-associated angina) in patients who
remain symptomatic desp e adequate doses of beta-blockers and/or organic nitrates or who caMot tolerate those

agents. NORVASC may be tried in combination with beta-blockers in chronic stable angina in patients With normal
ventricular function. 'Nhen such concomitant therapy is introduced, care must be taken to monitor blood pressure

~~~~'.:~=~";ion con occur from the combined effects of the drugs.
NORVASC famlodipine besylatel is contraindicated in patients with hypersensitivity to the drug or other
dihydropyridine• and in patients with severe hypotension floss than 90 mmHg systo~c) .
WARNINGS
lncrouo4 Allfino ertd/a< MyGcenliellllfon:tioa
~arety. pa ·enu, particularty those with severe obstructive coronary artery disease. have devetoped documented
mcreased frequency, duratiOn end/or severity of angtna or acute myocardial infarction on starting calcium channel
blocker therapy or at the time of dosage increase. The mechanism of this effect has not been etucidated

Olllllow OhtrtoctiH (Aomc SIHosis)
NORVASC should be used with caution in a presence of fixed left ventricular outflow obstruction

(aortic stenosisl.

Uso in Potients widllmpoirocl Hepotic Ftonction
There are no adequate studies in patients with liver dysfunction and dosage recommendations have not been
established. ln a sman number of patients with mild· to-moderate hepatic impairment given single dose of 5 mg,

amlodipine hd-f~e has been prolonged. ORVASC should. therefore, be administered with caution in those
patients and careful monitoring should bo performed. A lower starting dose may bo required (see DOSAGE AND
AOMINISTRAnON).
B...· blockor Wttlldrowol
NORVASC gives no protection against the dangers of abrupt beta-blocker withdrawal and such withdrawal should
be done by the gradual reduction of the dose of be •-blocker.
PRECAUTIONS
Use: ia PMints willl Cotttestiw H.. rt Fail•re
Although generllty caldum channel blockers should onty be used with caution in patients with heart failure, it has
been observed that NORVASC had no overall deleterious effect on survival and cardiovascular morbidRy tn both
short-term and long-term clinical trials in these patients. While a significant proportion of the patients in these
studies had a history of ischemic hean disease, ang•na or hypenension. the studies were not designed to
evaluate e treatment of angina or hypenension in patients with concomitant hean faiure.

HypototosiH
NORVASC famlodipine besylate) may occasionally precipitate symptomatic hypotension. Careful monitormg of
blood pressure 1s recommended, especiatty in patients with a history of cerebrovascular insufficiency, .,,d those
taking medications known to lower blood pressure.

Peripllorol Edot111
Mild·to·moderate peripheral edema was the most common adverse evant in the clinical trials (see ADVERSE

REACTIONS). The incidence of peripheral edema was dose-dependent and ranged in frequency from 3.0 to 10.11%
in 5 to 10 mg dose range. Care shoutd be taken to dffferentiate this peripheral edema from the effects of Jncrusing
left ventricular dysfunction.
Uso io f'rotNocy
Although arNod1pine was not teratogenic in the rat and rabbn. some dihydropyridine compounds have been found
to be teratogenic in animals. In rats, amlodipine has been shown to prolong both the gestation period and the
duration of labor. There is no clinical experience with NORVASC in pregnant women. NORVASC should be used
during pregnancy ontv if the potential benefit outweighs the potential risk to the mother and fetus.
N•rsi.. Modters
It is not known whether amlodipine is excreted in human m;lk. Since amlodipine safety in newborns has not been
established, NORVASC should not be given to nursing mothers.
Use: in Ctlildqn
The use ol NORVASC is not reconwnended in children since safety ond efficacy have not been established in that popula1ion.

Usoio EJclorty
In elderty patients (265 years) clearance of amlodipine is decreased with a resulting increase in AUC. In dnical
trials the incidence of adverse reactions in elderly patients was approxunatety 6" higher than that of younger

population 1<65 years). Adverse reactions include edema, muscle cramps and dizziness. NORVASC should bo used
cautiously in elderly patients. Dosage adjustment is advisable Isee DOSAGE AND AOMINISTRAnON ).
lnlorlctioo wid! Gropofno~ Juice
Published data indicate that through inhibition of the cytDchrome P450 system, gropefru~ juice can increase plasma
levels and augmem pharmacodynamic effects of some dihydropyridine calcium channel blockers. followmg oral
ad · ·stration of 10 mg amlodipine to 20 male volunteers, pharmacokinetics of amlodipine were sirrular when
amlodipine was admirvstered with and without grapefruit juice.
D... lotoroc:tiAs 'Nith al drugs, care shoukl be exercised when treating patients wRh rootbple medications. Dihydropyridine calcium
channel bk)ckers undergo biotransformation by the cytochrome P450 system, mainty via CYP 3A4 isoenzyme. Coad·
ministration of amlodipine with other drugs which follow the same route of biotransformation may resutt 1n altered
btoavailabiiRy of amlodipine or these drugs. Dosages of similarly metabolized drugs, particularty those of low therapeutic ratio, and especia in patients with renal and/or hepatic impairment. may raquire adjustment whan starting
or stopping concomitlntty administered amlodipina to maintain optimum therapeutic blood levels.
Drugs known to be inhibitors of tho cytochrome P450 system include: azote antifungals. cimetidine, cyclosporine,
arythromycin. quinidine, terfenadine. warfarin.

Drugs known to be inducers of the cytochrome P450 system include: phenobarbital, phenytOin, rifampin.
Drugs known to be l>iotansformed via P450 include: bonzodiazepines. ftecainide, imipramine, propofenone, theophylline.
Amlodipine has a low Irate of first-pass) hepatic clearonce and consequent high bioava~ability, and thus. may be
expected to have a low potential for clinicalty relevant effects associated with elevation of amlodipine plasma
levels when used concomitantly with drugs that compete for or inhibit the cytochrome P450 system.
Ci..tidiH, Warfarin. C,Ciosporia. Digoxia; Pharmacokinetic interaction studies with amlodipine in heatthy
volunteers haw indicated:
• ciiMtidina did not alter the pharmacokinetics of amlodipine.
• amlodipine did not change warfari•·induced prothrombin response time.
• amlodipine does not significandy alter the pharmacokinetics of ~lospori L
• amlodipine did not change serum digoxi• levels or digoxi• renal clearance.
Alotacids
Concomitant administration of Maatox- (magnesium hydroxide and aluminum hydroxide I had no effect on the dis·
position of a single 5 mg dose of amlodip10e in 24 subjects.

Bota-bloekers: When beta-adrenergic receptor blocking drugs are administered concomitantly with NORVASC,
patients should be carefully monitored since blood pressure lowering effect of beta-blockers may be augmented by
amlodipine's reduction in peripheral vascular resistance.

ADVERSE REACTIONS
ORVASC famlodipine bosylatel has been administered to 1,714 patients (1105 hypertensive and 909 angona
patients) in controled clinical trials fvs placebo alone and with active cornparatiivo agents). Most adverso

ltyportoosioa
In the 805 hypertensive patients treated with NDRVASC in comoled clinic II trials, adverse effects were reported in
29.9ll ol patients and requirod discontinuation ol therapy due to side effects in I A ol patients. The most common
adverse rwac:tions in comoled clinicll trials were: edema f8.9'Jf.land headache fti.J'JI~ The folowing adverse reactJOns
wore reported With an incidence of~" in the comoled clinical trials program fn=Ui~
Conliovosuler. edema I8.9'Jf.), palp~ations l2.0ll), tachycardia 10.7"1. poSilJral dizziness 10.5"1-Skio and
~ pruritus fD.n.). Mncolosltel...l: muscle cramps (0.5"1- Cootraleod Poripllorol Nervoa
SystoM: headache (8.3"1. diuiness IJ.Oll), paresthesia (0.5"1- - i c N.,.... SysteM: flushing (3.1"1.
increased sweating f0.9'Jf.), dry mouth fo.7"1- Psyc~iotric: somnolence (1.4"1- Gomoiotntioal: nausea 12.4"1.
abdominal pein 11.1"1. dys>epsia ID.6"1. constipation IO.S"I- GOMrlll: fa ·gue (4.1"1. pain 10.5"1AIIfioa
In the cootroled clinical trials in 909 angina patients treated with NORVASC. adverso effects were reported in
of patients and required discontinuation of therapy due to side effects in 0.6" of patients. The most common
adverse reactions reported in controlled clinical trials were: edema f9.9'Jf.land headache 0 .11%).
The following adve,.e reactions occurred at an incidence of~" in tho cootrolled cirical trials program fn=909):
Conliowasc:uler. edema I9.9'Jf.), palpitations I2.Dll). postural diuiness 10.6"1- Skio 1od Appoodegos: rash fi.Oll),
pruritus 10.11%~ Mncolosltelotat muscle cramps (l.!Jll). Cootralood Poripllofal No.- S,.U. headache
0 .11%), dizziness 14.5"1. partsthesll(l.Oll). hypoestheSio IDA~ - Nonooo SystoK ftushing (1.9'Jf.). Psyc~iotric: somnolanco(1.3 , insomrna I0.9'Jf.), nervousness ID.7"1- Gomoiotntioat nausea 14.3),
obdominal pein 12.2"1. dys:>epsi1 fU"I. diarrhea 11.1"1. flatulence II .alii, constipation I0.9'Jf.). Rospirotory Syst- dyspnea 11 . 1"~ Spoc:iel Senses: abnormal vision 11~1. tinnitus (0.6"1-G-rot fatigue (4.11%).
poin (l.Oll), asthenia fl .!Jll).
NORVASC has been evalueted for safety in about 11,000 patients with hypertension and angina.
The follow;ng events occurred in <1% but >0.1% of panents in comparative clinical trials (double· blind
comparative vs placebo or active agents; n = 2.,615) or under conditions of open trials or marketing experience

:ns"

where a causal relationshi:l is uncertain.

Conliowasc:olar. arrhythmia (including ventricular tachycardia and atrial fibrilation), bradycardia, hypotansion,
peripheral ischemia, sync ape, tachycardia, poSilJral dizziness, poSilJral hypotension. Cootralood Poripllofal
NOfVOft Systotn: hypoesthesia, tremor, vertigo. Gulroiotntioal: anorexia, constipation, dysphagia, vomiting,
gingival hyperplasia. Gnenl: asthenia'. back pain. hot flushes, malaise, rigors, weight gain. Mac•loskei.UI
Syst:eta: arthnlgia. arthros s. myalgiL Psycli•imic: sexual dysfunction (male' and fematat insomnia, nervous·
ness, depression. abnormal dreams. anxiety. depersoMiilltion. Respir-.tory Systeta: epistaxis. Skin aH
Appondogos: pruritus', rash erythematous, rash maculopapular, erythema mulliforme. Spoc:ial Sotosos: canjunctivilis.
diplopia, eye pa10. tinnitus. Urinary System: micturition frequency, micturition disorder, nocturia. Autnomic Ner-

, .... Systonl: dry mouth, increased sweating. M... bolic ond Nutritioo 1: thirst. H-iotic: purpura.

1"

These events occurred in less than 1" in placebo-controlled trials, but the incidence of these side effects was
between
and 2% in aU muttiple dose studies.
The foUowing events occurred in sO.
of patients: cardiac failure, skin discoloration. urticaria, skin dryness,
Stevens,.Johnson S'(Odrome,afopecie, twitching. ataxia, hypertonia, m.graina, apathy, amnesia. gastritis,
pancreatitis, increased appetite, coughing. rhinitis, parosmia, taste perversion, and xerophthalmia.
Isolated cases of angioedema have been reported. Angioedema may be accompanied by breathing difficulty. In
postrnarketing experience, jaundice and hepatic enzyme elevations (mostJy consistent with cholestasisl in some
cases severe enough to require hospitalization have been reported in association with use of amlodipine.
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SYMPTOMS AND TREATMENT OF OVERDOSAGE
s,..,._

Overdosage can cause ucessive peripheral vasodilabOn with marted and probably prolonged hypotension end

possibly a reflex tachycardia. In humans. experience with overdosage ol NORVASC famlodipine bosylate) is ·

ed.

When amlod1pine was ing sted at doses of 1()5..250 mg some patients remained normotensive with or without

gastric lavage while anothor patient experienced hypotansion 190150 mmHg) which normalized following plasma
expansion. A patiem who took 10 mg of amlodipine with banzodiazepine developed shock which was refractory
to treatment and died. In a 19 month-old child who ingested 3D mg of amlodipine Ia boot 2 mglkg) there was no
evtdance of hypotension but tachycerdia (180 bpm) was observed. Ipecac was administered 3.5 hrs after ingestJon
1nd on subsequent observation (overnight} no sequelae were noted.
TreltMIIt
Clinicalty significant hypotension due to overdosage requires active cardiovascular suppon including frequent
monn.oring of cardiac and respiratory function, elevation of extremities, and attention to circulating nuid volume
and urine output A vasoconstrictor (such as norepinephrine) may be elpful in restoring vascular tone and
bfood pressure. provided that there is no contraindica on to its use. As NORVASC is highty protein bound,
hemodialysis is not likety to be of benefit. Intravenous calcium gluconate may be beneficial in reversing the
effects of calcium channeJ blockade. Clearance of amlodipine is prolonged in eklerty patients and in pa ents
with impaired liver function. Sinceamlodipine absorption is stow. gastric lavage may be worthwhile in some cases.

DOSAGE AND ADMINISTRAnON
Dosage should be individu>fized depending on patien(s tolerance and responsiveness. For both hypertension
and angina, the recommended initial dose of NORVASC famlodipine besylate) is 5 mg once daily. ~necessary,
dose can be increased ah.er 1·2 weeks to a maximum dose of 10 mg once daity.
Uso iotloo Elclortya<io PotiHCswido hlopairociRooalfwctiH
The recommended initial dose in patients over 65 years of age or patie1'1tS with impaired renal function is 5 mg
once daily. ~ required, increasing in the dose should bo done gradually and with caution (see PRECAUTIONS).
Uso io Potieots widlhlopairocl Hepotic Ftooction
Dosage requirements have not been established in patients with impaired hepatic function. When NORVASC is
used in these patients, the dosage should be carefuttv and gradualty adjusted depending on patient's tolerance
and response. A lower starting dose of 2.5 mg once deity should be considered (see WARNINGSI.

DOSAGE FORMS
Availability
NORVASC is available as Ylhhe octagonal tablets contavnng amlodipine besytate equivalent to 2.5, Sand 10 mg
amlodipine per tablet The respective tablet strengths are debossed on one tablet face as ·NRV
·NRV 5'"

z.s·.

and "NRV 10" with "Pfaer· on the opposita face. The 5 mg tablet is scored. Supplied in wh~e plastic (high density
of I DO tablets for each strength. Also the 5 mg and 10 mg are supplied in bottles of250tablets.

~'7:ne) bottles

Store at 15-JO"C. Protect from 6ght
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